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 ABSTRACT OF DISSERTATION 
 
POLYCHLORINATED BIPHENYL LIGANDS OF THE ARYL HYDROCARBON 
RECEPTOR PROMOTE ADIPOCYTE-MEDIATED DIABETES 
 
Numerous epidemiology studies suggest a correlation between exposures 
to polychlorinated biphenyls (PCBs) and the development and severity of type 2 
diabetes (T2D); however, mechanisms remain largely unknown. Previous studies 
demonstrated that PCBs that are ligands of the aryl hydrocarbon receptor (AhR) 
promote the expression of proinflammatory cytokines, including tumor necrosis 
factor-α (TNF-α), that are linked to insulin resistance in adipocytes.  To explore 
potential mechanisms linking PCB exposures to diabetes, we developed a 
mouse model of glucose and insulin intolerance induced by acute and chronic 
exposures to PCB-77. We hypothesized that PCB ligands of AhR result in 
adipocyte-specific elevations in TNF-α and dysregulated glucose homeostasis.  
Results demonstrated that PCB77 resulted in rapid and sustained glucose and 
insulin intolerance in low fat (LF)-fed mice, and that these effects were 
associated with adipose-specific elevations in TNF-α.  When mice were made 
obese from consumption of a high fat (HF) diet, effects of PCB77 were lost 
presumably due to concentration of the toxin in adipose lipids.  However, upon 
weight loss, mice exposed to PCB77 exhibit impaired glucose homeostasis.  
These results suggest that lipophilic PCBs redistribute from adipose lipids with 
weight loss and mitigate beneficial effects to improve glucose homeostasis.  To 
define the role of adipocyte AhR in PCB-induced diabetes, we created a mouse 
model of adipocyte AhR deficiency using the Cre/LoxP system.  Adipocyte-AhR 
deficiency conferred protection from the development of PCB-77-induced 
impairments in glucose and insulin tolerance in obese mice undergoing weight 
loss.  Unexpectedly, adipocyte-AhR deficient mice fed the HF diet exhibited 
adipocyte hypertrophy, increased adipose mass and elevated body weight. 
These results suggest that (1) adipocyte AhRs are responsible for effects of 
PCB77 to impair glucose homeostasis during weight loss and (2) adipocyte AhRs 
respond to the HF diet to regulate adipose mass and body weight.   We used 
resveratrol as a putative AhR antagonist to determine if the polyphenol confers 
protection against PCB-77-induced diabetes. Resveratrol abolished acute effects 
of PCB77 to impair glucose and insulin tolerance in LF-fed mice.  Notably, 
PCB77 administration abolished insulin-induced phosphorylation of Akt in 
adipose tissue and these effects were abolished by resveratrol.  Resveratrol also 
abolished marked suppressions in glucose uptake in adipocytes exposed to 
PCB77.  These studies suggest the adipocyte AhR plays a potentially significant 
role in the development of diabetes and obesity, and that resveratrol may 
represent a novel therapeutic for PCB exposed populations. 
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SECTION I. BACKGROUND  
1.1 Polychlorinated biphenyls  
1.1.1 Polychlorinated biphenyls 
Polychlorinated biphenyls (PCBs) are the general name describing any of the 
209 arrangements of organochlorides with 1 to 10 chlorine atoms attached to a 
biphenyl structure (a molecule with two benzene rings) (Figure 1.1). They are 
synthetic compounds that were primarily used as dielectric and coolant fluids 
in transformers, capacitors, and electric motors. In light of emerging 
environmental concerns and health impacts in humans and wildlife, PCB 
manufacturing was banned by the United States Congress in 1979 and by 
the Stockholm Convention on Persistent Organic Pollutants (POPs) in 2001 
(1). According to the U.S. Environmental Protection Agency (EPA), PCBs can 
cause cancer in animals, and there is causal evidence for a link to cancer in 
humans (2-3). 
 The toxicity of PCBs became a topic of global concern when it was 
discovered that compounds within this group can share a structural resemblance 
and toxicity pathways with 3,4,7,8-tetrachlorodibenzo-p-dixon (TCDD). PCB 
compounds within this group have positive associations with toxic effects of 
TCDD; namely endocrine disruption, neurotoxicity, immune system suppression, 
and reproductive effects (4). 
1.1.1.1 PCB chemistry 
PCB congeners are odorless, tasteless, viscous liquids with the chemical 
formula C12H10-xClx (Figure 1.1). They are formed via electrophilic chlorination 
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of a biphenyl with chlorine gas. PCBs have low water solubility and low vapor 
pressure at room temperature, but they are highly soluble in most 
organic solvents, oils, and fats (5). PCBs have high dielectric constants, 
high thermal conductivity, high flash points and are fairly inert chemically; all 
qualities which made the compounds ideal for use as coolants in electrical 
systems (5). They are highly resistant to chemical degradation such 
as oxidation, reduction, addition, elimination, and electrophilic substitution, 
making PCB removal from the environment extremely problematic (5).  
 PCBs can be divided into two distinct categories with regards to their 
structural relationship to toxicity; (1) coplanar or non-ortho-substituted arene 
substitution patterns and (2) noncoplanar or ortho-substituted congeners. The 
coplanar group members have 2 phenyl rings which occupy the same plane, 
giving the molecule structural similarities to polychlorinated dibenzo-p-
dioxins (PCDDs) and  dibenzofurans, and allowing coplanar PCBs to elicit similar 
toxic effects via agonist activity at the aryl hydrocarbon receptor (AhR) in humans 
and animals (5). Noncoplanar PCBs have chlorine atoms at the ortho position on 
one or both of the biphenyl rings; this chlorine position causes steric hindrance 
and forces the molecule to twist out of plane. Members of the noncoplanar group 
have not been found to interact with AhR, but rather have been shown to bind 
both the constitutive androstane receptor (CAR) and the pregnane x receptor 
(PXR) (5).  
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1.1.1.2 PCB lipophilicity 
Part of the persistence of PCBs in the environment stems from their high 
lipophilicity; the octanol:water partition coefficient of > 104 for most congeners 
dictates that their accumulation in nonlipid substances will be minimal (6). We 
have previously reported that mice orally gavaged with two doses of PCB-77 
overwhelming accumulate the contaminant in adipose tissue, with secondary 
tissue accumulation in liver and trace amounts in serum (7). These findings are 
consistent with studies by Kodavanti et.al., in which rats were gavaged five times 
per week for 4 weeks with Aroclor 1254 and the reported mean ratio of total PCB 
in blood:liver:adipose tissue was 1:22:359 (8). Most likely as a result of their 
lipophilicity, obese subjects store approximately two to three times the quantity of 
total PCBs in adipose tissue, which would indicate that hydrophobic PCBs were 
highly attracted to the large lipid pools present during obesity. Conversely, in 
obese subjects experiencing drastic weight loss from bariatric surgery, serum 
levels of PCBs increased and were suggested to decrease the beneficial effects 
of weight loss with respect to liver toxicity markers and serum lipid parameters 
(9).   
These studies suggest that adipose tissue can store lipophilic PCBs and that 
adipose tissue might be a target for the adverse health effects associated with 
these chemicals. Furthermore, adipose tissue would represent a low-grade 
internal source of stored PCBs which could then act systemically upon release 
from adipose lipids.   
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1.1.1.3 General health effects of PCBs 
The toxicity of PCBs varies among congeners. The coplanar PCBs, due 
to dioxin-like properties, are among the most toxic congeners. Since PCBs are 
frequently found in complex mixtures due to their industrial use, the concept of 
toxic equivalency factors (TEFs) has been developed to aid in risk assessment 
and regulatory control. In the TEF system, more toxic PCB congeners are 
assigned higher TEF values on a scale from 0 to 1, and the highest TEF value of 
1 is assigned to TCDD (10) (Table 1.1). 
 Humans may be exposed to PCBs by breathing in contaminated air, 
eating contaminated food, and through accidental skin contact with contaminated 
materials. PCBs in foods tend to be most prevalent in meat (particularly beef) 
and dairy products which are high in fat and conversely less prevalent in grain, 
fruit, and vegetable food stuffs (11). Furthermore, PCB levels have been found to 
be greater in farm raised salmon compared to wild caught fish, apparently due to 
PCB contamination in commercial fish meal (12). PCBs can be excreted in feces 
or stored in adipose tissue (13). Due to high lipophilicity, PCBs also tend to 
collect in milk fat and can be transmitted to infants through breast-feeding (14-
15). 
 A frequently observed health effect in populations with very high levels of 
PCB exposure are skin conditions (chloracne and rashes). In the Japanese 
Yusho poisoning incident (1968), more than 14,000 people suffered mass 
poisoning when 280 kg of PCB-contaminated rice bran oil was used as chicken 
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feed (16). Reported symptoms included dermal and ocular lesions, including 
unusual skin sores, fatigue, and lowered immune responses (17).  
 A growing body of evidence suggests that PCB exposure may have a 
positive association with the development of non-Hodgkin lymphoma, a cancer of 
the immune system (18-19), and they may also mimic the action of estrogen in 
breast cancer cells and increase breast carcinogenesis (20). The U.S. EPA and 
the International Agency for Research on Cancer (IARC) have concluded that 
PCBs are probable carcinogens (2, 21). PCBs are also considered as probably 
carcinogenic to humans by the World Health Organization (22).  
 Finally, TCDD and PCB exposure are positively correlated with the 
development of T2D in numerous epidemiology studies (Tables 1.3, 1.4, and 
1.5).  These findings are consistent with the published opinion of the National 
Institutes of Environmental Health Sciences (NIEHS) Division of the National 
Toxicology Program (NTP), which reviewed many of the epidemiology studies 
examining the correlation between PCBs and diabetes and concluded that there 
is a positive association between these two factors and that more research is 
needed to understand underlying mechanisms (23). 
1.1.2 Aryl-hydrocarbon receptor (AhR) 
The aryl-hydrocarbon receptor (AhR) is a member of the family of basic helix-
loop-helix transcription factors. The endogenous ligands of this receptor remain 
unknown, although it binds numerous exogenous ligands including natural plant 
flavonoids, polyphenolics, and indoles, and additionally synthetic polycyclic 
aromatic hydrocarbons and dioxin-like compounds such as coplanar PCBs 
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(Table 1.2). AhR is a cytosolic transcription factor which is inactive when bound 
to several co-chaperones. Subsequent to ligand binding to chemicals such 
as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the chaperones dissociate and 
allow for AhR translocation to the nucleus and dimerization with aryl-hydrocarbon 
receptor nuclear translocator (ARNT), initiating changes in gene transcription 
(Figure 1.2).  
1.1.2.1 Protein functional domains 
The AhR protein contains a number of domains critical for function and is 
classified as a member of the basic helix-loop-helix/Per-Arnt-Sim 
(bHLH/PAS) family of transcription factors (24-25) (Figure 1.3). The bHLH motif 
is located in the N-terminal of the protein (26). Transcription factors of the bHLH 
superfamily have two highly conserved  and functionally distinctive domains; the 
basic-region (b), which is necessary for the binding of the transcription factor 
to DNA, and the helix-loop-helix (HLH) region, which promotes protein-protein 
interactions. In addition, the AhR contains  two PAS domains, PAS-A and PAS-B; 
sequences of 200 to 350 amino acids that display a high sequence homology to 
the protein domains that were originally discovered in the Drosophila genes 
period (Per), single-minded (Sim), and ARNT (27). The PAS domains facilitate 
particular secondary interactions with other PAS domain-containing proteins, 
specifically between AhR and ARNT, allowing the protein complex to form. The 
ligand binding site of AhR is located within the PAS-B domain (28) and contains 
conserved residues necessary for ligand binding (29). A Q-rich domain is 
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contained in the C-terminal region of AhR and is needed for co-activator 
recruitment and transactivation (30).  
1.1.2.2 Aryl-hydrocarbon receptor ligands  
AhR ligands can be broadly classified into synthetic or naturally occurring 
categories (Table 1.2). The first recognized AhR ligands were synthetic 
halogenated aromatic hydrocarbons (polychlorinated dibenzodioxins, 
dibenzofurans, and biphenyls) and polycyclic aromatic hydrocarbons (3-
methylcholanthrene, benzo(a)pyrene, and benzoflavones) (31-32). More recently, 
several studies have examined naturally occurring ligands, hinting toward the 
identity of an endogenous ligand. 
 Potential endogenous ligands of AhR include the following: derivatives 
of tryptophan such as indigo dye and indirubin (33), bilirubin (34), arachidonic 
acid and ecosanoid metabolites lipoxin A4 and prostaglandin G (35), modified 
low-density lipoprotein (36), and numerous dietary carotinoids (32). 
1.1.2.3 Aryl-hydrocarbon receptor signaling pathways 
AhR in the absence of ligand binding is located in the cytoplasm as an 
inactive protein complex consisting of a dimer of Hsp90 (37-38), prostaglandin E 
synthase 3 (Ptges3, p23) (39-42), the immunophilin-like protein hepatitis B virus 
X-associated protein 2 (XAP2) (43) (previously known as AhR interacting protein, 
AIP (44)), and AhR-activated 9 (ARA9) (45). The dimer of Hsp90 with p23 has 
several functions in the protection of AhR from proteolysis, holding the receptor 
in a conformation to facilitate ligand binding, and blocking the inappropriate 
binding of ARNT (28, 40, 42, 45-47). XAP2 interacts with the carboxyl-terminal of 
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Hsp90 and binds to the AhR nuclear localization sequence (NLS), 
which prevents the premature trafficking of the receptor into the nucleus (48-50). 
 After ligand binding to AhR, XAP2 is released resulting in exposure of the 
NLS and translocation into the nucleus (51). It is hypothesized that Hsp90 
dissociates from AhR in the nucleus, exposing the two PAS domains to facilitate 
the binding of ARNT (52-55). The activated AhR/ARNT heterodimer complex 
interacts with DNA by binding to recognition sequences located in the 5’- 
regulatory region of dioxin-responsive genes (52, 54, 56). 
 The conventional recognition motif of the AhR/ARNT heterodimer 
complex, known as either the AhR-, dioxin- or xenobiotic- responsive element 
(AHRE, DRE or XRE), includes the core sequence 5’-GCGTG-3’ (57) within the 
consensus sequence 5’-T/GNGCGTGA/CG/CA-3’ (58-59) in the promoter 
region of AhR responsive genes. The AhR/ARNT complex directly binds the 
AHRE/DRE/XRE core sequence in a manner such that ARNT binds to 5’-GTG-3’ 
and AhR binds 5’-TC/TGC-3’ (60-61). Current publications postulate that the 
element termed AHRE-II, 5’-CATG(N6)C[T/A]TG-3’, is capable of indirectly acting 
with the AhR/ARNT complex (62-63). The culmination of these steps results in an 
array of differential changes in gene expression. 
1.1.2.4 Functional role of AhR in physiology and toxicology  
Evolutionarily, the most primitive physiological role of AhR is in development. 
AhR is believed to have evolved from invertebrates where the receptor 
functioned in a ligand-independent manner in normal development processes 
(64). The AhR homolog in Drosophila, spineless (ss) is required for development 
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of the antenna and legs (65-66). In developing vertebrates, AhR appears to play 
a role in cellular proliferation and differentiation (6, 67). AhR has been shown to 
be involved in differentiation of several developmental pathways, including 
hematopoiesis (68), lymphoid systems (69-70), T-cells (71), neurons 
(72), hepatocytes (73), and adipocytes (6).   
 The adaptive response is evidenced by the induction of xenobiotic 
metabolizing enzymes. Proof of the adaptive response was first detected from 
the AhR-dependent induction of cytochrome P450, family 1, subfamily A, 
polypeptide 1 (CYP1A1) due to TCDD exposure (74-76). The hunt for the 
presence of DREs in the promoter region of genes has led to the identification of 
an AhR gene battery of Phase I and Phase II metabolizing enzymes consisting 
of CYP1A1, cytochrome P450, family 1, subfamily A, polypeptide 2 
(CYP1A2), cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), 
NADPH dehydrogenase quinine 1 (NQO1), aldehyde dehydrogenase family 3, 
member A1 (ALDH3A1), UDP-glucuronosyltransferase family 1, polypeptide A2 
(UGT1A2), and glutathione S-transferase A1 (GSTA1) (77). Through activation of 
the classical AhR gene battery, vertebrates can detect a wide range of chemicals 
at the cellular level which AhR is capable of binding to facilitate their 
biotransformation and elimination. Intriguingly, a recent study by Lensu et.al. 
implies that the AhR might signal the presence of toxins in food and cause 
aversion to those foodstuffs (78).  
 The toxic response is an expansion of the adaptive response induced by 
AhR activation. Toxicity may stem from two different arms of AhR signaling. In 
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the first arm, the induction of metabolizing enzymes can result in the generation 
of toxic metabolites. For instance, the AhR ligand benzo(a)pyrene (BaP), is 
converted to a toxic metabolite via the induction of CYP1A1 and CYP1B1 in a 
variety of tissues (79). The second arm of toxicity occurs through irregular 
changes in global gene transcription beyond those seen in the classical AhR 
gene battery, leading to global changes in gene expression and adverse 
modifications in cellular processes and function (67, 80-85). Interestingly, recent 
microarray analysis implies that different synthetic AhR ligands regulate distinct 
genetic networks (86). 
1.1.2.5 AhR in glucose homeostasis and metabolic studies 
While the toxicological functions of the AhR have been vigorously studied, the 
role of the AhR in glucose homeostasis and metabolism remains largely 
unexplored. Wang et.al. examined glucose tolerance, insulin resistance, 
expression of peroxisome proliferator–activated receptor-α (PPAR-α), and genes 
affecting glucose metabolism and fatty acid oxidation rhythms in wild-type (WT) 
versus AhR-deficient [knockout (KO)] mice (87). In this study, KO mice displayed 
enhanced insulin sensitivity and improved glucose tolerance, accompanied by 
decreased PPAR-α and key gluconeogenic and fatty acid oxidation enzymes, 
indicating a link between AhR signaling and glucose metabolism. The authors 
further conclude that hepatic activation of the PPAR-α pathway might be a 
mechanism underlying AhR-mediated insulin resistance. 
 Further clues to the role of AhR in glucose metabolism can be found by 
examining gene microarray studies utilizing high-affinity receptor ligands. Nault 
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et.al. utilized livers from chow-fed C57BL/6 mice for gene microarray, 1, 3 and 7 
days after a single oral gavage of 30 μg/kg TCDD (85). Administration of TCDD 
resulted in robust activation of not only genes involved in the xenobiotic 
response, but also genes associated with steroid, phospholipid, fatty acid, and 
carbohydrate metabolism. Arzuaga et.al. performed gene DNA analysis on livers 
from C57BL/6 mice fed diets enriched with high-linoleic acid oils (20% and 40% 
as calories), with half of each group exposed to PCB77 (84). This study 
demonstrated a significant interaction between dietary fat and PCB exposure, 
such that deregulated genes were organized into patterns describing the 
interaction of diet and PCB exposure. Control animals demonstrated a significant 
high-fat mediated induction of genes associated with fatty acid metabolism, 
triacylglycerol synthesis and cholesterol catabolism, but this effect was down-
regulated in animals exposed to PCB77. Several of these genes are regulated by 
PPAR-α and as predicted, changes in PPAR-α gene expression followed the 
same pattern as described above, demonstrating that dietary fat can interact with 
environmental pollutants to compromise lipid metabolism. Taken together, the 
results of these gene microarray studies would suggest not only that there is a 
distinctive role for the AhR in metabolism, but that overall nutritional status and 
the presence of lipids can modulate the interaction between AhR and exogenous 
ligands. 
 Recent studies demonstrated that consumption of farmed salmon 
containing persistent organic pollutants, including increased levels of seven 
different PCBs, promoted glucose intolerance associated with elevations in 
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adipose tissue expression of tumor necrosis factor-α (TNF-α) in high fat (HF) fed 
C57BL/6 mice (88).Interestingly, when levels of pollutants were decreased by 
feeding salmon purified fish oil, glucose tolerance improved and adipose 
expression of TNF-α decreased. This study suggested that the adipocyte AhR 
may be of importance in mediating some of the observed effects. 
 Another recent study tested the role of the AhR in obesity and fat 
metabolism in the absence of exogenous ligands (89). Utilizing two congenic 
mouse strains that differed at the AhR gene and encode AhRs with a 10-fold 
difference in signaling activity, the mouse strains were fed low-fat (LF) diet or HF 
diets. The HF diet differentially increased body weight and body fat to body mass 
ratios in the mouse strain expressing the higher affinity and higher response 
AhR. These results suggest that the AhR plays an important and broad role 
in obesity and associated complications.  
1.1.3 PCBs and type 2 diabetes 
1.1.3.1 The pathophysiology of type 2 diabetes 
Global estimates indicate 300 million people are affected by diabetes, with type 2 
diabetes (T2D) accounting for 90% of diabetes prevalence (90). Moreover, the 
world-wide diabetes incidence is anticipated to double in the next twenty years in 
tandem with global population aging, a general decrease in physical activity, and 
increasing rates of obesity. Women would appear to be at greater risk for 
developing T2D, as are certain ethnic groups (90-92). Traditionally considered a 
disease of adults, T2D is increasingly diagnosed in children in parallel with 
rising obesity rates (90). 
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 T2D is a metabolic disorder that is characterized by high blood glucose in 
the context of insulin resistance and relative insulin deficiency (93). This is in 
contrast to diabetes mellitus type 1, where there is an absolute insulin deficiency 
due to destruction of islet cells in the pancreas (93). Classical T2D symptoms 
are polyuria, polydypsia, polyphagia, and weight loss (91). Many people, 
however, have no symptoms during the first few years and are diagnosed on 
routine testing. Long-term complications from unregulated high blood glucose 
can include heart disease, strokes, diabetic retinopathy and subsequent 
blindness, kidney failure which may require dialysis, and poor circulation of limbs 
leading to amputations (91). The development of T2D is caused by a 
combination of lifestyle and genetic factors, with obesity believed to be a primary 
contributing factor (91, 94).  
 T2D is initially managed by increasing physical activity and improved diet. 
If blood glucose levels are not adequately lowered by these modifications, 
medications such as metformin (to suppress hepatic gluconeogenesis and 
enhance the insulin sensitivity of peripheral tissue) or insulin (in lieu of insufficient 
endogenous insulin from the pancreas) may be required. For those on insulin, 
patients must routinely check blood glucose levels. 
 T2D eventually progresses to insufficient insulin production from beta cells 
in the pancreas due to chronic insulin resistance (IR) in peripheral tissues (91). 
IR is typically observed in skeletal muscle, liver, and adipose tissue, and is 
characterized by the inability of cells to respond adequately to insulin (91). Insulin 
normally suppresses glucose production and release by the liver. In IR, because 
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the liver is no longer sensitive to insulin, inappropriate hepatic output of glucose 
can occur (91). Other potentially significant mechanisms associated with T2D 
and IR include the increased breakdown of lipids within adipocytes, high blood 
glucagon levels, increased kidney retention of salt and water, and the 
inappropriate regulation of metabolism by the central nervous system 
(93). However, not all people with IR are considered T2D, because an 
impairment of insulin secretion by pancreatic beta cells is also required (93). For 
example, prior to the development of T2D, most individuals will exhibit IR and a 
“pre-diabetic” physiology where in response to IR in peripheral tissues the 
pancreas will secrete more insulin than necessary. This disregulation of insulin 
secretion leads to the subsequent beta cell dysfunction present in T2D (93).  
1.1.3.2. General characteristics of adipose tissue 
Adipose tissue is connective tissue composed primarily of adipocytes, but also 
containing the stromal vascular fraction (SVF) of cells including preadipocytes, 
fibroblasts, vascular endothelial cells and variety of immune cells. Adipocytes are 
derived from preadipocyte stem cells. Adipose tissue stores energy in the form 
of lipids and acts as a major endocrine organ (95) producing numerous 
hormones such as adiponectin, estrogen, leptin, and the adipokine TNF-α. 
Adipose tissue is classified into two distinct types: white adipose tissue (WAT) 
and brown adipose tissue (BAT). In humans, adipose tissue is located beneath 
the skin (subcutaneous fat), around internal organs (visceral fat), and in specific 
locations (adipose depots).  
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 Visceral fat is white adipose tissue located inside the abdominal cavity and 
is composed of several depots, including mesenteric, epidydmal, and perirenal. 
An excess of visceral fat is linked to the development of T2D (96), IR 
(97), inflammatory diseases (98), and other obesity-related diseases (99).  
 Most of the remaining nonvisceral fat is subcutaneous adipose tissue 
found below the skin in the hypodermis. Subcutaneous fat is not thought to be 
related to the development of the classic obesity-related pathologies, such as 
heart disease and stroke, and some data even suggests it might be protective 
against metabolic disease pathogenesis (100). Females generally deposit body 
fat around the hips, thighs, and buttocks in subcutaneous fat depots (termed 
gynoid distribution) which are believed to pose a lower health risk than visceral 
fat that is typically present in males (termed android distribution) (100).  
 A specialized form of adipose tissue is brown adipose tissue (BAT), 
primarily located near the neck and thorax in humans. This specialized adipose 
tissue can generate heat via uncoupling of the respiratory chain of oxidative 
phosphorylation within mitochondria. When protons transit along the 
electrochemical gradient across the inner mitochondrial membrane, the energy 
from this process is released as heat instead of being used to 
generate adenosine triphosphate (ATP). This process is thought to be most 
critical in neonates exposed to cold which would require thermogenesis to keep 
warm (101). Until recently, BAT was thought to be found only in infants in 
humans, but new studies have disproven this hypothesis. Metabolically active 
tissue with temperature responses similar to BAT was first reported in adults in 
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2007 (102), and the presence of BAT in adults was later verified by others (103-
105). Strategies to direct the differentiation of BAT may become a weight loss 
therapy of the future. 
1.1.3.3. Mechanisms of IR in adipose tissue 
 Adipocytes have a significant physiological role in sustaining triglyceride 
and free fatty acid levels, in addition to contributing to IR.  Visceral fat is more 
prone than subcutaneous fat to display IR; thus, central obesity and waist 
circumference are markers of impaired glucose tolerance (100).  
 Oxidative stress is the broad term for an imbalance between the systemic 
expression of reactive oxygen species (ROS) and a biological system's capacity 
to readily detoxify the reactive intermediates or to repair the resultant damage. 
Disturbances in the normal redox state of cells can become the origin of toxic 
effects via the production of peroxides and free radicals that can damage any 
part of the cell, including proteins, lipids, and DNA. Additionally, some ROS act 
as cellular messengers in redox signaling, and therefore can cause disruptions in 
normal cellular signaling processes. The association between oxidative stress 
and IR, particularly in adipose tissue, has been recognized for some time (106-
109). Furukawa et.al. demonstrated that production of ROS increased selectively 
in the adipose tissue of obese mice, which was abolished by treatment with a 
NADPH oxidase inhibitor (110). The inhibitor also attenuated the dysregulation of 
adipocytokines, improved diabetes, and hyperlipidemia in obese mice (110). 
These results suggest that increased oxidative stress in adipose tissue is an 
early marker of metabolic syndrome. 
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 Adipokines also play a critical role in the development of adipose tissue 
IR, with TNF-α being a well recognized modulator of this effect. TNF-α is a multi-
functional regulatory cytokine with diverse roles in inflammation, cell apoptosis 
and survival, cytotoxicity, production of other cytokines, and induction of IR in 
adipose tissue (111-113). TNF-α is synthesized as a 26 kDa plasma membrane 
bound monomer (114), and a secreted trimer is formed by proteolytic 
cleavage of the membrane-bound precursor protein by the TNF-α converting 
enzyme (TACE, also known as ADAM17) (115-116). Two TNF-α receptors, type I 
and type II, mediate TNF-α signal transduction (117). 
 Both mRNA and protein levels of TNF-α are highly induced in the adipose 
tissue of obese animals (111) and humans (118). Despite the fact that adipose 
tissue is composed of a variety of cell types which are able to produce cytokines, 
adipocytes are the principal source of TNF-α in adipose tissue (111, 113, 119), 
and express both TNF-α receptors. Prolonged exposure of animals (120) to TNF-
α induces IR, and conversely neutralization of TNF-α increases insulin sensitivity 
(121-122). Additionally, TNF-α and TNF-α receptor knock out mice demonstrate 
improvements in insulin sensitivity in models of obesity (123-124). However, 
systemic administration of TNF-α neutralizing antibody to obese humans with 
type 2 diabetes did not improve insulin sensitivity (125). Because adipocyte-
derived TNF-α is hypothesized to function principally in an autocrine or paracrine 
manner in adipose tissue, systemic infusion might not be able to abolish the 
biological activity of endogenous TNF-α in adipose tissue.  
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 Free fatty acids (FFA) can reduce glucose uptake and metabolism; 
additionally, increased FFA oxidation can amplify the ratios of mitochondrial 
acetyl-CoA:CoA and NADH: NAD+, and thus impair insulin-mediated glucose 
utilization (126-127). FFA also inhibit insulin signaling (128-129) and glycogen 
synthesis in muscle (130-132), and promote hepatic glucose production (133). 
Systemic treatment with FFA inhibits glucose uptake in skeletal muscle in a 
dose-dependent manner (130, 134). Conversely, reducing systemic FFA 
improved glucose utilization (135-136) and ameliorated hyperinsulinemia in 
subjects with T2D. Although data suggest elevated blood FFA are involved in IR 
pathology, mechanisms which increase systemic FFA in T2D subjects are not 
completely understood. Systemic FFA are a balance between production and 
utilization, with lipolysis in adipocytes and in triglyceride-rich lipoproteins being 
principal sources of blood FFA. It has been postulated that systemic FFA levels 
are linearly correlated to the rate of adipose tissue FFA release (137), and that 
blockade of adipose tissue FFA release via insulin suppresses systemic FFA 
(138-139). It has been demonstrated that TNF-α is a significant 
autocrine/paracrine factor that can promote lipolysis and drive FFA release from 
adipose tissue (140-141).  
 Adiponectin is a secreted protein that is expressed primarily by adipocytes 
and is involved in regulating systemic glucose levels as well as fatty acid 
breakdown. Insulin stimulates adiponectin secretion in cultured adipocytes (142), 
however, TNF-α inhibits adiponectin mRNA levels (143). Adiponectin levels are 
down-regulated in humans and experimental animals with T2D (144-145). 
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Adiponectin knock out mice develop HF diet induced IR and hyperinsulimia, and 
have elevated FFA and blood glucose (146-147).  
 Additionally, adipose tissue is now considered an endocrine organ that 
can secrete several other bioactive molecules, such as leptin, resistin, IL-6, IL-
1ß, adipsin, metalloproteases, plasminogen activator inhibitor-1 (PAI-1), vascular 
cell adhesion molecule-1 (VCAM-1) and angiotensinogen. While over 50 
adipokines have been identified (148), it is probable that adipose tissue secretes 
additional proteins that have not been identified yet. Taken as a whole, these 
elements of adipose tissue constitute important factors in whole body energy 
metabolism and insulin sensitivity.  
1.1.3.4. Emerging evidence of a positive correlation between xenobiotic 
AhR ligand exposure and the development of T2D: Agent Orange and 
U.S. Vietnam veterans 
Agent Orange is the code name for the herbicide used by the U.S. military during 
the Vietnam War as part of its chemical warfare program known as Operation 
Ranch Hand. Agent Orange that was extensively sprayed on Vietnam and parts 
of Cambodia and Laos was later discovered to be contaminated with 2,3,7,8-
tetrachlorodibenzodioxin (TCDD). The purpose of Operation Ranch Hand was to 
defoliate forested and agricultural land for two reasons; to deprive guerrilla 
combatants of cover and to induce forced draft urbanization of Vietnam’s 
agrarian population to further limit their aid to guerrillas (149). 
 Numerous studies have examined health effects linked to Agent Orange, 
its component compounds, and its manufacturing byproducts (150). In 1969, it 
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was revealed that Agent Orange was contaminated with TCDD and that this was 
the likely cause of many of the previously unexplained negative health effects 
which were correlated with exposure to the herbicide (151).  Subsequently, 
TCDD has been heavily studied. The National Toxicology Program has classified 
TCDD as a known human carcinogen, associated with soft-tissue sarcoma, non-
Hodgkin's lymphoma, Hodgkin's lymphoma and chronic lymphocytic 
leukemia (152). 
 In 1991, the US Congress enacted the Agent Orange Act, giving 
the Department of Veterans Affairs the authority to declare certain conditions 
'presumptive' to exposure to Agent Orange, which meant veterans who served in 
Vietnam were eligible to receive treatment and compensation for these 
conditions (153). Through this process, the list of presumptive conditions has 
grown to include: prostate cancer, respiratory cancers, multiple myeloma, 
Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, chloracne and 
notably, T2D.  
 U.S. Air Force veterans of the Vietnam war exposed to Agent Orange 
contaminated with TCDD demonstrate increased risk of diabetes, reduced time-
to-onset of disease, and increased diabetes severity (154). Moreover, Fujiyoshi 
et.al. obtained adipose tissue samples from Agent Orange exposed veterans and 
unexposed comparison veterans and found a reliable indicator of dioxin-
induced diabetes to be the ratio of mRNA of glucose transporter 4 (GLUT4) and 
nuclear transcription factor kappa B (NFB) (155). This ratio demonstrated a 
significant correlation to serum TCDD levels and fasting glucose among the 
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Agent Orange exposed group. It is interesting to note that very low exposure 
levels were detected in the Agent Orange group, in fact not much higher than 
levels found in the general population, implying a need to address current 
exposure levels linked to the development of diabetes. For further epidemiology 
studies evaluating Agent Orange exposure and T2D risk, see Table 1.3. 
1.1.3.5. Evidence of a positive correlation between PCB exposure and the 
development of T2D: Anniston, AL Community 
As diabetes incidence increases worldwide in tandem with increasing prevalence 
of obesity and sedentary lifestyles, environmental factors are emerging as a 
potentially important element of T2D risk. PCBs and dioxins are believed to play 
a role in diabetes development, based on data from the National Health and 
Nutrition Examination Survey (NHANES) (Lee 2006; Lee 2007) and studies from 
the Slovak Republic (Langer 2002), Sweden (Lee 2011), Japan (Uemura 2008), 
Taiwan (Wang 2008), and the United States (Codru 2007; Lee 2010; Lee 2011; 
Vasiliu 2006)(see Tables 1.4 and 1.5 for summary of epidemiology studies 
examining PCB/dioxin exposure and diabetes development); however the results 
are not always consistent between studies and most focus on mixtures of POPs. 
Additionally, commentaries (Jones et al. 2008; Porta 2006) have highlighted the 
need for further research. 
 PCBs originating from the Monsanto Chemical Company in Anniston, 
Alabama, leeched into Snow Creek, which then spread to the broader water 
supply of northern Alabama. Today, the highest pollution levels remain 
concentrated in Snow and Choccolocco Creeks (156). PCBs were manufactured 
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at the Monsanto facility from 1929 to 1971. Residents of the Anniston community 
exhibit some of the highest total body burdens of PCBs than any other location in 
the world (157), making this unique population a focus of epidemiological study, 
in particular because this population was exposed primarily to only PCBs (versus 
exposure to POP mixtures in other studies). In a recent study by Silverstone 
et.al., 774 residents of Anniston were given physical examinations and serum 
PCBs were quantified to calculate the odds ratios to assess the relationship 
between PCBs and diabetes (158). A statistically significant association of serum 
PCB levels with increased diabetes prevalence was found in the population 
overall, with women having a stronger association than men. Moreover, the most 
highly exposed subjects who were more than 55 years old had an elevated risk 
of diabetes. These findings are consistent with a recent publication by the 
National Institutes of Environmental Health Sciences (NIEHS) Division of the 
National Toxicology Program (NTP) which reviewed the bulk of epidemiology 
studies examining the correlation between PCBs and diabetes and concluded 
that there is a positive association between these two factors and that more 
research is needed to understand underlying mechanisms (23)(see Tables 1.4 
and 1.5 for summary of epidemiology studies examining dioxin and PCB 
exposures, respectively, and diabetes development). 
 Most studies of PCB exposure in humans measure plasma or serum PCB 
levels as an index of environmental PCB exposure and systemic PCB burden. 
Efforts to associate PCB exposure with disease risk in many studies of this type 
are often confounded by the broad range of human PCB exposures and the 
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impact of statistically more powerful factors on overall disease risk. The 
Silverstone study is significant for two reasons. First, that it identified PCB 
exposure as a risk factor for development of T2D independent of other risk 
factors (158).  Second, the study gives clear ranges of serum PCB levels in 
humans which are positively associated with the development of T2D. Subjects 
were stratified by serum PCB levels and the adjusted odds ratio comparing the 
prevalence of diabetes in the fifth versus first quintile of serum PCB levels was 
2.78. In this study the fourth and fifth quintiles represented total serum PCB 
levels (the sum of 35 PCB congeners) in the range of 4.34-170 parts per billion 
(by weight). Assuming an average molecular weight of 325 and a serum density 
of 1g/ml this represents serum PCB concentrations of 0.01-0.52 μM.  
1.1.3.6. The role of PCBs in oxidative stress and inflammation 
Coplanar PCBs exhibit their toxicity by binding to AhR and subsequently 
increasing CYP1A1 gene expression. Coplanar PCBs can stimulate the 
production of ROS by uncoupling the catalytic cycle during their metabolism by 
CYP1A1 (159). Studies have shown that coplanar PCBs, including 
PCB 77 and PCB 126, are proinflammatory in vascular endothelial cells and can 
promote NF-B signaling (160-161). Arsenescu et.al. demonstrated that coplanar 
PCBs, but not noncoplanar PCBs, can stimulate inflammatory adipokines in 
adipose tissue (6). Besides stimulating an inflammatory response, PCBs can also 
promote inflammatory conditions such as obesity and diabetes (6-7). 
 Many mechanisms and signaling pathways associated with inflammatory 
diseases can be modulated by both diet and POPs. Several genes induced in 
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insulin resistant tissues are sensitive to oxidative stress as an initiating stimulus, 
suggesting that an imbalance in oxidative stress and/or ROS scavenging 
mechanisms is a significant factor that may mediate effects. There is emerging 
evidence to suggest that antioxidant nutrients might protect against exposure to 
environmental pollutants via down-regulation of signaling pathways involved in 
oxidative stress and inflammatory responses associated with diabetes (162). 
1.1.4. PCBs and obesity 
1.1.4.1 The pathophysiology of obesity 
The World Health Organization classifies people as obese with a body mass 
index (BMI) greater than 30 and overweight with a BMI of 25-29.9. Data from the 
NHANES in 2009-2010 indicated that 35.7% of adults and approximately 17% of 
children in the U.S. are obese (163). Obesity is an element of the metabolic 
syndrome, a cluster of risk factors that substantially increase the risk for diabetes 
development and includes increased waist circumference, blood pressure, 
fasting blood glucose, triglycerides, and reduced HDL (164). Visceral obesity is a 
primary factor of the metabolic syndrome and is independently associated with 
each of the other factors (165).  
 Obesity is thought of as a problem representing an imbalance between 
energy intake and expenditure, which can be influenced by any number of 
genetic and environmental factors, including physical activity, regulation of 
satiety, eating behaviors, hormonal imbalance, fetal programming, or exposure to 
POPs. Regardless of cause, modifications in adipose tissue growth, function, and 
remodeling dictate if an obese subject will develop obesity-associated disorders. 
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In developing obesity, excessive caloric intake drives increases in adipocyte size. 
Obesity is also correlated with increased macrophage infiltration into adipose 
tissue (166) due to inappropriate adipose tissue remodeling to make room for 
hypertrophied adipocytes (167). Chronic adipose tissue inflammation, in 
combination with ectopic lipid deposition in other tissues, link obesity with other 
elements of the metabolic syndrome to increase the risk of insulin resistance and 
the subsequent development of diabetes (168). 
1.1.4.2. Polychlorinated biphenyl-77 induces adipocyte differentiation and 
proinflammatory adipokines and promotes obesity 
Due to their lipophilicity, PCBs accumulate in adipose tissue and therefore the 
total body burden of PCBs increases with obesity (7, 9, 169-170), but the effects 
of PCBs on adipocytes, adipose tissue, obesity and diabetes are largely 
undefined. 
 Arsenescu et.al. examined in vitro and in vivo effects of coplanar 3,3’,4,4’-
tetrachlorobiphenyl (PCB-77) on adipocyte differentiation, proinflammatory 
adipokines, adipocyte morphology, and body weight. 3T3-L1 adipocytes were 
incubated with PCB-77 either during adipocyte differentiation or in already 
differentiated adipocytes. Low concentrations of PCB-77 increased adipocyte 
differentiation and expression of peroxisome proliferator–activated receptor 
gamma (PPAR), while higher concentrations inhibited adipocyte differentiation. 
This result is consistent with adipose wasting effects and reduced preadipocyte 
differentiation seen at high doses of TCDD in other published in vitro and in vivo 
studies (171-173). PCB-77 promoted the expression and release of numerous 
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proinflammatory cytokines from 3T3-L1 adipocytes, including TNF-α. In in vivo 
studies, C57BL/6 wild-type (WT) or AhR deficient (AhR–/–) mice were treated 
with vehicle or PCB-77 (49 mg/kg, by intraperitoneal injection) and body weights 
were measured over a six week period. Administration of PCB-77 increased body 
weight gain in WT but not AhR–/– mice. These findings suggest that PCB-77 
may promote the development of obesity and obesity-associated diseases such 
as T2D. 
1.2 Resveratrol 
Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid, a natural polyphenol 
commonly found in food stuffs such as red wine, grapes, peanuts, and chocolate, 
albeit in very minute quantities (red wine contains  approximately 0.1-14.3 mg/L 
(174)). Resveratrol can also be chemically (175) and biotechnologically 
synthesized (176-177), and is sold as a nutritional supplement. The effects of 
resveratrol are currently a topic of numerous animal and human studies. In 
animal studies, anticancer (178-181), anti-aging (182-183), anti-inflammatory 
(184-186), anti-diabetic (182, 187-192), anti-obesity (187, 193-198) and 
additional beneficial cardiovascular effects (199-211) of resveratrol have been 
reported. Conversely, a limited number of human studies have reported generally 
positive effects on measured outcomes, but certainly not the robust disease 
ablation effects of resveratrol reported from animal studies. Very high doses (3–
5 g) of resveratrol used in one small positive human trial significantly 
lowered blood glucose in T2D patients (212). A larger clinical trial which 
administered 250 mg/d of resveratrol to sixty-two T2D diabetes patients for 3 
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months also reported a significant reduction in fasting blood glucose and mean 
hemoglobin A1C (213). Timmers et.al. reported that in eleven healthy but obese 
men treated with 150 mg/d of resveratrol for 30 days fasting blood glucose was 
reduced and HOMA index of insulin sensitivity improved (214). Conversely, a 
recent study demonstrated that resveratrol had no effect on glucose homeostasis 
in lean individuals (215), suggesting that resveratrol requires the presence of an 
existing metabolic disturbance for efficacy in relation to glucose or insulin 
tolerance. Due to some promising results and the easy availability of resveratrol, 
research on beneficial effects of the compound are expanding.  However, the 
long-term effects of resveratrol supplementation in humans are not known (174). 
1.2.1. General mechanism of action of resveratrol 
Resveratrol’s effects to increase longevity appear to mimic the biochemical 
effects of calorie restriction. Resveratrol has been shown to activate Sirtuin 1 
(SIRT1) (216) and peroxisome proliferator-activated receptor gamma coactivator 
1-alpha (PGC-1α), which are thought to contribute to the compounds effects to 
improve mitochondrial function (187). However, evidence is conflicting as other 
studies have not link resveratrol to activation of SIRT1 and effects of calorie 
restriction (217-219). 
 Resveratrol has been shown to interfere with the initiation, promotion, and 
progression of certain cancers. In vitro experiments demonstrate that potential 
mechanisms could include modulation of the transcription factor NF-κB (220) 
and inhibition of CYP1A1 (221) (however this mechanism may not be pertinent to 
CYP1A1-mediated bioactivation of POPs) (222).  
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 Resveratrol also possesses potent antioxidant and anti-
inflammatory properties (183, 223). Resveratrol has been shown to increase 
intracellular glutathione in a nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
dependent manner via upregulation of gamma-glutamylcysteine ligase in lung 
epithelial cells, which subsequently conferred protection against cigarette smoke 
extract-induced oxidative stress (224). Additionally, a recently published study 
showed that male C57BL/6 fed a HF diet supplemented with 0.4% resveratrol 
had lower levels of TNF-α systemically and in adipose tissue (225). 
 Resveratrol can competitively inhibit key phosphodiesterases, resulting in 
increased cyclic adenosine monophosphate (cAMP), a second messenger for the 
activation of the pathway Epac1/CAMMKß/AMPK/SIRT1/PGC-1α. Rising cAMP 
levels increase fatty acid oxidation, mitochondrial biogenesis, mitochondrial 
respiration, and gluconeogenesis (226-227). 
1.2.2. Resveratrol dosing in rodent and human studies 
Approximately 70% of orally administered resveratrol is absorbed by humans; 
however oral bioavailability is about 1% as a result of extensive hepatic 
gluconuridation and sulfation (228). When subjects were administered a 
substantial oral dose of resveratrol (2.5 and 5 g), blood resveratrol levels did not 
reach the concentration believed to be essential for systemic cancer prevention 
(229). A proprietary formulation of oral resveratrol, SRT-501 (3 or 5 g), resulted in 
blood resveratrol levels which were five to eight times higher than those reported 
by Walle et.al., which did mirror concentrations  with demonstrated efficacy in 
animal and in vitro experiments (212). However, in 2010 GlaxoSmithKline 
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suspended a small clinical trial of SRT-501 being used as a treatment for patients 
with multiple myeloma due to safety concerns, and ultimately terminated the 
study later in the same year when several patients developed kidney failure 
(230). It should be noted that it is not clear if the kidney failure resulted from 
SRT-501 administration or from the underlying disease (the type of kidney failure 
observed in this trial is a common complication of multiple myeloma) (231). 
 Bioavailability of resveratrol would seem to be dependent in some cases 
on meal composition. In a pharmacokinetic study of oral resveratrol (2 g) 
administered twice daily in humans, interactions of resveratrol during concurrent 
ingestion of ethanol, quercetin, and high fat meals were examined (232). Mean 
peak serum resveratrol levels were 1,274 ng/ml at steady-state, but this was 
reduced by 46% when ingested with a high fat meal, although there was no effect 
of concurrent oral administration of quercetin or ethanol. This study reported no 
adverse health effects, but was limited by the small number of subjects (8) who 
were observed in the two week study. 
 In humans and rats less than 5% of the oral dose has been reported as 
the parent molecule resveratrol in blood (228, 233-236). The most abundant 
resveratrol metabolites in humans, rats, and mice are trans-resveratrol-3-O-
glucuronide and trans-resveratrol-3-sulfate (237). Walle et.al. hypothesized that 
sulfate conjugates are the primary source of resveratrol bioactivity (228), Wang 
et. al. suggest that it is the glucuronides (238), and Boocock et al. emphasize the 
need for further research on the effects of resveratrol metabolites (233).  
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 Some have suggested that resveratrol from wine might have higher 
bioavailability than resveratrol from supplements (234). However, this concept 
has been refuted by several studies (239-240). Studies which have administered 
moderate amounts of wine to human subjects have only detected trace amounts 
of resveratrol in blood that are insufficient to explain the French paradox, 
suggesting that the beneficial effects of wine might require the presence of 
alcohol (239) or the complex of substances that wine contains (240).  
1.2.3. Effects of resveratrol on glucose and insulin tolerance 
Resveratrol has well documented anti-diabetic effects in rodents, which has 
driven a number of clinical trials to utilize the compound as a therapy for 
diabetes. Resveratrol has been demonstrated to lower blood glucose and lipids 
in rats with streptozotocin (STZ)-induced diabetes as well as rats with STZ-
nicotinamide-induced diabetes (189, 193). In numerous studies in rodents, 
resveratrol demonstrates antidiabetic effects such as the abolishment of IR and 
glucose intolerance (182, 187-193). A recent clinical study of T2D patients 
treated with oral resveratrol supplements for three months reported significant 
improvements in nearly all biomarkers associated with the disease (213). 
However, evidence also suggests that resveratrol has no effect in lean 
individuals (215), or that resveratrol improves adipose tissue glucose 
homeostasis only under insulin resistant conditions (241). In general, resveratrol 
has been shown to improve symptoms of T2D via three main mechanisms: 
reduction of blood glucose, preservation of pancreatic ß cells, and improvement 
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in insulin action. Studies indicate that the beneficial effects of resveratrol in 
relation to T2D comprise all these mechanisms. 
 Maintenance of blood glucose in the physiological range is pivotal for the 
treatment of T2D, because hyperglycemia causes numerous diabetic 
complications (242). Thus, treatment with hypoglycemic drugs (metformin or α-
glucosidase inhibitors) are administered in clinical practice to lower blood 
glucose, but these drugs are not without unfavorable side effects (243). 
Resveratrol has been well documented to lower hyperglycemia in humans and 
animals, with apparently limited side effects. The blood glucose lowering action 
of resveratrol has been demonstrated in obese rodents (244) and in two animal 
models of diabetes: in rats with streptozotocin-induced diabetes or streptozotocin 
nicotinamide-induced diabetes (189, 192-193, 245-247). Administration of 
resveratrol to diabetic rats lowered levels of glycosylated hemoglobin (HbA1C), 
which suggests the prolonged reduction of glycemia (189, 248). The blood 
glucose lowering effect of resveratrol seen in diabetic animals is believed to stem 
from a stimulatory action on intracellular glucose transport. Interestingly, in 
experiments on isolated hepatocytes, adipocytes, and skeletal muscle from 
diabetic rats, resveratrol stimulated glucose uptake in the absence of insulin 
(193). Enhanced glucose uptake induced by resveratrol appears to occur due to 
increased activity of glucose transporters in the plasma membrane. Studies of 
rats with experimentally induced diabetes administered resveratrol showed 
increased expression of the insulin-dependent glucose transporter (GLUT4) 
compared to controls (192, 249).  
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 Development of T2D is a prolonged process, usually accompanied by 
insulin resistance. Initially, blood glucose is maintained in the physiological range 
because of the compensatory increase in insulin secretion. Chronic 
overstimulation of pancreatic ß cells exhausts and degrades these cells, 
diminishing insulin secretion over time (250). Resveratrol appears to modulate 
blood insulin concentrations in rodents. Resveratrol effectively reduced blood 
insulin in animal models of hyperinsulinemia; in mice on a high-fat diet (182, 187, 
251-252), in rats on a high cholesterol-fructose diet (188), and in obese Zucker 
rats (253). In vitro, resveratrol reduced insulin secretion by isolated rat pancreatic 
islets (254-256). The inhibition of insulin secretion caused by resveratrol was 
shown to result from metabolic changes in pancreatic ß cells. During 
physiological conditions, glucose-induced insulin secretion from ß cells is 
predicated on the following series of events: intracellular transport of glucose and 
its oxidative metabolism, hyperpolarisation of the  inner mitochondrial membrane, 
increased ATP synthesis, closure of ATP-sensitive potassium channels, 
depolarization of the plasma membrane, opening of voltage-sensitive calcium 
channels, and the rise in cytosolic calcium ions.The increase in cytosolic calcium 
ions triggers secretion of insulin (93). In this sequence leading to increased 
secretion of insulin, resveratrol has been shown to act on ATP formation. 
Pancreatic islets treated with resveratrol released more lactate, and glucose 
oxidation was decreased compared to controls (255). It should be noted that the 
inhibition of insulin secretion by resveratrol was apparently reversible and was 
not due to permanent changes in pancreatic ß cells (254-255). Because chronic 
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overstimulation of ß cells is known to stimulate their degradation, inhibition of 
insulin secretion by resveratrol might attenuate these effects.  
 Resveratrol may also protect the endocrine pancreas via other 
mechanisms. In vitro, exposure of isolated rat pancreatic islets to cytokines 
resulted in increased DNA binding of NF-B, increased production of NO, and 
expression of iNOS, with all effects being suppressed by resveratrol (257). The 
protective effect of resveratrol against cytokine-induced dysfunction of ß cells is 
due in part to the ability of resveratrol to activate NAD+ dependent protein 
deacetylase SIRT1 (257).  
 Resveratrol may also protect against T2D via antioxidant activity. 
Pancreatic ß cells are known to be uniquely sensitive to the oxidative damage 
(258-259). In a recent study of diabetic rats, the levels of lipid peroxides and 
protein carbonyls in the pancreatic tissue were significantly increased compared 
with non-diabetic animals, indicative of oxidative damage; inversely, the activity 
of enzymes involved in radical scavenging was significantly reduced (260). 
Administration of resveratrol abolished the oxidative damage and increased the 
activities of antioxidant responsive enzymes (248).  
 T2D is typically accompanied by insulin resistance, defined as the 
impaired action of insulin on target cells, mainly adipocytes, hepatocytes, and 
skeletal muscle cells. IR develops primarily in overweight or obese individuals 
with T2D (261), and decreased adiposity improves insulin action (262). Calorie 
restriction and exercise are clinical recommendations to improve insulin 
sensitivity in T2D. Numerous animal studies have demonstrated that resveratrol 
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improves insulin action during diet-induced T2D symptoms, likely by acting as a 
calorie restriction or exercise mimetic (182, 187, 194, 251, 253).  
 The improvement in insulin action caused by resveratrol may stem from a 
variety of effects, including reduced adiposity. High doses of resveratrol reduce 
body weight / fat mass in rodents on a HF diet (187, 194-198), with effects which 
are similar to those induced by calorie restriction (183, 263). Consistent with 
rodent studies, in vitro experiments demonstrated decreased ATP content (264) 
and reduced accumulation of triglycerides in isolated rat adipocytes treated with 
resveratrol (265). Moreover, resveratrol increased lipolytic response to 
epinephrine and decreased lipogenesis (266), results that are suggestive as to 
how resveratrol may contribute to reduced adiposity in rodents. Kennedy et.al. 
utilized human adipocytes to demonstrate that resveratrol abolished linoleic acid-
induced insulin resistance (267). Furthermore, resveratrol suppressed 
inflammatory cytokines induced by linoleic acid. Potential mechanisms of the 
protective effects of resveratrol on human adipocytes include the attenuation of 
oxidative stress, prevention of activation of extracellular signal-related kinase, 
inhibition of inflammatory gene expression, and increase in peroxisome 
proliferator-activated receptor  (PPAR-) activity (267). 
 Resveratrol-induced improvement in insulin action has also been 
attributed to the activation of SIRT1 and 5’-AMP-activated protein kinase (AMPK) 
(182, 187, 195-196, 257). In AMPK-deficient mice fed a high-fat diet, resveratrol 
had no effect and neither reduced body fat nor improved insulin action (194). 
However, contrary findings have been reported by Pacholec et al., which 
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demonstrated that resveratrol is not a direct activator of SIRT1, which would 
suggest that the role of SIRT1 in the mechanism of resveratrol action should be 
reconsidered. While the exact mechanism of resveratrol action is still poorly 
understood, there is ample evidence that this compound is able to improve 
insulin action in a variety of animal models of insulin resistance. 
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Figure 1.1 Chemical Structure of PCBs 
 
 
 
Figure 1.2 AhR Signaling Pathway 
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Figure 1.3 Protein functional domains of AhR 
 
Compound                    WHO TEF 
2,3,7,8‐TCDD  1 
3,3',4,4'‐tetraCB (PCB‐77)  0.0001 
3,3',4,4',5‐pentaCB (PCB‐126)  0.1 
 
Table 1.1 World Health Organization TEF values of TCDD and selected 
PCBs 
 
Synthetic  Naturally Occuring 
2,3,7,8‐TCDD  Derivatives of tryptophan 
Coplanar PCBs  Lipoxin A4 
Polychlorinated dibenzofurans  Bilirubin 
Benzo (a) pyrene  Prostaglandin G2 
Benzoflavones  Curcumin 
Benzanthracenes  Modified low‐density lipoprotein 
 
Table 1.2 Synthetic and naturally occuring AhR ligands 
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Publication Population Diagnosis Exposure Risk Estimate 
ADVA 2005b Vietnam veterans 
Diabetes (death 
certificate) Vietnam service 
SMR = 0.52 (Vietnam veterans vs. 
general population) 
ADVA 2005a Vietnam veterans 
Diabetes (death 
certificate) Agent Orange 
SMR = 0.3 (deployed vs. non-
deployed) 
AFHS 2005 Vietnam veterans 
Diabetes (verified 
history) Agent Orange 
RR = 1.3 (within Ranch Hand 
veterans, adjusted for prior TCDD 
measurements) 
CDC 1988 Vietnam veterans Diabetes (self report) Vietnam service 
adjOR = 1.2 (deployed vs. non-
deployed) 
Fujiyoshi 2006 Vietnam veterans 
Diabetes (physican 
diagnosed) TCDD 
r = 0.07, p = 0.40 (Operation Ranch 
Hand veterans vs. non-Ranch Hand 
veterans) 
Henriksen 1997 Vietnam veterans 
Diabetes (physican 
diagnosed) TCDD 
RR = 1.5 (time to develop diabetes 
decreased with high TCDD 
exposure) 
Kang 2006 Vietnam veterans Diabetes (self report) Vietnam service 
OR = 1.50 (sprayed herbicides in 
Vietnam vs. never) 
Kim 2003 Vietnam veterans 
Diabetes (clinical 
exam) Agent Orange 
OR = 2.69 (Vietnam veterans vs. 
non-veterans) 
Kern 2004 Vietnam veterans 
Insulin sensitivity 
(ivGTT,QUICKI) TCDD 
ß = -0.00639, p = 0.02 (w/in pair 
differences for lower insulin 
sensitivity in Operation Ranch Hand 
veterans) 
Longnecker 2000 Vietnam veterans Diabetes (self report) TCDD 
adjOR = 1.56 (4th quartile of TCDD 
exposure, Operation Ranch Hand 
veterans vs. non-Ranch Hand 
veterans) 
Michalek 2003 Vietnam veterans 
Diabetes (physican 
diagnosed) TCDD 
no relationship after adjustment for 
covariates (diabetic Operation Ranch 
Hand veterans vs. non-diabetic 
Ranch Hand veterans) 
Michalek 2008 Vietnam veterans 
Diabetes (physican 
diagnosed) TCDD 
RR = 1.21, p = 0.16 (Operation 
Ranch Hand veterans vs. non-Ranch 
Hand veterans) 
Steenland 2001 Vietnam veterans 
Diabetes (physican 
diagnosed) TCDD 
OR = 1.18, (TCDD exposed 
Operation Ranch Hand veterans vs. 
non-exposed Ranch Hand veterans) 
SMR = standardized mortality ratio 
RR = relative risk 
adjOR = adjusted odds ratio 
 
Table 1.3 Summary of studies investigating the correlation between Agent 
Orange/TCDD exposure in Vietnam veterans and the development of type 2 
diabetes. 
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Publication Population Diagnosis Exposure Risk Estimates 
Bertazzi 2001 
Residents of Seveso 
during 1976 incident 
Diabetes (death 
certificate) TCDD 
RR = 1.7 (males), RR = 0.8 (females) 
(cause of death vs. reference population) 
Calvert 1999 
Workers employed at 
plants in NJ and MO 
Diabetes 
(physician 
diagnosis) TCDD 
adjOR = 1.97 (4th quartile of TCDD 
exposure vs. unexposed workers) 
Chang 2010 
Residents living near 
dioxin factory 
Non-diabetics w/ 
metabolic 
syndrome dioxins 
adjOR = 1.7 (insulin resistance in lowest 
3 quartiles vs. 4th quartile of TCDD 
exposure) 
Chen 2006 
Recidents living near 
municipal waste 
incinerators in Tiawan 
Diabetes 
(physician 
diagnosis) 
PCDDs, 
PCDFs 
adjOR = 2.44 (PCDD/PCDF 
concentration and diabetes vs. non-
diabetics) 
Chen 2008 
Non-diabetic pregnant 
women living near 
incinerators in Tiawan Non-diabetics 
PCDDs, 
PCDFs, 
PCBs 
no significant correlations with serum 
insulin or QUICKI results in adjusted 
models 
Collins 2009 
Plant workers w/ 
occupational 
exposure vs. US 
population 
Diabetes (death 
certificate) TCDD SMR = 1.1 (workers vs. US population) 
Consonni 
2008 
Residents of Seveso 
during 1976 incident 
Diabetes (death 
certificate) TCDD 
RR = 1.03 (Zone A), 1.32 (Zone B), 1.26 
(Zone R) (reference territory vs. Zones A, 
B, and R) 
Cranmer 2000 
Residents living near 
AK Superfund site 
Fasting insulin 
and glucose; 
OGTT TCDD 
adjOR = 8.5 (high fasting insulin for 
highest exposure percentile vs. lowest 
exposure percentile) 
Fierens 2003 
Residents living near 
Belgium industrial 
sites vs. rural areas 
Diabetes (self 
report) 
dioxins, 
PCBs 
adjOR = 5.07 (17 dioxins or PCDD/Fs), 
13.3 (4 coplanar PCBs [77, 81, 126, 
169]), 7.58 (12 other PCBs [3, 8, 28, 52, 
101, 118, 138, 153, 180, 194, 206, 209]) 
(highest percentile for dioxin vs. all other 
percentiles) 
Lee 2007 
Adults from NHANES 
1999 - 2002 
Insulin sensitivity 
(HOMA) 
PCDDs, 
PCDFs, 
coplanar 
PCBs, 
noncoplanar 
PCBs, OC 
pesticides 
adjOR = 2.3 (PCDD), 1.4 (coplanar 
PCBs), 2.3 (noncoplanar PCBs) (highest 
percentile vs. lowest percentile) 
Pesatori 1998 
Residents of Seveso 
during 1976 incident 
Diabetes (death 
certificate) TCDD 
RR = 1.1 (males, Zone R), 1.2 (females, 
Zone R) (Zone R vs. population of 
Lombardy region) 
Steenland 
1999 
Workers from 12 US 
plants that produced 
TCDD-contaminated 
products 
Diabetes (death 
certificate) TCDD 
SMR = 1.08 (diabetes, multiple causes 
and beyond) (total cohort industrial 
cohorts vs. US population) 
Sweeney 1997 
Workers from NJ and 
MO plants that 
produced TCDD-
contaminated 
products 
Diabetes (medical 
exam) TCDD 
OR = 1.12 (workers [mean 220 pg/g lipid] 
vs. referents [mean 7 pg/g lipid]) 
Turunen 2008 
Finnish fishermen and 
fishermen's wives 
Diabetes (death 
certificate) 
dioxins, 
PCBs SMR = 0.43 (males), 0.83 (females) 
Uemura 2008 
General population of 
Japan from urban, 
agrarian, and fishing 
areas 
Diabetes (self 
report) 
7 PCDDs, 
10 PCDFs, 
12 coplanar 
PCBs 
adjOR = 2.21 (highest tertile for 
PCDDs+PCDFs), 6.82 (highest tertile for 
coplanar PCBs), 3.81 (highest tertile for 
total dioxins) 
Vena 1998 
Research on Cancer 
International (IARC) 
study of herbicide 
production workers 
Diabetes (death 
certificate) TCDD 
RR = 2.25 (Poisson regression analysis 
of diabetes mortality) 
Table 1.4 Summary of studies investigating the correlation between dioxin 
exposure and the development of type 2 diabetes. 
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Publication Population Diagnosis Exposure Risk Estimates 
Chen 2008 
Non-diabetic 
pregnant women  Non-diabetics 
PCDDs, PCDFs, 
PCBs 
no significant correlations with serum insulin 
or QUICKI results in adjusted models 
Codru 2007 
Mohawks from 
Akwesasne River 
for > 5 years 
Diabetes (use 
of diabetes 
medication) 
PCBs, PCB-153, 
PCB-74, DDE, 
mirex, HCB 
OR = 3.2 (total PCBs), 2.4 (PCB-153), 4.5 
(PCB-74) (Diabetes, highest tertile vs. 
lowest tertile) 
Everett 2007 
NHANES 1999 – 
2002 (adults) 
Diabetes (self 
report) 
PCB-126, p,p'-
DDT, HxCDD 
adjOR = 1.67 (PCB-126) (total diagnosed 
and undiagnosed diabetes) 
Fierens 2003 
Belgians living 
near industrial 
sites vs. rural 
areas 
Diabetes (self 
report) dioxins, PCBs 
adjOR = 5.07 (17 dioxins or PCDD/Fs), 13.3 
(4 coplanar PCBs [77, 81, 126, 169]), 7.58 
(12 other PCBs [3, 8, 28, 52, 101, 118, 138, 
153, 180, 194, 206, 209])  
Jorgensen 
2008 
Greenlanders 
from three areas 
of West 
Greenland 
Diabetes 
(OGTT or FBG; 
IR by HOMA) 
Coplanar (3) and  
noncoplanar (10) 
PCBs, 11 OC 
pesticides 
adjOR = 1.2 (coplanar PCBs [105, 118, 
156]), 1.2 (noncoplanar PCBs [28, 52, 99, 
101, 128, 138, 153, 163, 170, 180]) (1st 
[referent] vs. 4th quartile) 
Langer 2002 
Workers from a 
PCB factory vs. 
residents of rural 
East Slovakia 
Anti-GAD 
antibody serum 
levels > 1.21 
U/mL PCBs 
40.4% vs. 10.5% (frequency of anti-GAD 
antibodies in exposed workers vs. 
unexposed rural dwellers) 
Langer 2009 
Adults from 
industrial areas of 
Slovakia 
glucose, 
insulin, lipids, 
BMI PCBs 
chi-square = 110.55, p < 0.0001 (increased 
FG), 11.89, p = 0.0182 (increased fasting 
insulin)  
Lee 2006 
Adults from 
NHANES 1999 - 
2002 
Diabetes (self 
report) 
PCB-153, DDE, 
HpCDD 
adjOR = 6.8 (PCB-153) (diabetes in highest 
percentile vs. non detectable) 
Lee 2007 
Adults from 
NHANES 1999 - 
2002 
Insulin 
sensitivity 
(HOMA) 
PCDDs, PCDFs, 
PCBs, OC 
pesticides 
adjOR = 2.3 (PCDD), 1.4 (coplanar PCBs), 
2.3 (noncoplanar PCBs) (highest percentile 
vs. lowest percentile) 
Lee 2010 
Young Adults 
CARDIA cohort 
Diabetes (use 
of diabetes 
medication) 55 POPs 
OR = 2.8 (PCB-74), 2.0 (PCB-153), 2.2 
(PCB-170), 2.8 (PCB-180) (2nd quartile vs. 
1st quartile of incident diabetes) 
Mullerova 
2008 
Obese women vs. 
non-obese 
women 
HOMA index; 
fasting glucose 
and insulin PCB-153 
no correlation between PCB-153 and study 
group (p > 0.05) 
Patel 2010 
NHANES 1999 - 
2006 (total of four 
cohorts) 
Diabetes (FG > 
126 mg/dL) 
heptachlor 
epoxide, PCB-
170 
OR for PCB-170 = 2.3, p = 0.02 (1999-2000 
cohort), 4.5, p = 0.01 (2003-2004 cohort), 
2.2, p < 0.001 (1999-2004, 3 cohorts)  
Rignell-
Hydbom 
2009 
Fisherman's wives 
from the Swedish 
east and west 
coasts 
Diabetes (self 
report) 
PCB-153, p,p'-
DDE 
OR = 1.4 (PCB-153) (PCB-153 per 100 
ng/g lipid increase in serum level) 
Rignell-
Hydbom 
2007 
Participants of 
WHILA diagnosed 
w/ T2D 
Diabetes 
(OGTT) 
PCB-153, p,p'-
DDE 
OR = 1.6 (PCB-153) (> 7 years after 
baseline) 
Rylander 
2005 
Swedish 
fisherman and 
fisherman's wives 
Diabetes (self 
report) 
PCB-153, p,p'-
DDE 
OR = 1.20 (men, PCB-153), 1.06 (women, 
PCB-153) (PCB-153 per 100 ng/g lipid 
increase in serum level) 
Turunen 
2008 Finnish fishermen  
Diabetes (death 
certificate) dioxins, PCBs SMR = 0.43 (males), 0.83 (females) 
Turyk 2009a 
Participants of 
GLCHA 
Diabetes (self 
report) DDE, total PCBs RR = 1.8 (total PCBs) 
Turyk 2009b 
Participants of 
GLCHA 
Diabetes (self 
report) DDE, total PCBs 
OR = 1.9 (highest quartile for total PCBs), 
2.1 (highest tertile for total coplanar PCBs) 
Uemura 2008 
Japanese from 
urban, agrarian, 
and fishing areas 
Diabetes (self 
report) 
7 PCDDs, 10 
PCDFs, 12 
coplanar PCBs 
adjOR = 2.21 (highest tertile for 
PCDDs+PCDFs), 6.82 (highest tertile for 
coplanar PCBs), 3.81 (highest tertile for 
total dioxins) 
Vasiliu 2006 
Adults in the 
Michigan PBB 
cohort 
Diabetes (self 
report) PBBs, PCBs 
Incidence density ratio = 1.74 (males, 
highest PCB quartile), 2.33 (females, 
highest PCB quartile) 
Wang 2008 
Yucheng cohort 
study 
Diabetes (self 
report) PCBs OR = 1.7 (males), 5.5 (females)  
 
Table 1.5 Summary of studies investigating the correlation between PCB 
exposure and the development of type 2 diabetes. 
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STATEMENT OF THE PROBLEM  
Emerging evidence supports a link between exposures to polychlorinated 
biphenyls (PCBs) and the development of type 2 diabetes (T2D).  However, 
mechanisms for this link are unclear.  Because of their lipophilicity, PCBs 
accumulate markedly in adipose lipids.  Thus, obesity increases the body burden 
of PCBs.  Notably, studies have demonstrated that weight loss results in 
redistribution of PCBs to the systemic circulation, and this redistribution is 
associated with adverse health effects.  However, it is unclear if release of 
greater quantities of PCBs stored in adipose tissue of obese subjects following 
weight loss adversely influences the control of glucose homeostasis.  Moreover, 
it is unclear if therapeutic strategies can be developed to mitigate harmful effects 
of liberated PCBs on glucose homeostasis. 
Previous studies in our laboratory demonstrated that coplanar PCBs that 
are ligands of the aryl hydrocarbon receptor (AhR) promote the expression and 
release of proinflammatory cytokines from cultured adipocytes.  Tumor necrosis 
factor-α (TNF-α), an inflammatory cytokine known to exert several effects that 
impair insulin sensitivity, was increased by PCB-77 in 3T3-L1 adipocytes.  
However, mechanisms for PCB-induced increases in inflammatory cytokine 
expression in adipocytes and the pathophysiologic consequences of this effect 
on glucose homeostasis are unknown. 
The purpose of this study was to determine mechanisms linking coplanar PCB 
exposures to the development of T2D.  We initially defined effects of coplanar 
PCBs (dose-dependency, sustainability) on measures of glucose homeostasis in 
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lean mice.  To determine potential sites for PCB-induced impairment of glucose 
homeostasis, we quantified effects of PCBs on TNF-α expression in adipose 
tissue, liver and muscle, tissues that are major sites of insulin-mediated glucose 
uptake.  Since obesity is a well known contributor to the development of T2D, we 
defined effects of a coplanar PCB on measures of glucose homeostasis during 
the weight gain phase in mice with diet-induced obesity.  Moreover, we examined 
effects of PCBs administered during the weight gain phase of obesity on glucose 
homeostasis during weight loss.  We hypothesized that release of increased 
body burdens of PCBs in obese mice experiencing weight loss would impair 
glucose homeostasis.  To determine if effects of coplanar PCBs to impair glucose 
homeostasis were adipose-specific and AhR-mediated, we examined effects of 
PCBs on glucose homeostasis in lean and obese mice (during the weight gain 
and weight loss phase) lacking AhR specifically in adipocytes.  Finally, we used 
supplemental doses of resveratrol as a therapeutic entity to prevent PCB-induced 
impairment of glucose homeostasis in lean mice.  We also defined mechanisms 
of resveratrol to protect against PCB-induced oxidative stress, impairment of 
glucose uptake and disruptions in insulin signaling.  We focused on stimulation of 
anti-oxidant pathways by resveratrol.  
 
The overall hypothesis of this dissertation is that coplanar PCBs act at adipocyte 
AhR to impair insulin signaling and glucose uptake and that resveratrol protects 
against PCB-induced impairment of glucose homeostasis.  The following specific 
aims were designed to test this hypothesis:  
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Specific Aim 1: Define effects of coplanar PCBs (PCB-77, PCB-126) on glucose 
homeostasis in lean versus obese C57BL/6 mice.  
A. Define effects (dose-dependency, sustainability) of PCB-77 on glucose 
homeostasis in lean mice. 
B.  Define effects of PCB-77 on glucose homeostasis in mice during the weight 
gain versus weight loss phases of diet-induced obesity.   
C. Define mechanisms for PCB-induced impairment of glucose homeostasis in 
3T3-L1 adipocytes.  
Specific Aim 2: Determine if dietary administration of resveratrol is an effective 
nutritional therapy against PCB-77 induced diabetes in lean C57BL/6 mice.  
A. Determine the effect of resveratrol supplementation in mice with acute PCB-
77 exposure.  
B. Determine the effect of resveratrol on oxidative stress and glucose uptake in 
3T3-L1 adipocytes exposed to PCB-77.  
Specific Aim 3: Determine the role of the adipocyte AhR on the development of 
PCB-77 induced diabetes.  
A. Determine the effect of adipocyte-AhR deficiency on parameters of glucose 
and insulin tolerance in lean versus obese (with and without weight loss) mice 
administered vehicle or PCB-77. 
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SECTION II. SPECIFIC AIM 1  
2.1 Summary 
  Previous studies demonstrated that coplanar polychlorinated biphenyls 
(PCBs) promote proinflammatory gene expression in adipocytes. PCBs are 
highly lipophilic and accumulate in adipose tissue, a site of insulin resistance in 
persons with type 2 diabetes. We investigated the in vitro and in vivo effects of 
coplanar PCBs on adipose expression of tumor necrosis factor α (TNF-α) and on 
glucose and insulin homeostasis in lean and obese mice.  
  We quantified glucose and insulin tolerance, as well as TNF-α levels, in 
liver, muscle, and adipose tissue of male C57BL/6 mice administered vehicle, 
PCB-77, or PCB-126 and fed a low fat (LF) diet. Another group of mice 
administered vehicle or PCB-77 were fed a high fat (HF) diet for 12 weeks; the 
diet was then switched from HF to LF for 4 weeks to induce weight loss. We 
quantified glucose and insulin tolerance and adipose TNF-α expression in these 
mice. In addition, we used in vitro and in vivo studies to quantify aryl hydrocarbon 
receptor (AhR)-dependent effects of PCB-77 on parameters of glucose 
homeostasis.  
 Treatment with coplanar PCBs resulted in sustained impairment of 
glucose and insulin tolerance in mice fed the LF diet. In PCB-77–treated mice, 
TNF-α expression was increased in adipose tissue but not in liver or muscle. 
PCB-77 levels were strikingly higher in adipose tissue than in liver or serum. 
Antagonism of AhR abolished both in vitro and in vivo effects of PCB-77. In 
45 
 
obese mice, PCB-77 had no effect on glucose homeostasis, but glucose 
homeostasis was impaired after weight loss.  
 Coplanar PCBs impaired glucose homeostasis in lean mice and in obese 
mice following weight loss. Adipose-specific elevations in TNF-α expression by 
PCBs may contribute to impaired glucose homeostasis. 
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2.2 Introduction 
 Type 2 diabetes (T2D) affects 300 million people, and diabetes prevalence 
is anticipated to double world-wide over the next 20 years (90). Recent 
epidemiological studies suggested that exposure to low concentrations of 
polychlorinated biphenyls (PCBs) similar to current exposure levels in humans 
increases diabetes risk (268). Multiple cross-sectional analyses of National 
Health and Nutrition Examination Survey (NHANES) cohorts from 1999–2006 
found concentrations of PCB-170 in urine or blood with an adjusted odds ratio of 
4.5 for T2D, predicting up to 15% risk (269). Remarkably, this increased risk 
appeared in individuals who were not overweight or obese (270). Similar 
observations linking PCB exposures to T2D have been reported in other 
populations (271-272). Recently, a significant association between elevated PCB 
levels and diabetes was found in the Anniston Community Health Survey (158). 
Collectively, accumulating evidence supports a link between PCB exposure 
levels and the development of diabetes, but mechanisms linking PCBs to 
diabetes are largely unknown. 
 Because of their lipophilicity, PCBs accumulate in lipid stores of adipose 
tissue (8), suggesting that adipocytes experience continuous low-grade expo-
sures to PCBs. Extension of these findings to the setting of obesity suggests that 
the total body burden of PCBs would increase in obese subjects because of the 
inherent lipophilicity of these compounds. Recent studies demonstrated an 
inverse relationship between serum levels of several PCBs and body mass 
index, suggesting that sequestration of PCBs in adipose tissue is enhanced by 
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obesity (273). It is unclear whether this enhanced sequestration limits effects of 
PCBs systemically. Given the epidemic of obesity and T2D in the United States, 
a large percentage of the population strives to lose weight. Weight loss, through 
dietary restriction or increased physical activity, typically reduces adipose tissue 
mass through liberation of lipid stores (274). Lim et al. (275) reported that plasma 
concentrations of organochlorines were increased and significantly correlated to 
reductions in body mass index in obese subjects undergoing a weight-loss 
program. Further, Pelletier et al. (276) found that plasma concentrations of 13 of 
17 organochlorines in serum increased in obese subjects experiencing weight 
loss. The consequences of increased liberation of PCBs following weight loss in 
obese subjects with T2D are unknown.  
 Previous studies in our laboratory demonstrated that low concentrations of 
coplanar PCB-77 (3,3´,4,4´-tetrachlorobiphenyl), a ligand of the aryl hydrocarbon 
receptor (AhR), promoted adipocyte differentiation and the production of 
proinflammatory adipokines (6). Recent studies showed that PCB-126 
(3,3´,4,4´,5-pentachlorobiphenyl), a coplanar AhR ligand, promoted inflammatory 
gene expression in human preadipocytes and adipocytes, and also increased 
inflammatory gene expression in adipose tissue from wild-type, but not AhR-
deficient, mice (277). Among several inflammatory cytokines stimulated by 
coplanar PCBs in adipocytes (6, 277), tumor necrosis α (TNF-α) is a recognized 
contributor to insulin resistance (278-279). TNF-α promotes insulin resistance 
through downstream alternative phosphorylation of the insulin receptor (IR) 
docking protein, insulin receptor substrate-1 (IRS-1) (280), which prevents 
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phosphorylation of protein kinase B (Akt) (281) and impairs transport of glucose 
transporter type 4 vesicles in skeletal muscle and adipose tissue to the plasma 
membrane (282). TNF-α can indirectly contribute to adipocyte insulin resistance 
by promoting lipolysis (283) and/or by inhibiting differentiation (284). 
 In the present study, we defined dose-dependent effects of coplanar PCBs 
on glucose homeostasis in lean mice. To define mechanisms for PCB-induced 
impairment of glucose and insulin tolerance, we quantified expression levels of 
TNF-α in organs contributing to insulin resistance. Moreover, we defined the 
sustainability of PCB-induced impairment of glucose homeostasis in lean mice in 
reference to organ and serum concentrations of PCBs. To delineate the role of 
AhR in effects of PCBs, we examined in vitro and in vivo effects of an AhR 
antagonist on parameters of glucose homeostasis. Because T2D is frequently 
associated with obesity, we examined effects of a coplanar PCB on glucose 
homeostasis in obese mice. In addition, because PCBs redistribute from adipose 
tissue to the circulation during weight loss, we determined effects of previous 
PCB exposures on glucose homeostasis in obese mice experiencing weight loss.  
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2.3 Materials and Methods 
2.3.1 Chemicals  
 We purchased PCB-77 and PCB-126 from AccuStandard Inc. (New 
Haven, CT). 2-Methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-
phenyl-amide; CH-223191) was a generous gift from H. Swanson (University of 
Kentucky, Lexington, KY).  
2.3.2 Animal treatments and sample collection 
 All experimental procedures met the approval of the Animal Care and Use 
Committee of the University of Kentucky. We treated animals humanely and with 
regard for alleviation of suffering. Male C57BL/6 mice (2 months of age; The 
Jackson Laboratory, Bar Harbor, ME) were given ad libitum access to food and 
water and housed in a pathogen-free environment. Initial studies examined 
glucose and insulin tolerance in mice administered vehicle (tocopherol-stripped 
safflower oil), PCB-77 (2.5, 50, or 248 mg/kg; by oral gavage given as two 
separate doses over 2 weeks; n = 10 mice/group), or PCB-126 (0.3, 1.6, or 3.3 
mg/kg once by oral gavage; n = 10 mice/group). Mice in dose–response studies 
were fed a low fat diet (LF; 10% kcal as fat; Research Diets Inc., New Brunswick, 
NJ).  
 To define the sustainability of PCB effects, we performed temporal studies 
in mice fed a LF diet. Mice were administered vehicle or PCB-77 (50 mg/kg by 
oral gavage) once in week 1 and once in week 2. For mice examined at later time 
points (12 weeks), a second set of treatment by oral gavages was administered 
in weeks 9 and 10. Mice in each treatment group (vehicle or PCB-77) were 
50 
 
examined at weeks 2, 4, or 12 after onset of feeding with LF diet. Body weights 
were quantified weekly in all studies. At the study end point, mice were 
anesthetized (ketamine/xylazine, 10/100 mg/kg, by intraperitoneal (ip) injection] 
for exsanguination and tissue harvest (liver, soleus muscle, and visceral 
adipose). A subset of mice (n = 5/group) in each treatment group were 
administered insulin [10 U/kg (285)] 10 min before exsanguination to elicit insulin 
signaling pathways. 
 For studies examining obesity and weight loss, male C57BL/6 mice (2 
months of age; n = 10/group) were fed a high fat diet (HF; 60% kcal as fat; 
Research Diets Inc.) for 12 weeks and administered vehicle or PCB-77 (50 
mg/kg by oral gavage) at weeks 1, 2, 9, and 10. Body weight was quantified 
weekly. At 12 weeks of HF feeding, a subset of mice (n = 3/group) was 
anesthetized for exsanguination and tissue harvest. The remaining mice in each 
treatment group were then fed the LF diet for 4 weeks to induce weight loss. 
 To determine whether in vivo effects were AhR-mediated, we fed male 
C57BL/6 mice (2 months of age; n = 7/group) the LF diet and orally gavaged 
them with vehicle or CH-223191 daily (10 mg/kg/day) (286-287) starting 1 week 
before administration of vehicle or PCB-77 and through the remainder of the 
study. After 1 week of pretreatment with CH-233191, mice were administered 
vehicle or PCB-77 (50 mg/kg by oral gavage, given as two separate doses in 
weeks 1 and 2). Within 48 hr after the last dose of vehicle/PCB-77, we performed 
glucose and insulin tolerance tests.  
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2.3.3 Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) 
 Mice were fasted for 6 hr or 4 hr prior to quantification of GTT or ITT, 
respectively. Blood collected from the tail vein was tested for glucose 
concentration using a handheld glucometer (Freedom Freestyle Lite; Abbott 
Laboratories, Abbott Park, IL). Mice were injected with d-glucose (20% in saline, 
ip) or human insulin (Novolin, 0.0125 μM/g body weight, ip) and blood glucose 
was quantified at 0–120 min. Total area under the curve (AUC; arbitrary units), 
which is obtained without the presence of a baseline, calculates the area below 
the observed concentrations and, in comparison studies, was reported to 
compare favorably to the positive incremental area method for statistical 
analyses of glucose tolerance data (288). 
2.3.4 Quantification of PCBs 
 Frozen tissue samples (epididymal adipose tissue, liver, and skeletal 
muscle) or mouse sera were spiked with surrogate standards (100 μL of 0.35 
ng/μL PCB-166 in isooctane). After the addition of 1.0 g of diatomaceous earth, 
the mixture was grained into fine powders and transferred into an extraction cell 
filled with Ottawa Sands (Thermo Fisher Scientific, Pittsburgh, PA). Extraction 
with hexane (30 mL) was performed using an ASE 200 accelerated solvent 
extractor (Dionex Corporation, Sunnyvale, CA). Lipids were removed by the 
addition of an equal volume of concentrated sulfuric acid. For adipose samples 
containing high lipid content, hexane extracts were subjected to delipidation by 
passing them over a Florisil SPE column, according to the manufacturer’s 
instructions, before acid treatment. The hexane layer containing PCBs was 
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collected and concentrated to 2 mL using a Heidolph Synthesis1 evaporator 
(Heidolph, Schwabach, Germany) and then to 100 μL using a gentle stream of 
nitrogen. Then, 10 μL of of internal standard PCB-209 (1.0 ng/μL) was added.  
 Gas chromatographic analysis was performed with a gas chromatography 
(GC)–mass spectrometry (MS) system (Agilent 6890N GC, G2913A auto 
sampler, and 5975 MS detector; Agilent Technologies, Santa Clara, CA) using an 
HP-5MS 5% phenyl methyl siloxane column (30 m length, 0.25 mm internal 
diameter, 0.25 μm film thickness). The column temperature was held at 60°C for 
1 min, increased to 200°C at a rate of 40°C/min, followed by a rate of 4°C/min to 
280°C, and then held for 5.5 min. The injector temperature was 250°C. The 
carrier gas was ultrapure helium, and the makeup gas was nitrogen. PCBs were 
identified on the basis of their retention times relative to standards. Quantification 
was achieved based on calibration curves obtained using PCB standards. The 
recovery efficiency was calculated from the surrogates and the sample weight. 
2.3.5 Quantification of plasma components  
 We quantified plasma insulin concentrations using a commercial ELISA 
(Crystal Chem, Downers Grove, IL). Plasma TNF-α and interleukin-6 (IL-6) 
concentrations were quantified using a commercial Milliplex MAP Mouse Serum 
Adipokine kit (Millipore, St. Charles, MO). 
2.3.6 Extraction of RNA and quantification of mRNA abundance using real-
time polymerase chain reaction (PCR)  
 Total RNA was extracted from tissues using the SV Total RNA Isolation 
System kit (Promega Corporation, Madison, WI) (6). RNA concentrations were 
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quantified and cDNA was synthesized from total RNA and amplified using an 
iCycler (Bio-Rad, Hercules, CA) with the Perfecta SYBR Green Fastmix for iQ 
(20 μL; Quanta Biosciences, Gaithersburg, MD). Using the difference from 18S 
rRNA (reference gene) and the ΔΔCt method, we calculated the relative 
quantification of gene expression. The PCR reaction was 94°C for 5 min, 40 
cycles at 94°C for 15 sec, 58°C or 64°C (based on tested primer efficiency) for 40 
sec, 72°C for 10 min, and 100 cycles from 95°C to 45.5°C for 10 sec. Primer 
sequences were as follows: 18S, forward 5´AGTCGGCATCGTTTATGGTC-3´, 
reverse 5´-CGAAAGCATTTGCCAAGAAT-3´; CYP1A1 (cytochrome P450 1A1), 
forward 5´AGTCAATCTGAGCAATGAGTTTGG-3´, reverse 5´-
GGCATCCAGGGAA GAGTTAGG-3´; F4/80 (macrophage marker), forward 5´-
CTTTGGCTATGGGCTTCCAGTC-3´, reverse 5´-
GCAAGGAGGACAGAGTTTATCGTG-3´; TNF-α, forward 5´-
CCCACTCTGACCCCTTTACTC-3´, reverse 5´-TCACTGTCCCAGCATCTTGT-
3´.  
2.3.7 Western blotting 
 Tissues (liver, soleus muscle, and epididymal adipose tissue) were 
homogenized in mammalian protein extraction reagent (M-PER; Thermo 
Scientific, Rockford, IL), sonicated, and centrifuged, and supernatants were used 
to quantify protein. Proteins were resolved on 4–15% precast polyacrylamide 
gels (Bio-Rad) and transferred onto a polyvinylidene difluoride transfer mem-
brane (GE Healthcare, Buckinghamshire, UK); nonspecific proteins were blocked 
for 1 hr at room temperature [5% nonfat milk in phosphate-buffered saline (PBS) 
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in 0.1% Tween-20 for 60 min at 25°C]. Membranes were then incubated with 
primary antibody: rabbit anti-TNF-α (1:1,000; Novus Biologicals, Littleton, CO), 
mouse β-actin (1:5,000; Cell Signaling Technology, Beverly, MA) in diluted PBS 
overnight at 4°C. After stripping primary antibody, membranes were incubated 
with secondary goat anti-rabbit IgG horseradish peroxidase–linked antibody 
(1:5,000; Cell Signaling Technology) for 1 hr at room temperature. Protein levels 
were quantified using Kodak Molecular Imaging Software (Carestream Health 
Inc., Rochester, NY). 
2.3.8 Cell culture  
 3T3-L1 mouse preadipocytes, obtained from American Type Culture 
Collection (Manassas, VA) were cultured as described previously (6). 
Differentiation was induced by incubating cells for 2 days with media containing 
insulin (0.1 μM; Sigma Chemical Co., St. Louis, MO), dexamethasone (1 μM; 
Sigma), and isobutylmethyl xanthine (IBMX; 0.5 mM; Sigma), and then 
incubating with insulin for 1 additional day. Assays (n = 3/group) were performed 
on duplicate wells of cells. Differentiated adipocytes (day 8) were incubated with 
vehicle [0.03% dimethyl sulfoxide (DMSO)] or PCB-77 (3.4 μM) for 24 hr (6). The 
concentration of PCB-77 was based on the maximum serum level of PCB-77 
(0.84 μg/g, converted to ≈ 3 μM) measured in experimental mice, as described 
above, at week 2 after administration of PCB-77 (50 mg/kg). Adipocytes from 
each treatment group were incubated with the AhR antagonist α-naphthoflavone 
(α-NF; 20 μM) for 30 min before adding vehicle or PCB-77 (3.4 μM).  
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2.3.9 Statistical analysis  
 Data are represented as mean ± SE. Total AUC and mRNA abundance 
data were log-transformed. We used one-way analysis of variance (ANOVA; 
SigmaPlot, version 12.0; Systat Software Inc., Chicago, IL) to define treatment 
effects of different doses of PCBs and for studies using CH-223191. In studies 
examining sustainability of PCB effects in lean mice, total AUC was analyzed 
using two-way ANOVA with the Holm-Sidak method for post hoc analysis. In 
studies of obese mice and mice undergoing weight loss, we performed a mixed 
model analysis of repeated measures and analyzed total AUC using two-way 
ANOVA (JMP, version 10; SAS Institute Inc., Cary, NC). Statistical significance 
was defined as p < 0.05. 
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2.4 Results 
2.4.1 Coplanar PCBs dose-dependently impair glucose and insulin tolerance 
in LF-fed mice in an AhR-dependent manner  
 We defined dose-dependent effects of two coplanar PCBs (PCB-77 and 
PCB-126)—both of which are prevalent in the environment (289) and/or linked to 
T2D (270, 290)—on glucose and insulin tolerance in LF-fed mice. Forty-eight 
hours after the final dose, animals treated with PCB-77 (50 mg/kg) or PCB-126 
(1.6 mg/kg) showed a significant increase in blood glucose concentrations, 
compared with controls, in response to a bolus of administered glucose (Figure 
2.1A and B, respectively; p < 0.05). The total AUC for blood glucose 
concentrations was significantly increased in mice treated with PCB-77 or 
PCB-126 (Figure 2.1C and D, respectively; p < 0.05). Similarly, blood glucose 
concentrations in response to insulin administration were significantly increased 
in mice administered PCB-77 (50 mg/kg) or PCB-126 (3.3 mg/kg) (Figure 2.2A 
and B, respectively; p < 0.05), resulting in a significant increase in total AUC 
(Figure 2.2C and D, respectively; p < 0.05). Fasting plasma insulin con-
centrations were similar in mice administered vehicle (mean ± SE, 0.18 ± 0.10) or 
PCB-77 (0.19 ± 0.09 ng/ml; p > 0.05). On the basis of a higher prevalence of 
PCB-77 in food compared with PCB-126 (291), we used PCB-77 in further 
studies examining mechanisms of glucose and insulin intolerance.  
 To determine whether in vivo effects of PCB-77 are AhR-mediated, we 
defined effects of CH-223191, an AhR antagonist, on PCB-77–induced 
impairment of glucose and insulin tolerance in LF-fed mice. Administration of 
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PCB-77 significantly impaired glucose and insulin tolerance compared with 
vehicle, and these effects of PCB-77 were abolished in mice administered CH-
223191 (Figure 2.3; p < 0.05). 
2.4.2 PCB-77 treatment results in sustained impairment of glucose and insulin 
tolerance in LF-fed mice  
 To define the duration of PCB-induced impairment of glucose tolerance, 
we administered vehicle or PCB-77 (50 mg/kg) to LF-fed (12 weeks) male 
C57BL/6 mice in two doses in weeks 1 and 2 of LF feeding, and then again in 
weeks 9 and 10 of LF feeding. Body weight was not significantly different in mice 
administered vehicle (mean ± SE, 27 ± 1 g) or PCB-77 (28 ± 1 g; p > 0.05). 
Glucose tolerance was significantly impaired in PCB-77–treated mice compared 
with controls from weeks 2 to 12 of LF feeding (Figure 2.4A). Insulin tolerance 
was significantly impaired in PCB-77–treated mice compared with controls on 
weeks 2 and 4 (Figure 2.4B). 
 Due to their lipophilicity, PCBs accumulate in adipose tissue (8). We 
quantified levels of PCB-77 in retroperitoneal white adipose (RPF), liver, skeletal 
muscle, and serum following administration of PCB-77. PCB-77 levels were 
undetectable in tissues or serum from vehicle-treated mice; in addition, PCB-77 
was not detected in skeletal muscle from either treatment group. At week 2, 
PCB-77 levels in RPF (mean ± SE, 192 ± 36 μg/g) were 10 and 384 times those 
in liver or serum (19 ± 1 and 0.5 ± 0.2 μg/g, respectively). At week 3, PCB-77 
levels in RPF (91 ± 37 μg/g) were decreased (by 53%) compared with those in 
week 2 (192 ± 36 μg/g) and were markedly decreased by weeks 4 and 12.  
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 Previous studies showed that PCB-77 increased TNF-α mRNA abundance 
in 3T3-L1 adipocytes (6). Thus, we contrasted effects of PCB-77 on TNF-α 
expression in adipose tissue compared with liver and skeletal muscle. As 
evidence of AhR activation by PCB-77, mRNA abundance of CYP1A1, an AhR 
target gene (32), was significantly increased in adipose tissue from PCB-77–
treated mice compared with controls (Figure 2.5A). By comparison, CYP1A1 
mRNA abundance was significantly increased in livers of PCB-77–treated mice 
compared with controls at week 2 but not at later time points (Figure 2.5B). 
Although TNF-α mRNA expression in adipose tissue of PCB-77–treated mice did 
not reach statistically significant levels (Figure 2.6A), TNF-α protein was 
significantly increased at week 4 (Figure 2.7; p < 0.05). Plasma concentrations of 
TNF-α were significantly increased in PCB-77–treated mice compared with con-
trols (Figure 2.8A; p < 0.05). Plasma concentrations of IL-6 were significantly 
increased at week 12 in mice administered PCB-77 compared with vehicle 
controls (Figure 2.8B; p < 0.05).  
 Infiltration of macrophages into adipose tissue has been suggested as a 
mechanism contributing to low-grade inflammation from obesity and the 
development of insulin resistance (292). Adipose tissue from mice administered 
PCB-77 exhibited statistically similar mRNA abundance of the macrophage 
marker F4/80 compared with controls (Figure 2.6B). 
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2.4.3 Effects of PCB-77 to promote glucose and insulin intolerance are lost in 
mice with diet-induced obesity, but manifest when obese mice lose weight   
 Obesity is associated with the development of insulin resistance in T2D 
(293). Moreover, obesity increases the total body burden of lipophilic PCBs (9). 
Thus, we examined effects of PCB-77 on glucose and insulin tolerance in mice 
fed a HF diet for 12 weeks (weight gain phase). In addition, we examined effects 
of PCB-77 on glucose and insulin tolerance in HF-fed obese mice (12 weeks) 
that were switched to the LF diet for 4 weeks to induce weight loss (weight loss 
phase). During the weight gain phase, PCB-77 treatment had no significant effect 
on body weight in mice fed either the LF or HF diet compared with controls 
(Figure 2.9A). Surprisingly, PCB-77 treatment had no effect on glucose or insulin 
tolerance in HF-fed mice (weeks 4 or 12; Figure 2.10A and B; weight gain 
phase). Moreover, abundance of TNF-α mRNA in adipose tissue was not 
significantly different in PCB-77–treated mice compared with controls (Figure 
2.11). At 12 weeks, adipose tissue levels of PCB-77 (1.8 ± 0.5 μg/g tissue, wet 
weight) in mice fed the HF diet were 2 times those observed in adipose tissue 
from LF-fed mice.  
 Previous studies showed that plasma concentrations of PCBs increased in 
obese subjects experiencing weight loss (294). Thus, we defined effects of 
PCB-77 administered during the weight gain phase of HF feeding on glucose 
homeostasis during weight loss. Administration of PCB-77 during the weight gain 
phase had no effect on body weight reductions during the weight loss phase 
(Figure 2.9B). Glucose tolerance was significantly improved by weight loss in 
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vehicle- or PCB-77–treated mice (week 16 vs. week 12; Figure 2.10A; p < 0.05). 
Insulin tolerance was also significantly improved by weight loss in vehicle-treated 
mice (week 16 vs. week 12; Figure 2.10B; p < 0.05). However, compared with 
controls, mice administered PCB-77 exhibited impaired glucose (Figure 2.10A; p 
< 0.05) and insulin tolerance (Figure 2.10B; p < 0.05) during the weight loss 
phase. Weight loss resulted in a significant decrease in TNF-α mRNA abundance 
in adipose tissue from mice administered vehicle or PCB-77 (Figure 2.11; p < 
0.05). However, PCB-77–treated mice had significantly increased TNF-α mRNA 
abundance in adipose tissue during weight loss (Figure 2.11; p < 0.05).  
2.4.4 PCB-77 results in an AhR-dependent increase in expression of TNF-α in 
3T3-L1 adipocytes  
 Previous studies demonstrated that PCB-77 increased mRNA abundance 
of TNF-α in 3T3-L1 adipocytes (6). TNF-α is an intermediate in reactive oxygen 
species generated by 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD), an AhR 
ligand (295). To define mechanisms for effects of coplanar PCBs to promote 
glucose and insulin intolerance, we examined effects of PCB-77 on TNF-α 
expression in 3T3-L1 adipocytes. Moreover, to determine whether effects of 
PCB-77 are AhR-mediated, we incubated cells with an AhR antagonist, α-NF. 
Incubation of differentiated 3T3-L1 adipocytes with PCB-77 significantly 
increased CYP1A1 mRNA abundance, indicative of AhR activation (Figure 
2.12A; p < 0.05), which was abolished by α-NF. Similarly, PCB-77-induced 
increases in TNF-α mRNA were abolished by α-NF in 3T3-L1 adipocytes (Figure 
2.12B; p < 0.05). 
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2.5 Discussion 
 Results from this study indicate that coplanar PCBs induce rapid and 
sustained glucose and insulin intolerance in lean mice in an AhR-dependent 
manner. These effects were associated with pronounced accumulation of PCB to 
adipose tissue, most likely contributing to adipose-specific increases in 
expression of TNF-α. Remarkably, in PCB-exposed mice that became obese 
from consumption of a HF diet, the harmful effects of the toxicant promotion of 
glucose and insulin intolerance were lost. However, when the PCB-exposed 
obese mice lost weight, glucose and insulin tolerance were impaired, mitigating 
the beneficial effects of weight loss to improve glucose homeostasis. Moreover, 
adipose expression levels of TNF-α, while not influenced by PCB-77 during the 
weight gain phase of HF feeding, were increased upon weight loss. In cultured 
adipocytes, PCB-77 promoted TNF-α expression through an AhR-dependent 
mechanism. These results suggest that PCBs could promote insulin resistance 
through adipose-specific increases in TNF-α. Moreover, these results suggest 
that in obese mice with a greater body burden of PCBs, the concentration of PCB 
was increased in adipose tissue, resulting in increased adipose TNF-α 
expression and insulin resistance upon liberation of PCBs during weight loss.  
 Increasing evidence suggests that background exposure to persistent 
organic pollutants is linked to the development of T2D. U.S. Air Force veterans of 
the Vietnam War who were exposed to Agent Orange contaminated with dioxin 
had increased risk of diabetes, reduced time-to-onset of disease, and increased 
diabetes severity (154). In a cross-sectional study among the general population 
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of Japan and covering the years 2002–2006, blood levels representing the 
highest quartiles of PCB-126 and PCB-105 had adjusted odds ratios of 9.1 and 
7.3, respectively (296). Recent results from the Anniston Community Health 
Survey demonstrated significant associations between elevated PCB levels and 
diabetes (158). Serum levels of PCB-77 in the present study (≈ 3 μM) were 
similar to levels (1.43 ppb, equivalent to ≈ 0.5 μM) observed in the lowest quartile 
of subjects from the Anniston study (158). Our results demonstrate that lean mice 
respond to coplanar PCBs with impaired glucose and insulin tolerance, 
supporting an interaction between PCB exposures and the development of 
insulin resistance. We used this mouse model of PCB-induced glucose and 
insulin intolerance to define mechanisms linking PCB exposures to dysregulated 
glucose homeostasis. 
 In the present study we demonstrated that PCB-77, a coplanar PCB 
abundant in the environment (289), as well as PCB-126, a coplanar PCB that has 
been linked to diabetes (290), both resulted in dose-dependent rapid impairment 
of glucose and insulin tolerance in lean mice. Interestingly, mice exposed to the 
highest dose of either PCB did not have impaired glucose or insulin tolerance; 
however, these mice demonstrated abnormal behavior (lethargy, tremors), 
polyuria, and gained minimal weight (unpublished observations), suggesting that 
higher doses of PCB had deleterious health consequences. Recent studies 
demonstrated that consumption of farmed salmon containing persistent organic 
pollutants, including increased levels of seven different PCBs, promoted glucose 
intolerance associated with elevations in adipose tissue expression of TNF-α in 
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HF-fed mice (88). Interestingly, when levels of pollutants were decreased by 
feeding farm-raised salmon purified fish oil, glucose tolerance improved and 
adipose expression levels of TNF-α decreased. Our results are in agreement with 
these findings, and extend these studies by demonstrating that individual 
coplanar PCBs promote glucose and insulin intolerance associated with adipose-
specific elevations in expression of TNF-α. Moreover, similar to previous findings 
(88), adipose contained markedly higher PCB levels than did liver and serum, 
suggesting that chronic exposures of adipocytes to PCBs most likely contributed 
to selective increases in TNF-α expression in adipose tissue but not in liver or 
muscle. 
 Previous studies in our laboratory demonstrated that coplanar PCBs 
increased abundance of TNF-α mRNA in cultured adipocytes (6). Results from 
the present study demonstrate that PCB-77–induced increases in TNF-α 
expression are AhR mediated. Moreover, the concentrations (3.4 μM) of PCB-77 
used in our in vitro studies with cultured adipocytes were comparable to serum 
levels (3 μM) of PCB-77 that induced glucose and insulin intolerance in mice. 
Kim et al. (277) reported that exposures of 3T3-L1 adipocytes to dioxin increased 
mRNA abundance of several proinflammatory factors, including TNF-α receptors. 
In that study, when dioxin was administered to mice fed standard mouse diet, 
abundance of TNF-α mRNA in adipose tissue was markedly increased, and this 
effect was abolished in AhR deficient mice. Results of the present study confirm 
and extend previous studies by demonstrating that in vivo effects of PCB-77 to 
impair glucose homeostasis are AhR mediated. An interesting finding of our 
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study was that levels of PCB-77 in adipose tissue were markedly decreased 4 
weeks after the last dose; however, mice continued to exhibit glucose and insulin 
intolerance. PCB-induced activation of AhR induces CYP1A1 gene expression, 
which hydroxylates the toxicant to increase water solubility for elimination. Our 
findings of rapid declines in levels of PCB-77, in the face of sustained impairment 
of glucose homeostasis, suggest that metabolites of PCB-77 may have 
contributed to long-lasting impairment of glucose and insulin intolerance in mice.  
 In this study, although PCB-77 impaired glucose and insulin tolerance in 
lean mice, these effects were lost when mice were fed a HF diet. The lipophilic 
nature of PCBs results in their accumulation in adipocyte lipid-containing 
droplets. For example, in humans, body mass index is inversely correlated with 
serum levels of PCBs, supporting the concept that an expanded adipose mass 
results in redistribution of PCBs away from the circulating compartment (273). In 
support, Kim et al. (9) reported an increased (2.9-fold) total body burden of PCBs 
in obese subjects. Thus, sequestration of PCB-77 in adipocyte lipid pools, as 
demonstrated by higher levels in adipose tissue from HF-fed mice in the present 
study, most likely resulted in restricted access to AhR, contributing to a lack of 
effect of PCB-77 on glucose and/or insulin tolerance in obese mice. Alternatively, 
effects of PCB-77 to impair glucose homeostasis may have become apparent 
with longer durations of HF-feeding. Previous studies found that plasma levels of 
13 of 17 measured organochlorines in human serum increased with weight loss 
(276). Similarly, obese subjects experiencing drastic weight loss from bariatric 
surgery had increased serum levels of PCBs, which decreased the beneficial 
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effects of weight loss (9). In agreement with previous findings, our results 
demonstrate that beneficial effects of weight loss to improve glucose and insulin 
tolerance in mice were blunted in mice administered PCB-77. Moreover, our 
results extend previous findings by showing that elevations in TNF-α in adipose 
tissue may have contributed to impaired glucose and insulin tolerance in PCB-
exposed mice experiencing weight loss. 
 Results from this study demonstrate that coplanar PCBs cause rapid and 
sustained impairment of glucose and insulin tolerance in mice through an AhR-
dependent mechanism associated with an adipose-specific increase in TNF-α 
expression. Although harmful effects of PCB-77 on glucose and insulin tolerance 
were absent in obese mice, beneficial effects of weight loss to improve glucose 
and insulin tolerance were mitigated in mice previously exposed to PCB-77. 
These results suggest that sequestration of lipophilic coplanar PCBs to adipose 
tissue may contribute to AhR-mediated increases in TNF-α and the development 
of adipocyte insulin resistance, an effect manifest in lean conditions as well as 
during weight loss when adipose-derived toxicants may be liberated. 
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Figure 2.1.  PCB-77 (A) and PCB-126 (B) impair glucose tolerance in LF-fed 
mice.  (A), Blood glucose concentrations following a bolus of glucose in mice 
administered vehicle (VEH), 2.5, 50 or 248 mg/kg of PCB-77 (48 hours after the 
second dose).  (B), Blood glucose concentrations following a bolus of glucose in 
mice administered vehicle, 0.3, 1.6 or 3.3 mg/kg of PCB-126 (48 hours after the 
second dose).  Data are mean ± SEM from n = 5 mice/dose of PCB.  *, P < 0.05 
compared to VEH within a time point.  (C,D), Quantification of total area under 
the curve (AUC) for data in A, B, respectively.  *, P < 0.05 compared to VEH. 
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Figure 2.2.  Insulin tolerance tests in mice administered vehicle (VEH), 
PCB-77 (2.5, 50 or 248 mg/kg, A) or PCB-126 (0.3, 1.6 or 3.3 mg/kg, B).  At 48 
hours after the last dose, insulin (0.0125 µM/gm body weight) was administered 
to mice from each treatment group and blood glucose concentrations quantified 
at several time points.  (C, D), Total area under the curve (AUC) for data in A, B, 
above.  Data are mean ± SEM from n = 5 mice/group.  *, P < 0.05 compared to 
vehicle.
70 
 
 
71 
 
Figure 2.3.  Glucose (A) and insulin (B) tolerance tests in mice administered 
vehicle (VEH), CH-223191 (10 mg/kg/day), or PCB-77 (50 mg/kg).  (C, D) 
Total area under the curve (AUC) for data in A, B, above.  Data are mean ± SEM 
from n ≥ 7 mice/group.  *, P < 0.05 compared to vehicle.  **, P < 0.05 compared 
to PCB77. 
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Figure 2.4.   PCB-77 results in sustained impairment of glucose (A) and 
insulin (B) tolerance in LF-fed mice.  Mice were administered vehicle (VEH) or 
PCB-77 (50 mg/kg, two divided doses during weeks 1 and 2, a second set of 2 
doses during weeks 9 and 10 for mice studied at 12 weeks).  At 2, 4 or 12 weeks, 
mice in each treatment group were administered a bolus of glucose (20% 
glucose, A) or insulin (0.0125 µM/gm body weight, B) and blood glucose 
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concentrations were quantified.  Total area under the curve (AUC) for blood 
glucose concentrations were quantified.  Data are mean ± SEM from n > 5 
mice/group.  *, P < 0.05 compared to VEH within time point. 
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Figure 2.5.  PCB-77 increases mRNA abundance of CYP1A1 in adipose (A) 
and liver (B) of LF-fed mice.  Mice were administered vehicle (VEH) or PCB-77 
(50 mg/kg, 2 doses in weeks 1 and 2, second 2 doses in weeks 9 and 10 for 12 
week mice).  (A), CYP1A1 mRNA abundance was increased in adipose at 1 and 
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4 weeks, but not 12 weeks after PCB-77 administration.  (B), CYP1A1 mRNA 
abundance was increased in liver at week 2, but not week 4 after PCB-77 
administration.  Data are mean ± SEM from n > 3 mice/group.  *, P < 0.05 
compared to VEH. 
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Figure 2.6.  TNF-α (A) and F4/80 (B) mRNA abundance in adipose from mice 
administered vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses in weeks 1, 2, and 
then in weeks 9, 10 for mice euthanatized at week 12).  Data are mean ± SEM 
from n = 6 mice/group. 
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Figure 2.7.  PCB-77 results in elevated TNF-α expression in adipose, but 
not in liver or soleus muscle of LF-fed mice.  Mice were administered vehicle 
(VEH) or PCB-77 (50 mg/kg, 2 doses) and expression levels of TNF-α quantified 
in adipose, liver or soleus muscle 2 weeks later (week 4).  Data are mean ± SEM 
from n = 3 mice/group.  *, P < 0.05 compared to VEH. 
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Figure 2.8.  Plasma concentrations of TNF-α (A) and IL-6 (B) following 
administration of vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses in weeks 1 and 
2, second 2 doses in weeks 9 and 10).  Data are mean ± SEM from n = 10 
mice/group.  *, P < 0.05 compared to VEH.   
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Figure 2.9.  Body weight in LF and HF-fed mice administered vehicle (VEH) 
or PCB-77 (50 mg/kg, doses in weeks 1, 2,  9, and 10) during the weight 
gain phase of HF feeding (A), and after mice are switched to a LF diet at 
week 12 – 16 to induce weight loss (B).  Body weight was increased in HF 
compared to LF-fed mice beginning on week 4 (A).  Data are mean ± SEM from 
n > 5 mice/group.   
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Figure 2.10.  PCB-77 has no effect on glucose (A) or insulin (B) tolerance in 
HF-fed mice during weight gain, but impairs glucose homeostasis during 
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weight loss.  (A), Total area under the curve (AUC) for glucose tolerance in mice 
administered vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses during weeks 1 and 2 
and a second 2 doses during weeks 9 and 10) during weight gain (weeks 4, 12 of 
HF feeding) or weight loss (at week 16 after mice are switched to a LF diet).  
Data are mean ± SEM from n > 5 mice/group.  *, P < 0.05 compared to week 12 
within treatment group.  **, P < 0.05 compared to VEH within time point.    
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Figure 2.11.  TNF-α mRNA abundance in adipose from mice during weight 
gain (week 12 of HF feeding), and after mice are switched to a LF diet to 
induce weight loss (week 16).  Data are mean ± SEM from n > 3 mice/group.  *, 
P < 0.05 compared to week 12 within treatment group.  **, P < 0.05 compared to 
VEH within time point. 
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Figure 2.12.  CYP1A1 (A) and TNF-α (B) mRNA abundance in 3T3-L1 
adipocytes incubated with vehicle, α-NF, PCB-77, or PCB-77 + α-NF.  Data 
are mean ± SEM from n = 3 experiments.  *, P < 0.05 compared to vehicle.  **, P 
< 0.05 compared to PCB-77. 
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SECTION III. SPECIFIC AIM 2 
3.1 Summary 
 Resveratrol (RSV) is a plant polyphenol that exhibits several favorable 
effects on glucose homeostasis in adipocytes.  Recent studies from our 
laboratory demonstrated that coplanar polychlorinated biphenyls (PCBs) that are 
ligands of the aryl hydrocarbon receptor (AhR) impair glucose homeostasis in 
mice. PCB-induced impairment of glucose homeostasis was associated with 
augmented expression of inflammatory cytokines in adipose tissue, a site for 
accumulation of lipophilic PCBs.  This study determined if RSV protects against 
PCB-77 induced impairment of glucose disposal in vitro and in vivo, and if these 
beneficial effects are associated with enhanced nuclear factor erythoid 2-related 
factor 2 (Nrf2) signaling in adipose tissue.  PCB-77 increased oxidative stress 
and abolished insulin stimulated 2-deoxy-D-glucose (2DG) uptake in 3T3-L1 
adipocytes.  These effects were restored by RSV, which resulted in a 
concentration-dependent increase in NAD(P)H:quinone oxidoreductase 1 
(NQO1), a downstream target of Nrf2 signaling.  We quantified glucose and 
insulin tolerance and components of Nrf2 and insulin signaling cascades in 
adipose tissue of male C57BL/6 mice administered vehicle or PCB-77 (50 mg/kg) 
and fed a diet with or without resVida® (0.1%, or 160 mg/kg/day).  PCB-77 
impaired glucose and insulin tolerance, and these effects were reversed by RSV.  
PCB-77 induced reductions in insulin signaling in adipose tissue were also 
abolished by RSV, which increased NQO1 expression.  These results 
demonstrate that coplanar PCB-induced impairment of glucose homeostasis in 
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mice can be prevented by RSV, potentially through stimulation of Nrf2 signaling 
and enhanced insulin stimulated glucose disposal in adipose tissue. 
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3.2 Introduction 
 Polychlorinated biphenyls (PCBs) are persistent organic pollutants that are 
highly lipophilic and tend to bio-accumulate in the environment.  Although 
industrial use of these compounds was banned in the U.S. in the 1970’s, recent 
studies have estimated that the average American is exposed to approximately 
33 ng of PCBs per day through the diet (11).  Several epidemiological studies 
suggest that exposure to low concentrations of PCBs may promote type 2 
diabetes (T2D) in humans (268, 297).  Notably, recent results from the Anniston 
Community Health Survey demonstrated significant associations between 
elevated PCB levels and diabetes risk (158).  Largely resulting from 
accumulating evidence linking PCB exposures to diabetes, the National Institute 
of Environmental Health Studies (NIEHS), Division of the National Toxicology 
Program (NTP) hosted a workshop to review approximately seventy-five different 
epidemiology studies linking persistent organic pollutants (POPs), including 
coplanar PCBs, to T2D outcomes.  A publication from the workshop concluded 
that there is evidence for a positive association between POP exposures and the 
development of T2D (23).  The summary of the workshop also called for 
additional studies to define mechanisms linking PCBs and other POPs to 
increased risk for diabetes. 
 We recently demonstrated that coplanar PCBs that are ligands of the aryl 
hydrocarbon receptor (AhR) impair glucose homeostasis in C57BL/6 mice (7).  
These effects were associated with inflammation in adipose tissue, a site for 
pronounced PCB accumulation (7).  Similarly, recent studies demonstrated that 
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2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD), an AhR ligand, promoted low grade 
inflammation in adipocytes in vitro and in vivo (277).  Generation of reactive 
oxygen species (ROS) by AhR ligands such as TCDD or PCBs in adipocytes 
may contribute to low grade inflammation and the development of insulin 
resistance (298).   
 The plant polyphenol, resveratrol (RSV), exerts several protective effects 
in adipocytes.  In 3T3-L1 adipocytes RSV inhibited stimulation of inflammatory 
adipokines (265, 299-304).  As a mechanism for protective effects of RSV, 
reductions in oxidative stress by RSV are associated with activation of nuclear 
factor erythoid 2-related factor 2 (Nrf2) (247, 305-306), a component of the anti-
oxidant pathway.  RSV had been demonstrated to protect against insulin 
resistance in cultured adipocytes (241).  Moreover, administration of RSV 
improves glucose tolerance and reduces insulin resistance resulting from 
consumption of a high fat diet (182, 187, 307), in genetically obese rodents (253, 
308-309) and in humans with T2D (213).  Notably, RSV interacts with the AhR, 
resulting in translocation of the receptor to the nucleus; however this interaction 
does not appear to result in transactivation (310-311).  Accordingly, RSV 
attenuates toxic effects of AhR ligands in vitro and in vivo (310, 312-315).  
However, it is unclear if protective effects of RSV extend to PCB ligands of AhR, 
and whether this protection includes restoration of measures of insulin sensitivity 
in adipocytes, a primary site for PCB-induced activation of inflammatory 
cytokines that are linked to the development of insulin resistance (6-7).   
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 In this study, we tested the hypothesis that RSV protects against in vitro 
and in vivo effects of a coplanar PCB (PCB-77) to induce measures of insulin 
resistance.  We selected coplanar PCB-77 for these studies based on its high 
toxicity and abundance within the food chain (289, 291).  Since PCBs 
accumulate markedly in adipose tissue and have been demonstrated to promote 
inflammatory cytokines linked to insulin resistance (6-7), we focused on 
adipocytes as the cell target of PCBs and/or RSV to regulate glucose 
homeostasis.  As a mechanism for effects of PCB and/or RSV, we quantified 
oxidative stress and induction of the Nrf2 anti-oxidant signaling pathway.  Our 
results suggest that RSV may provide therapeutic benefit against PCB-induced 
dysregulation of glucose homeostasis and the development of diabetes. 
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3.3 Materials and Methods 
3.3.1 Materials 
 3,3’,4,4’-tetrachlorobiphenyl (PCB-77) was purchased from AccuStandard 
Inc. (New Haven, CT). 2-deoxyglucose (2DG), bovine insulin (0.1 μM for 
adipocyte differentiation), dexamethasone (1 μM), and isobutylmethyl xanthine 
(0.5 mM, IBMX) were obtained from Sigma Aldrich (St. Louis, MO). The resVida® 
(>99% pure trans-resveratrol) was provided by DSM Nutrition Products, Inc 
(Heerlen, NL). 
3.3.2 Quantification of PCB-77, RSV, and metabolites in serum and tissues  
 PCB-77, hydroxyPCB-77 and RSV were measured using a Shimadzu 
UFLC coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap triple 
quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode. d6-
PCB-77 was used as internal standard for PCB-77 and hydroxyPCB-77 
measurements. D4-RSV was used as an internal standard for resveratrol and its 
metabolite measurements. The mass spectrometer was operated in the positive 
APCI mode for PCB-77 measurements and in negative ESI mode for 
hydroxyPCB-77 and RSV measurements with optimal ion source settings 
determined by synthetic standards. PCB-77 was analyzed using Kinetex 2.6 u 
C18, 100 A, 100 X 2.10 mm (Phenomenex) column. The mobile phase consisted 
of water as solvent A and acetonitrile as solvent B. For the analysis of PCBs the 
separation was achieved using a gradient of 20 % B to 60 % B for 1 min, 60% B 
to 100% B in the next 7 min, and maintained at 100% B for the last 2 min with a 
flow rate of 0.25 ml/min. MRM transitions monitored were as follows: 291.9/ 
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222.1 and 291.9/220 for PCB-77; and 297.9/228.1 and 297.9/226.2 for d6-PCB-
77. In the MRM ion transition the precursor ion represents the M⁺· and the 
product ion represents either [M-Cl] ⁺ or [M-2Cl]⁺.  
 HydroxyPCB-77 was analyzed using Luna 3 u C18 (2), 100 A, 250 X 2.00 
mm (Phenomenex) column with a flow rate of 0.25 mL/min. The mobile phase 
consisted of 75/25 of methanol/ water with formic acid (0.5%) and 5 mM 
ammonium formate (0.1%) as solvent A and 99/1of methanol/ water with formic 
acid (0.5%) and 5 mM ammonium formate (0.1%) as solvent B. HydroxyPCB-77 
was eluted using a gradient of 10 % B to 100 % B in 4 min and maintained at 
100% B for the next 11 min. MRM transitions monitored were as follows: 
352.8/306.9 for hydroxyPCB-77 and 368.8/322.9 for dihydroxyPCB-77. Precursor 
ion of the ion transition is a formic acid adduct: [M+FA-H]- and product ion is [M-
H]-.  
3.3.3 Cell culture 
 3T3-L1 mouse preadipocytes purchased from Zen-Bio (Research Triangle 
Park, NC) were cultured in standard Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA) enriched with 10% fetal bovine serum (FBS; 
Gemini Bio-Products, Woodland, CA) and 1% penicillin/streptomycin in 6-well 
culture dishes.  Cells (passage number 5 or lower) were grown to 100% 
confluence at 37°C in a humidified 5% CO2 atmosphere.  Differentiation to 
mature adipocytes was induced as previously described (7). Assays (n = 
2/group) were performed in triplicate.   
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 To examine the effects of PCBs, we incubated differentiated adipocytes 
(day 8) with vehicle [0.03% dimethyl sulfoxide (DMSO)] or PCB-77 (3.4 µM (6-7)) 
for 24 hours in the absence or presence of RSV (0.1 μM, 1 μM, or 10 μM).  RSV 
was added to culture media 30 minutes prior to the addition of vehicle or PCB-77. 
Cells were harvested for glucose uptake and oxidative stress assays in addition 
to mRNA quantification of gene expression. 
3.3.4 Measurement of insulin-stimulated uptake of 2DG 
 To measure uptake of 2DG, differentiated 3T3-L1 adipocytes were 
incubated with appropriate treatments in serum-free media for 6 hours.  Cells 
were washed three times and then incubated with insulin (1 µM) in glucose-free 
Krebs buffer (pH 7.4) containing 2% bovine serum albumin for 20 minutes at 
37oC.  2DG (1 mM) was added to each well and incubated at 37oC for 20 
minutes.  Cells were washed three times with buffer, and 10 mM Tris-HCl was 
added to each well. Following sonication, cell lysates were collected and 2DG 
uptake was quantified per the manufacturer’s instructions (2-Deoxyglucose 
Uptake Measurement kit, Cosmo Bio Co. Ltd., Tokyo, Japan).  2DG uptake was 
normalized to cellular protein. 
3.3.5 Measurement of oxidative stress 
To measure oxidative stress, differentiated 3T3-L1 adipocytes were incubated 
with appropriate treatments for 24 hours.  Cellular oxidation was determined by 
2’,7’-dichlorofluorescein (DCF) fluorescence via the OxiselectTM Intracellular ROS 
Assay kit (Cell Biolabs, Inc., San Diego, CA).  Briefly, this method is based on the 
conversion of 2’,7’-dichlorofluorescin into fluorescent  DCF through oxidation by 
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reactive oxygen species, including super oxide radicals and peroxides.  Following 
appropriate treatments, cells were incubated with 100 µM 2’,7’-dichlorofluorescin 
diacetate for 30 minutes.  A multi-well fluorescent plate reader (Molecular 
Devices, CA) was utilized for measuring relative oxidative stress; excitation and 
emission wavelengths were 480 and 530 nm, respectively. 
3.3.6 Animals and experimental diets 
 All experimental procedures met the approval of the Animal Care and Use 
Committee of the University of Kentucky. Two month old, male, C57BL/6 mice 
(The Jackson Laboratory, Bar Harbor, ME) were housed in a pathogen-free 
environment and given ad libutum access to water and standard mouse diet in 
the absence or presence of  0.1% resVida® (#5SSG, 14.6% kcal as fat, TestDiet, 
Richmond, IN).  Mice were pre-fed diets for 1 week prior to administration of 
vehicle (tocopherol stripped safflower oil, Dyets Inc., 10 µL/g of body weight) or 
PCB-77 (49.6 mg/kg)(n=10 mice/group), given in two divided doses during weeks 
1 and 2.  Body weights were recorded bi-weekly.  Glucose and insulin tolerance 
tests were performed within 48 hours after the second dose as described below.  
At study endpoint, mice were fasted for 4 hours and anesthetized with 
ketamine/xylazine (100/10 mg/kg intraperitoneal (ip) injection). Following 
ketamine injection, a sub-set of mice in each group were injected (i.p.) with 10 
U/kg body weight human insulin (Novolin) to stimulate insulin signaling pathways, 
using methods as described previously (285).   
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3.3.7 Glucose tolerance test (GTT) and insulin tolerance test (ITT) 
 For glucose (GTT) and insulin tolerance tests (ITT), sub-sets of mice in 
each group were examined within 48 hours after the second dose.  Mice were 
fasted for 4 or 6 hours for ITT or GTT, respectively, and fasted blood glucose 
was measured by tail vein using a hand held glucometer (Freedom Freestyle 
Lite, Abbott Laboratories, Abbott Park, IL).  Mice were injected (i.p.) with D-
glucose (Sigma, 20% in saline, 10 µL/g of body weight) for GTT and blood 
glucose was measured at 15, 30, 60, 90, and 120 minutes later.  For ITT, mice 
were injected (i.p.) with human insulin (Novolin, 0.0125 µM in saline/g of body 
weight), and plasma glucose was measured at 30, 60, 90, and 120 minutes later. 
Total area under the curve (AUC; arbitrary units) was calculated as previously 
described (7). 
3.3.8 Quantification of adipose tissue Akt and P-Akt. 
 Epididymal adipose tissue was homogenized and centrifuged, and 
supernatants were stored in 1X Cell Lysis Buffer (Cell Signaling, Danvers, MA). 
Akt and p-Akt concentrations were quantified as per the manufacturer’s 
instructions using a commercial ELISA (Cell Signaling, Beverly, MA), and 
normalized to adipose tissue protein.   
3.3.9 RNA isolation and gene expression analysis using real-time polymerase 
chain reaction (PCR) 
 Total RNA was extracted from epididymal adipose tissue using the SV 
Total RNA Isolation System kit (Promega Corporation, Madison, WI), per the 
manufacturer’s instructions.  RNA from 3T3-L1 cells was extracted in Trizol.  
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RNA concentrations were determined using a NanoDrop 2000 spectophotometer 
and associated software (Thermo Scientific, Logan, UT). cDNA was synthesized 
from 0.4 µg total RNA with qScript cDNA SuperMix (Quanta Biosciences, 
Gaithersburg, MD) in the following reaction:  25°C for 5 minutes, 42°C for 30 
minutes, and 85°C for 5 minutes. The cDNA was diluted 1:50 to achieve a 
concentration of 0.4 ng/µL. The diluted cDNA was amplified with an iCycler (Bio-
Rad, Hercules, CA) and the Perfecta SYBR Green Fastmix for iQ (Quanta 
Biosciences, Gaithersburg, MD).  Components of the PCR reaction were as 
follows: Perfecta SYBR Green FastMix (10 µL), forward and reverse primers 
(0.125 µL), nuclease free water (4.75 µL), and diluted cDNA (5 µL for 2 ng of 
cDNA/reaction).  Using the difference from GAPDH (glyceraldehydes 3-
phosphate dehydrogenase) rRNA (reference gene) and the comparative Ct 
method, the relative quantification of gene expression in each sample was 
calculated. Primers (Eurofins MWG Operon, Huntsville, AL) were designed using 
the primer design program available from PubMed.gov (sequences presented in 
Table 3.1).  The PCR reaction was as follows: 94°C for 5 minutes, 40 cycles at 
94°C for 15 seconds, 58°C or 64°C (based on tested primer efficiency) for 40 
seconds, 72°C for 10 minutes, and 100 cycles from 95°C to 45.5°C for 10 
seconds.  
3.3.10 Statistical analysis 
 Data are represented as mean + standard error of the mean (SEM).  Data 
was log transformed prior to statistical analysis.  A one-way or two-way analysis 
of variance (ANOVA; SigmaPlot, version 12.0; Systat Software Inc., Chicago, IL) 
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were used as appropriate to determine statistical significance, which was defined 
as p < 0.05.  Glucose and insulin tolerance tests were analyzed using repeated 
measure, two-way ANOVA. Holm-Sidak method was used for post-hoc analyses, 
except in Figures 3.1D and 3.4B which used Dunnett’s method and basal and 
non-insulin stimulated groups as controls for comparison, respectively. 
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3.4 Results 
3.4.1 RSV promotes Nrf2 signaling, suppresses oxidative stress, and restores 
insulin-stimulated glucose uptake in PCB-77 treated adipocytes. 
 RSV has been demonstrated to promote the anti-oxidant Nrf2 signaling 
pathway and reduce oxidative stress in a variety of cell types (247, 306, 316).  
We quantified effects of PCB-77 on Nrf2 and one of its downstream signaling 
targets, NQO1, and oxidative stress in the absence or presence of increasing 
concentrations of RSV in 3T3-L1 adipocytes.  In the absence of RSV, PCB-77 
had no significant effect on mRNA abundance of Nrf2 or NQO1 in 3T3-L1 
adipocytes (Fig. 3.1A,B, respectively).  However, in the presence of PCB-77, 
RSV significantly increased mRNA abundance of Nrf2 and NQO1 in a 
concentration-dependent manner (Fig. 3.1A,B; P<0.05).  PCB-77 significantly 
increased fluorescence of DCF as a measure of oxidative stress, and this effect 
was abolished by RSV (1 µM; Fig. 3.1C, P<0.05).   
 To determine if PCB-77-induced oxidative stress influenced glucose 
homeostasis in 3T3-L1 adipocytes, and whether RSV could restore adipocyte 
function, we quantified 2DG uptake.  In the presence of insulin, 2DG uptake 
increased 4-fold in 3T3-L1 adipocytes (DMSO versus basal; Fig. 1D, P<0.05).  
However, PCB-77 totally abolished 2DG uptake in insulin-stimulated adipocytes 
(Fig. 3.1D).  Effects of PCB-77 to impair glucose uptake by adipocytes were 
reversed in a concentration-dependent manner by RSV (Fig. 3.1D, P<0.05). 
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3.4.2 RSV has no effect on tissue levels of PCB-77 or PCB-77 metabolites.  
 RSV has been demonstrated to have AhR antagonist properties (310-
311), which could influence metabolism of PCBs by cytochrome P-450 1A1 
(CYP1A1).  We quantified mRNA abundance of CYP1A1 as an index of AhR 
activation in adipose tissue of mice administered PCB-77 in the absence or 
presence of RSV.  PCB-77 resulted in a significant increase in CYP1A1 mRNA 
abundance in adipose tissue of mice administered vehicle (VEH) or RSV (Fig. 
3.2; P<0.05).  We then quantified levels of PCB-77 and its major metabolites 
(hydroxyPCB-77, dihydroxyPCB-77) in serum, liver or adipose tissue from mice 
in each treatment group.  Similarly, we quantified levels of the parent compound, 
trans-RSV, and 2 metabolites (RSV-3-O-glucuoride, trans-RSV-3-O-sulfate).  As 
demonstrated previously (7), adipose tissue concentrations of PCB-77 were 
markedly higher than liver or serum (Table 3.2).  Moreover, the ratio of PCB-77 
to its quantified metabolites was greater in adipose tissue (5:1) than liver 
(0.02:1).  Significantly higher concentrations of RSV metabolites were detected in 
serum, liver and adipose tissue than the parent molecule, RSV.  However, there 
was no significant effect of RSV on levels of PCB-77 or its metabolites.  In 
addition, administration of PCB-77 had no significant effect on levels of RSV or 
its metabolites.   
3.4.3 RSV improves glucose tolerance and insulin signaling in adipose tissue 
of mice administered PCB-77  
 There was no significant effect of PCB-77 or RSV on body weight (data 
not shown).  As reported previously (7), PCB-77 significantly impaired glucose 
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and insulin tolerance (Fig. 3.3A,B, respectively), as indicated by a significant 
increase in the area under the curve (AUC) for blood glucose levels following 
administration of glucose (GTT) or insulin (ITT) (Fig. 3.3C,D, respectively).  While 
RSV had no effect on either glucose or insulin tolerance in mice administered 
vehicle, RSV totally abolished effects of PCB-77 to impair glucose and insulin 
tolerance.  Based on findings from 3T3-L1 adipocytes demonstrating that RSV 
stimulated the Nrf2 signaling cascade (Fig. 3.1A), we quantified mRNA 
abundance of Nrf2 and NQO1 in epididymal adipose tissue from insulin-
stimulated mice.  There were no significant effects of PCB-77 or RSV on Nrf2 
mRNA abundance in adipose tissue (data not shown).  However, in mice 
administered PCB-77, RSV resulted in a significant increase in mRNA 
abundance of NQO1 (Fig. 3.4A, P<0.05).  We quantified levels of phosphorylated 
Akt (pAkt, normalized to total Akt) as an index of the insulin signaling pathway in 
adipose tissue of mice administered insulin.  Administration of insulin significantly 
increased pAkt expression in adipose tissue, which was totally abolished by 
PCB-77 (Fig. 3.4B, P<0.05).  While RSV had no effect in the absence of PCB-77, 
it totally restored insulin-stimulated levels of pAkt in adipose tissue (Fig. 3.4B, 
P<0.05).   
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3.5 Discussion 
 Results from this study demonstrate that supplementation with RSV in the 
diet totally prevents PCB-77 induced impairment of glucose and insulin tolerance 
in mice.  Notably, PCB-77 resulted in pronounced suppression of insulin-
stimulated levels of pAkt in adipose tissue, and this effect was abolished by RSV.  
In cultured adipocytes, PCB-77 increased oxidative stress and reduced insulin-
stimulated glucose uptake, and these effects were attenuated in a concentration-
dependent manner by RSV.  Mechanisms of RSV to protect against PCB-
induced oxidative stress and impairment of glucose uptake in 3T3-L1 adipocytes 
may involve activation of the anti-oxidant Nrf2 signaling pathway, as RSV 
stimulated Nrf2 and/or NQO1 expression in cultured adipocytes and elevated 
NQO1 expression in adipose tissue of mice.  In contrast, RSV did not alter 
systemic or tissue distribution of PCB-77 and/or its major metabolites, or levels of 
CYP1A1 in adipose tissue, suggesting that regulation of PCB metabolism did not 
contribute to effectiveness of RSV.  These results demonstrate that RSV can 
attenuate PCB-77-induced insulin resistance in adipose tissue potentially by 
stimulating the NRF2 pathway and preventing oxidative damage.  RSV may 
provide an effective therapy to protect against PCB-induced dysregulation of 
glucose homeostasis. 
 Increasing evidence suggests that exposures to environmental pollutants, 
including PCBs, may be a contributing factor for an increased risk of T2D 
development.  Similar to recent findings (7), in the present study administration of 
PCB-77 to C57BL/6 mice resulted in impaired glucose and insulin tolerance.  
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Results from this study extend previous findings by demonstrating that PCB-77 
administration totally abolished levels of phosphorylated Akt in adipose tissue as 
an index of insulin signaling.  We recently reported that serum levels of PCB-77 
in experimental mice are lower than total serum PCB levels in populations with 
known accidental exposures (7).  In the present study, mice administered PCB-
77 had serum levels of approximately 0.07 + 0.01 µM, consistent with total PCB 
levels reported in subjects from the highest quintile of the Anniston Community 
Health Survey Population that exhibit an increased odds ratio for T2D (158).  
Moreover, as reported previously (7-8), PCB-77 accumulated markedly in 
adipose tissue compared to serum or liver.  An interesting finding of the present 
study was the higher ratio of parent PCB-77 compound to its metabolites in 
adipose tissue, as compared to liver.  These results suggest that in comparison 
to liver where PCBs are predominately metabolized through CYP1A1 activation, 
sequestration of the parent PCB-77 molecule in adipose lipids may hinder 
effective metabolism of the toxin.  However, upon release of sequestered PCBs 
from adipose tissue during lipolysis, adipocytes may experience more 
pronounced effects of the toxin at adipocyte AhR. 
 In the present study, serum RSV concentrations (0.6 nM) in 4 hour fasted 
mice were lower than concentrations (1 µM) that effectively abolished PCB-77 
induced oxidative stress and impaired glucose uptake by 3T3-L1 adipocytes.  
Previous investigators demonstrated that fasted (4 hrs) C57BL/6 mice 
administered 100 mg/kg of RSV via oral gavage had appreciable amounts of the 
RSV-3-O-glucuronide metabolite (317).  These results suggest that protective 
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effects of RSV observed during fasting of mice in this study may have resulted 
from RSV metabolites.  Importantly, neither levels of RSV and metabolites, nor 
levels of PCB-77 and metabolites, were influenced by co-administration of these 
compounds to mice, suggesting that protective effects of RSV against PCB-
induced impairment of glucose homeostasis did not result from changes in 
distribution or metabolism of either compound. 
 In the present study we demonstrated that supplementation with RSV 
effectively protected against the diabetogenic effects of PCB-77 in vitro and in 
vivo.  A recent clinical study of T2D patients treated with oral RSV supplements 
for three months reported significant improvements in nearly all biomarkers 
associated with the disease (213).  However, other groups have not been able to 
show improvements in insulin sensitivity or glucose regulation with RSV (215, 
318).  The dietary dose of RSV used in this study (approx. 160 mg/kg/day) 
equates to a human equivalent dose of just under 800 mg/day for a 60 kg 
individual (319).  This dose of RSV would not be achievable in humans without 
the aid of supplementation.  A potential RSV treatment therapy in PCB exposed 
populations should be regarded cautiously, since the drug interaction potential of 
the high doses of RSV typically utilized in clinical trials remains poorly 
understood (320).  Interestingly, plant food sources that are high in RSV also 
tend to be conversely low in PCBs, as total PCB concentrations in food tend to 
be higher in meats and fish than other sources (11). This would suggest that a 
diet that enhances consumption of vegetables and limits PCB containing foods 
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(e.g., meat) would simultaneously confer antioxidant protection and lower the 
total body burden of these environmental contaminants. 
 Another interesting finding from this study was that RSV had little effect on 
any measured parameter in the absence of PCB-77 administration.  This finding 
is consistent with recent studies that demonstrate that RSV had no effect in lean 
individuals (215), or that RSV improved adipose tissue glucose homeostasis only 
under insulin resistant conditions (241).  These results suggest that RSV would 
not adversely influence glucose homeostasis in the absence of an insult, in this 
case, exposure to an environmental toxin.  Indeed, protective pathways (e.g., 
NQO1) targeted by RSV are typically quiescent and become activated in 
response to an external stimuli (e.g., PCB-77). 
 Mechanisms for protective effects of RSV in the present study include 
reductions in oxidative stress associated with stimulation of the anti-oxidant Nrf2 
signaling pathway.  Several studies have demonstrated that RSV stimulates Nrf2 
expression in various cell types (247, 306, 316).  As described above, RSV 
stimulated Nrf2 and NQO1 gene expression only in adipocytes incubated with 
PCB-77, suggesting that stimulation of the anti-oxidant system by RSV requires 
induction of oxidative stress by a damaging stimulus.  These results are 
consistent with in vivo data from the present study demonstrating that RSV 
favorably influenced a measure of insulin signaling and NQO1 gene expression 
in adipose tissue only when mice were exposed to PCB-77.   
 In conclusion, results from this study indicate that RSV reduces PCB-77 
induced oxidative stress in adipose tissue by enhancing Nrf2 signaling, protecting 
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against PCB-77-induced impairment of glucose and insulin tolerance. These 
results suggest that supplementation with resveratrol may be a potential therapy 
for populations with known PCB exposures to lower the risk of developing 
diabetes. 
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Abbreviations: CYP1A1, cytochrome P-450 1A1; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2, 
nuclear factor erythoid 2-related factor 2. 
 
Table 3.1. Primer sequences for real-time PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Forward Reverse 
CYP1A1 AGTCAATCTGAGCAATGAGTTTGG GGCATCCAGGGAAGAGTTAGG
GAPDH GCCAAAAGGGTCATCATCTC GGCCATCCACAGTCTTCT 
NQO1 AGGATGGGAGGTACTCGAATC TGCTAGAGATGACTCGGAAGG 
Nrf2 CCATATTCCATTCCCTGTCG TAAGTGGCCCAAGTCTTGCT 
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PCB77 (µM) 
Tissue type  VEH  VEH+RSV  PCB77  PCB77+RSV  p‐value 
Serum  N.D.  N.D.  0.07 + 0.02  0.08 + 0.02  0.249
Liver  N.D.  N.D.  4.78 + 2.88  3.16 + 2.19  0.347
RPF  N.D.  N.D.  29.90 + 10.44  19.12 + 8.65  0.113
Hydroxy PCB77 (µM) 
Tissue type  VEH  VEH+RSV  PCB77  PCB77+RSV  p‐value 
Serum  N.D.  N.D.  1.53 + 0.38  1.73 + 0.48  0.492
Liver  N.D.  N.D.  216.19 + 301.58  75.22 + 69.03  0.338
RPF  N.D.  N.D.  4.25 + 0.98  3.14 + 0.17  0.282
Dihydroxy PCB77 (µM) 
Tissue type  VEH  VEH+RSV  PCB77  PCB77+RSV  p‐value 
Serum  N.D.  N.D.  0.31 + 0.08  0.45 + 0.14  0.096
Liver  N.D.  N.D.  1.50 + 2.07  2.39 + 4.47  0.695
RPF  N.D.  N.D.  1.77 + 1.11  1.21 + 0.33  0.346
trans‐Resveratrol (nM) 
Tissue type  VEH  VEH+RSV  PCB77  PCB77+RSV  p‐value 
Serum  N.D.  0.60 + 0.17  N.D.  0.75 + 0.15  0.174
Liver  N.D.  0.08 + 0.07  N.D.  0.06 + 0.10  0.819
RPF  N.D.  0.57 + 0.71  N.D.  2.87 + 3.44  0.181
Resveratrol‐3‐O‐glucuronide (nM) 
Tissue type  VEH  VEH+RSV  PCB77  PCB77+RSV  p‐value 
Serum  N.D.  22.44 + 8.21  N.D.  76.90 + 52.18  0.059
Liver  N.D.  13.15 + 24.13  N.D.  7.24 + 3.76  0.603
RPF  N.D.  1.11 + 0.54  N.D.  1.97 + 1.02  0.134
trans‐Resveratrol‐3‐O‐sulfate (nM) 
Tissue type  VEH  VEH+RSV  PCB77  PCB77+RSV  p‐value 
Serum  N.D.  34.06 + 19.93  N.D.  30.95 + 9.15  0.759
Liver  N.D.  17.34 + 19.22  N.D.  62.63 + 83.76  0.272
RPF  N.D.  0.99 + 0.64  N.D.  3.58 + 3.31  0.125
 
Table 3.2.  Levels of PCB-77, RSV, and their metabolites in serum, liver, and 
retroperitoneal fat of mice. Values are mean + SEM from n = 5/group. P-values 
established via Student’s t-test of independendent means comparing detectable 
groups. N.D., Not detected; VEH, vehicle; RSV, resveratrol; RPF, retroperitoneal 
fat. 
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Figure 3.1. Resveratrol protects 3T3-L1 adipocytes against PCB-77-induced 
oxidative stress and impaired glucose uptake.  A, RSV results in a 
concentration-dependent increase in Nrf2 mRNA abundance in 3T3-L1 
adipocytes incubated with PCB-77 (3.4 µM).  B, RSV (1, 10 µM) promotes NQO1 
mRNA abundance in 3T3-L1 adipocytes incubated with PCB-77.  C, PCB-77 
increases DCF fluorescence as an index of oxidative stress, which is abolished 
by RSV (1 µM).  D, PCB-77 abolishes insulin-stimulated 2DG uptake in 3T3-L1 
adipocytes, and RSV restores insulin-stimulated glucose uptake.  Data are mean 
± SEM from n = 2 experimental triplicates.  *, P<0.05 compared to DMSO within 
RSV concentration or compared to basal in Figure 3.1D; **, P<0.05 compared to 
0 within treatment. 
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Figure 3.2.  PCB-77 increases CYP1A1 mRNA abundance in adipose tissue.  
Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg) in 2 divided doses 
and fed standard mouse diet without and with RSV (0.1%).  At 48 hours after the 
second PCB-77 dose, adipose tissue was harvested for quantification of gene 
expression.  PCB-77 administration significantly increased CYP1A1 mRNA 
abundance in adipose tissue of mice in each diet group.  Data are mean ± SEM 
from n = 5 mice/group.  *, P<0.05 compared to VEH within diet group. 
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Figure 3.3.  RSV prevents PCB-77-induced impairment of glucose or insulin 
tolerance.  Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg) in 2 
divided doses.  Mice in each treatment group were fed either standard mouse 
diet or diet enriched with Resvida™ (RSV, 0.1%).  A, Blood glucose levels after 
administration of glucose.  B, Blood glucose levels after administration of insulin.  
C, Area under the curve (AUC) for data in A.  D, AUC for data in B.  Data are 
mean ± SEM from n = 5 mice/group.  *, P<0.05 compared to PCB77+RSV (A,B) 
or compared to VEH (C,D). 
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Figure 3.4.   RSV promotes the anti-oxidant NRF2 target, NQO1, and 
reverses PCB-77-induced impairment of insulin signaling in adipose tissue.  
Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg) in 2 divided doses, 
and fed either standard mouse diet or a diet enriched with RSV (0.01%).  A, 
NQO1 mRNA abundance in adipose tissue from mice in each treatment group.  
B, Levels of phosphorylated Akt (pAkt), normalized to total Akt, in adipose tissue 
from mice in each treatment group in the absence (no insulin) or presence of 
insulin.  Data are mean ± SEM from n = 5 mice/group.  *, P<0.05 compared to 
VEH (A) or compared to no insulin (B).  
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SECTION IV. SPECIFIC AIM 3 
4.1 Summary 
 Previous studies in our laboratory demonstrated that coplanar 
polychlorinated biphenyls (PCBs) promote adipose tissue inflammation and 
impair glucose homeostasis in mice in an aryl hydrocarbon receptor (AhR)- 
dependent manner. PCBs are highly lipophilic, accumulating in adipose tissue, a 
recognized site of insulin resistance in type 2 diabetes (T2D). The current study 
tested the hypothesis that adipocyte AhR deficiency confers a protective effect 
on PCB-77 induced impairments of glucose disposal in vivo. We determined the 
effects of adipocyte AhR deficiency on responsiveness to PCB-77 (50 mg/kg)-
induced disruptions in glucose homeostasis in mice fed low-fat (LF) or high-fat 
(HF) diets, as well as in obese mice undergoing weight loss. Mice expressing 
transgenic Cre recombinase under the control of the adiponectin (AdQ) promoter 
were bred with AhR-floxed mice to generate littermate controls (AhRfl/fl) and 
adipocyte AhR deficient mice (AhRAdQ). AhR mRNA abundance was reduced 
significantly in both white and brown adipose tissue from AhRAdQ mice compared 
to AhRfl/fl mice. Adipocyte AhR deficiency resulted in greater fat mass and 
reduced lean mass in two month old, chow-fed mice, but this did not significantly 
influence body weight.  However, when AhRAdQ mice were challenged with a HF 
diet, body weight was significantly increased compared to AhRfl/fl controls.  
Notably, body weight increases in HF-fed AhRAdQ mice were associated with 
greater deposition of subcutaneous adipose tissue. HF-fed AhRAdQ mice had 
significantly increased numbers of adipocytes in both visceral and subcutaneous 
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adipose tissue compared to control. Importantly, adipocyte AhR deficiency 
protected against PCB-77 induced impairments in glucose and insulin tolerance 
following both acute and chronic exposure. We also examined effects of 
adipocyte AhR deficiency on PCB-77-induced impairment of glucose 
homeostasis during weight loss in obese mice.  During LF feeding and post 
weight loss, AhRAdQ mice had greater total fat mass than littermate controls. 
Additionally, AhRAdQ mice dosed with PCB-77 during obesity and then subjected 
to weight loss had decreased levels of PCB-77 metabolites in adipose tissue, as 
well as decreased expression of cytochrome P450 1A1 (CYP1A1) and tumor 
necrosis factor-alpha (TNF-α) in adipose tissue compared to littermate controls. 
These results suggest that PCB-77 sequesters to the expanded adipocyte lipid 
pools present during obesity, and that weight loss facilitates the interaction of 
contaminants with the adipocyte AhR and facilitates subsequent metabolism. 
These results demonstrate that the adipocyte AhR is critical in mediating the 
disruptive effects of coplanar PCBs on glucose homeostasis, and that the 
adipocyte AhR might have novel importance in the regulation of obesity and body 
fat deposition. 
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4.2 Introduction 
 The aryl-hydrocarbon receptor (AhR) has well-established roles in 
toxicology and phase I drug metabolism, and also influences developmental cell 
proliferation and differentiation (67). Studies have demonstrated that adipose 
tissue can store xenobiotic ligands of AhR, namely coplanar PCBs (289), likely 
contributing to a low-grade internal source of PCBs which can act in an 
autocrine or paracrine manner. Adipocytes express AhR, and are likely 
chronically exposed to ingested lipophilic POPs given that this cell type stores 
most triglyceride in the body (32, 169). Moreover, storage of lipophilic PCBs in 
adipose tissue suggests that tonic low grade exposures may influence adipocyte 
differentiation and/or inflammation (6-7). While results have demonstrated that 
adipocyte AhR influence adipocyte differentiation and expression of 
inflammatory cytokine (6, 277, 321), the precise role that this receptor plays in 
normal or disease-related dysfunction of adipose tissue is unclear. Previous 
studies demonstrated that whole body deficiency of AhR resulted in improved 
insulin sensitivity and glucose tolerance in mice (87), suggesting that the 
endogenous AhR influences whole body glucose metabolism.  However, the 
contribution of adipocyte AhR to effects of whole body AhR deficiency on 
glucose homeostasis are unclear.   
 Studies in humans undergoing weight loss have demonstrated that serum 
values of PCBs are inversely correlated with BMI (275-276), and that obese 
individuals store a greater body burden of total PCBs than lean counterparts 
(294). PCBs stored in adipose tissue may be released to blood to act 
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systemically, or alternately interact with the cytosolic adipocyte AhR. We have 
previously demonstrated that obese mice administered PCB-77 and 
subsequently subjected to weight loss experienced impaired glucose and insulin 
tolerance; this effect was also observed in lean mice acutely exposed to PCB-77 
(7). One possible explanation for this observation is that weight loss results in 
release of hydrophobic PCBs from lipid pools during lipolysis of adipocytes. 
Indeed, levels of PCB-77 in adipose tissue were increased by obesity, but 
reduced to non-detectable levels following weight loss (7).   
 Interaction of coplanar PCBs with the adipocyte AhR could impact adipose 
tissue insulin sensitivity via several potential mechanisms. Alsharif et. al. 
demonstrated that mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
experienced an AhR-dependent increase in superoxide anion (295). Cytochrome 
P450, family 1, member A1 (CYP1A1), the detoxifying enzyme activated by AhR, 
is known to produce superoxide anion and hydrogen peroxide as part of the 
catalytic cycle of xenobiotic hydroxylation (322-323). The association between 
oxidative stress and insulin resistance, particularly in adipose tissue, has been 
recognized for some time (106-109).  However, the role of adipocyte AhR as a 
contributor to oxidative stress of adipocytes has not been well defined. 
 An additional mechanism of PCB-induced insulin resistance mediated by 
the adipocyte AhR may stem from the promotion of chronic, low-grade 
inflammation in adipose tissue by these toxicants. Previous studies in our 
laboratory demonstrated that coplanar PCBs result in concentration-dependent 
increases in expression of several proinflammatory cytokines in 3T3-L1 
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adipocytes (6).  Moreover, administration of PCB-77 to lean mice impaired 
glucose and insulin tolerance, and these effects were associated with adipose-
specific elevations in expression of tumor necrosis factor-α (TNF-α) (7).  PCB-
induced impairment of glucose homeostasis was lost when mice were made 
obese from consumption of a high fat (HF) diet. However, when obese mice 
exposed to PCB-77 were subjected to weight loss they did not demonstrate the 
same degree of improvement in adipose levels of TNF-α compared to control (7). 
Collectively, these results suggest that coplanar PCBs act at adipocyte AhR to 
influence glucose homeostasis. 
 In this study, we hypothesized that coplanar PCBs promote insulin 
resistance in adipose tissue through direct effects at adipocyte AhR. To test this 
hypothesis, we examined effects of PCB-77 in lean and obese mice (with and 
without weight loss) on glucose homeostasis in mice lacking AhR in adipocytes.  
Results from these studies may have therapeutic implications for populations 
exposed to PCBs (from environmental accidents, or from higher levels due to 
obesity).  In addition, results from these studies suggest that PCBs released from 
adipose stores during weight loss act at adipocyte AhR to blunt beneficial effects 
of weight loss.   
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4.3 Materials and Methods 
4.3.1 Chemical Procurement  
3,3’,4,4’-tetrachlorobiphenyl (PCB-77) was purchased from AccuStandard Inc. 
(New Haven, CT).  
4.3.2 Quantification of PCB-77 and hydroxylated metabolites in serum and 
tissues  
Tissue samples were weighed and homogenized in dH20.  Cold acetonitrile and 
50 µL of internal standard (10 µM 13C labeled d6-PCB-77) were added to 
homogenates and vortexed, sonicated, and centrifuged at 15,000 rpm for 5 
minutes. Supernatants were transferred to glass vials and cold acetonitrile was 
added to the pellets and vortexed, sonicated, and centrifuged. Supernatants 
were transferred again and 50:50 acetonitrile:dH20 was added to the pellet and 
repeated vortex, sonication, and centrifugation. All supernatants were pooled and 
dried under nitrogen. The dried samples were reconstituted in 100 µL of 99/1 
methanol/dH20 and 0.5% formic acid and 0.1% ammonium formate solution. 
 PCB-77 was measured using a Shimadzu UFLC coupled with an AB Sciex 
4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer in multiple 
reaction monitoring (MRM) mode. d6-PCB-77 was used as internal standards.  
PCBs were separated using Kinetex 2.6 u C18, 100 A, 100 X 2.10 mm 
(Phenomenex) column. The mobile phase consisted of water as solvent A and 
acetonitrile as solvent B. For the analysis of PCBs the separation was achieved 
using a gradient of 20% B to 60% B for 1 min, 60% B to 100% B in the next 7 
min, and maintained at 100% B for the last 2 min with a flow rate of 0.25 ml/min. 
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Column was equilibrated back to the initial conditions in 3 min. Column 
temperature was maintained at 30 °C. The sample injection volume was 10 µL. 
The mass spectrometer was operated in the positive APCI mode with optimal ion 
source settings determined by synthetic standards of PCB-77 and d6-PCB-77 
with a declustering potential of 36 V, entrance potential of 10 V, collision energy 
of 53 V, collision cell exit potential of 10 V, curtain gas of 20 psi, nebulizer current 
of 3, ion source gas1 of 40 psi and temperature of 550 °C. MRM transitions 
monitored were as follows: 291.9/ 222.1 and 291.9/220 for PCB-77 and 
297.9/228.1 and 297.9/226.2 for d6-PCB-77. In the MRM ion transition the 
precursor ion represents the M+· and the product ion represents either [M-Cl]+ or 
[M-2Cl]+.  
 Hydroxy PCB-77 was analyzed using Luna 3 u C18 (2), 100 A, 250 X 2.00 
mm (Phenomenex) column. The mobile phase consisted of 75/25 of methanol/ 
water with formic acid (0.5%) and 5 mM ammonium formate (0.1%) as solvent A 
and 99/1of methanol/ water with formic acid (0.5%) and 5 mM ammonium 
formate (0.1%) as solvent B. Hydroxy PCB-77 was eluted using a gradient of 
10% B to 100% B in 4 min and maintained at 100% B for the next 11 min. 
Column was equilibrated back to the initial conditions in 3 min. The flow rate was 
0.25 mL/min with a column temperature of 30 °C. The sample injection volume 
was 10 µL. The mass spectrometer was operated in the negative ESI mode with 
optimal ion source settings determined by synthetic standards of 2-hydroxy-2’, 3’, 
5’, 6’-tetrachlorobiphenyl with a declustering potential of -60 V, entrance potential 
of -10 V, collision energy of -6 V, collision cell exit potential of -7 V, curtain gas of 
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20 psi, ion spray voltage of -4200 V, ion source gas1/gas2 of 40 psi and 
temperature of 550 °C. MRM transitions monitored were 352.8/306.9 for hydroxy 
PCB-77. Precursor ion of the ion transition is a formic acid adduct: [M+FA-H]- and 
product ion is [M-H]-.  
4.3.3 Animals and experimental diets 
All experiments met the approval of the Animal Care and Use Committee of the 
University of Kentucky. AhR-floxed (AhRfl/fl) mice were a generous gift of Dr. 
Mary Walker, University of New Mexico. Female AhRfl/fl mice were bred to 
hemizygous transgenic male Cre mice under control of an 
adiponectin/promoter/enhancer (B6;FVB-Tg(Adipoq-cre)1Evdr/J; The Jackson 
Laboratory, Bar Harbor, ME). Male AhRfl/fl littermates were used for comparison 
to mice with adipocyte AhR deficiency. Initial studies examined effects of 
adipocyte AhR deficiency on PCB-induced impairment of glucose homeostasis in 
lean mice. Male mice (8-9 weeks of age) of each genotype were administered 
vehicle (tocopherol-stripped safflower oil) or PCB-77 (50 mg/kg; by oral gavage 
given as two separate doses over 2 weeks; n = 3-8 mice/group and were fed a 
low fat diet (LF; 10% kcal as fat, D12450B; Research Diets, New Brunswick, NJ)  
for 2 or 4 weeks. 
 Follow up studies examined glucose and insulin tolerance in male mice 
administered vehicle or PCB-77 (50 mg/kg; by oral gavage given as 4 doses in 
weeks 1,2, 9, and 10; n = 6-8 mice/group) and fed a HF diet (60% kcal as fat, 
D12492; Research Diets) for 12 weeks to promote the development of obesity. 
After 12 weeks of HF feeding, subsets of mice from each genotype/treatment 
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group were euthanatized for tissue harvest. Remaining subsets of mice were 
placed on the LF diet for 4 additional weeks to induce weight loss. 
 Body weights were quantified weekly in all studies. At study end point, 
mice were anesthetized (ketamine/xylazine, 10/100 mg/kg, ip) for exsanguination 
and tissue harvest (liver, soleus muscle, and visceral adipose).  
4.3.4 Measurement of body composition 
Body weights of mice were recorded weekly. The body composition of mice was 
determined by nuclear magnetic resonance spectroscopy [EchoMRI (magnetic  
resonance imaging)] before mice began study diets and within 1 week of study 
endpoint. 
4.3.5 Measurement of glucose and insulin tolerance 
For glucose (GTT) and insulin tolerance tests (ITT), mice were examined at week 
2 (LF), 4 (LF), 12 (HF) and 16 (HF then switched to LF diet from week 12-16).  
Mice were fasted for 4 or 6 hours for ITT or GTT, respectively, and fasted blood 
glucose was quantified by tail vein puncture using a hand held glucometer 
(Freedom Freestyle Lite, Abbott Laboratories, Abbott Park, IL). Mice were 
injected i.p. with D-glucose (Sigma, 20% in saline, 10 µL/g of body weight) for 
GTT and blood glucose was quantified at 15, 30, 60, 90, and 120 minutes post 
the bolus injection. For ITT, mice were injected i.p. with human insulin (Novolin, 
0.0125 µM in saline/g of body weight), and plasma glucose was quantified at 30, 
60, 90, and 120 minutes post ip injection. Total area under the curve (AUC; 
arbitrary units) was calculated as previously described (7). The GTT and ITT 
results of two vehicle treated mice were excluded from the acute (2 week) PCB-
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77 findings when adipose tissue from these animals was found to be 
contaminated with PCB-77. 
4.3.6 Quantification of mRNA abundance 
Total RNA was extracted from tissues using the SV Total RNA Isolation System 
kit (Promega Corporation, Madison, WI), per the manufacturer’s instructions. 
RNA from 3T3-L1 cells was extracted in Trizol. RNA concentrations were 
determined using NanoDrop 2000 spectophotometer and associated software 
(Thermo Scientific, Logan, UT). cDNA was synthesized from 0.4 µg total RNA 
with qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) in the 
following reaction:  25°C for 5 minutes, 42°C for 30 minutes, and 85°C for 5 
minutes. The cDNA was diluted 1:50 for a concentration of 0.4 ng/µL. The diluted 
cDNA was amplified with an iCycler (Bio-Rad, Hercules, CA) and the Perfecta 
SYBR Green Fastmix for iQ (Quanta Biosciences, Gaithersburg, MD). The 
components of the PCR reaction were as follows: Perfecta SYBR Green FastMix 
(10 µL), forward and reverse primers (0.125 µL), nuclease free water (4.75 µL), 
and diluted cDNA (5 µL for 2 ng of cDNA/reaction). Using the difference from 
GAPDH rRNA (reference gene) and the comparative Ct method, the relative 
quantification of gene expression in each sample was calculated. Primers 
(Eurofins MWG Operon, Huntsville, AL) were designed using the primer design 
program available from PubMed.gov (sequences presented in Table 1). The PCR 
reaction was as follows: 94°C for 5 minutes, 40 cycles at 94°C for 15 seconds, 
58°C or 64°C (based on tested primer efficiency) for 40 seconds, 72°C for 10 
minutes, and 100 cycles from 95°C to 45.5°C for 10 seconds. Primer sequences 
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were as follows: CYP1A1, forward 5’-AGTCAATCTGAGCAATGAGTTTGG-3’, 
reverse 5’-GGCATCCAGGGAAGAGTTAGG-3’; GAPDH, forward 5’-
GCCAAAAGGGTCATCATCTC-3’, reverse 5’-GGCCATCCACAGTCTTCT-3’; 
TNF-α, forward 5’-CCCACTCTGACCCCTTTACTC-3’, reverse 5’-
TCACTGTCCCAGCATCTTGT-3’. 
4.3.7 Determination of adipocyte size and cell number 
Sections of formalin (10% wt/vol) fixed pieces of epidydmal or subcutaneous 
adipose tissue were stained with hematoxylin and eosin. Images of slides were 
taken at 10 magnification. Via use of the “detect edges” setting, image 
threshold, and object count features of NIS Elements software (Nikon 
Instruments, Inc., Tokyo, Japan), the area of each adipocyte and the number of 
adipocytes within a 700  700 µm measurement frame were quantified. 
Adipocyte size and number were calculated on three measurement frames within 
each section of adipose tissue (n = 3 sections/mouse) from mice in each group (n 
= 3 mice/group). 
4.3.8 Differentiation of preadipocytes from SVC 
Subcutaneous adipose tissue was taken from the inguinal region, minced, and 
incubated in basal medium (OM-BM; Zenbio, Research Triangle Park, NC) 
supplemented with collagenase (1 mg/ml) and penicillin/streptomyocin mixture 
(5%) for 1 h with shaking at 37°C as previously described (324). Two days after 
cells had reached 100% confluence, media was changed to differentiation 
medium (OM-DM; Zenbio) and changed every other day for 8 days. Cells were 
harvested for RNA using TRIzol.  
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4.3.9 Statistical analysis 
Data are represented as mean + SEM.  Data was log transformed prior to 
statistical analysis.  A two-way analysis of variance (ANOVA; SigmaPlot, version 
12.0; Systat Software Inc., Chicago, IL) was used to determine statistical 
significance, which was defined as p < 0.05.  Glucose and insulin tolerance tests 
were analyzed using repeated measure, two-way ANOVA. Holm-Sidak method 
was used for post-hoc analyses. 
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4.4 Results  
4.4.1 Generation of mice with adipocyte AhR deficiency. 
To confirm effective and specific deletion of exon 2 of AhR in adipocytes, AhR 
mRNA abundance was quantified in adipose tissues, liver, brain, heart, and 
kidneys from mice fed standard laboratory diet (2 months of age). AhR mRNA 
abundances were not significantly different in liver, kidney, or brains from AhRfl/fl 
compared to AhRAdQ mice (Figure 1A; P>0.05). In heart, AhR mRNA abundance 
was reduced in AhRAdQ compared to AhRfl/fl mice, but did not meet criteria for 
statistical significance (p = 0.08) (Figure 4.1A). In retroperitoneal (RPF) white 
adipose tissue and brown adipose tissue (BAT), AhR mRNA abundance was 
decreased significantly in AhRAdQ compared to AhRfl/fl mice (Figure 4.1A; 
P<0.05). While no significant difference between genotypes was detected in AhR 
mRNA abundance in stromal vascular cells (SVCs) , AhRAdQ mice had no 
detectable AhR mRNA in isolated adipocyte fractions from epidydmal adipose 
tissue compared to AhRfl/fl mice (Figure 4.1B; P<0.05). 
 We examined the ability of preadipocytes within SVCs isolated from mice 
of each genotype to differentiate into mature adipocytes. No visual differences in 
cell morphology or size were noted at any day during differentiation (data not 
shown). AhR mRNA abundance was significantly decreased in adipocytes (day 
8) differentiated from SVCs of AhRAdQ mice compared to AhRfl/fl controls (Figure 
4C, AhRfl/fl, 1.46 ± 0.27; AhRAdQ, 0.60 ± 0.31,  Ct method, 18S used as 
reference gene; P < 0.05). 
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 Chow-fed, two month old male AhRAdQ mice did not have significant 
differences in body weight compared to littermate controls (Figure 4.2A); 
however, these mice had significantly increased fat mass and reduced lean mass 
compared to age-matched AhRfl/fl mice (Figure 4.2B; P<0.05). Additionally, chow-
fed AhRAdQ mice had significantly larger visceral adipose depots and moderately 
larger subcutaneous adipose depots (Figure 4.2C). Because differences in body 
fat deposition could potentially affect glucose and insulin tolerance in the 
absence of PCB and/or diet, we conducted baseline glucose and insulin 
tolerance tests in chow-fed male mice. Neither glucose nor insulin tolerance were 
influenced by adipocyte AhR deficiency in chow-fed mice (data not shown). 
4.4.2 Adipocyte AhR deficiency improves glucose and insulin tolerance in 
lean mice acutely exposed to PCB-77.  
We have previously demonstrated that lean mice acutely exposed to PCB-77 
develop impaired glucose and insulin tolerance within 48 hours of the last dose 
(7). To determine the role of adipocyte AhR in mediating the acute effects of 
PCB-77 on glucose homeostasis, LF-fed AhRAdQ mice and littermate controls 
were dosed twice with vehicle or PCB-77 (50 mg/kg) and glucose and insulin 
tolerance tests (GTT and ITT) were performed. AhRfl/fl mice, but not AhRAdQ 
mice, exposed to PCB-77 had impaired glucose and insulin tolerance compared 
to vehicle treated controls (Figures 4.3A and 4.3B, respectively; P<0.05). 
Surprisingly, regardless of treatment (vehicle, PCB-77), adipocyte deficiency of 
AhR resulted in improved insulin tolerance compared to AhRfl/fl controls, as 
shown by the area under the curve (AUC) for ITT (Figure 4.3C; P<0.05). An 
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additional unexpected finding was an effect of PCB-77 to increase total fat mass, 
regardless of genotype (Figure 4.3D; P<0.05).  
 Due to their lipophilicity, PCBs accumulate in adipose tissue (8). We 
quantified levels of PCB-77 and the metabolite hydroxy PCB-77 in retroperitoneal 
white adipose (RPF) and serum of AhRfl/fl and AhRAdQ mice following 
administration of PCB-77. At week 2 following acute PCB-77 exposure, PCB-77 
levels in serum or RPF of AhRfl/fl mice (mean ± SE, serum: 0.77 + 0.09 µM; RPF: 
74.35 ± 7.91 μM) were not significantly different from values measured in AhRAdQ 
mice (serum: 0.61 ± 0.07 µM, P = 0.61 compared to AhRfl/fl mice; RPF: 53.89 + 
4.65, P = 0.06 compared to AhRfl/fl mice). Additionally, serum and RPF levels of 
hydroxy PCB-77 were not significantly different in AhRfl/fl mice (serum: 0.01 + 
0.01 µM; RPF: 0.69 ± 0.26 μM) and AhRAdQ mice (serum: 0.01 + 0.01 µM, P = 
0.84 compared to AhRfl/fl mice; RPF: 0.41 ± 0.15 μM, P = 0.35 compared to 
AhRfl/fl mice) with acute PCB-77 exposure. 
4.4.3 Adipocyte AhR deficiency promotes the development of obesity during 
HF-feeding and alters body fat distribution.  
Given that lean mice with adipocyte AhR deficiency displayed increased fat mass 
when fed chow diet (Figure 4.2B) in the absence of PCB exposure, we examined 
effects of adipocyte AhR deficiency on the development of obesity. Interestingly, 
deficiency of adipocyte AhR resulted in significant increases in the development 
of obesity (Figure 4.4A,B; P<0.05). There was a trend for adipocyte AhR deficient 
mice to exhibit impairments of glucose and insulin tolerance (Figure 4.5A,B), with 
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these findings tracking body weight differences between groups (i.e., heavier 
groups were more glucose and insulin intolerance than leaner groups).  
4.4.4 Adipocyte AhR deficiency resulted in adipose depot-specific changes in 
adipocyte cell number in HF-fed mice. 
In subcutaneous adipose tissue from HF-fed AhRAdQ mice, adipocytes were 
larger in size resulting in fewer number of cells per field compared to tissue from 
AhRfl/fl mice (Figure 4.6A,B; P<0.05). In epidydmal adipose tissue, similar trends 
were observed with increased adipocyte size of HF-fed AhRAdQ mice compared 
to control (Figure 4.6B); however, these increases did not reach statistical 
significance in epididymal adipose. Notably, epididymal adipose tissue from HF 
fed AhRAdQ mice exhibited pronounced macrophage infiltration, as evidenced by 
increased mRNA abundance of F4/80 as a macrophage marker compared to 
adipose tissue from AhRfl/fl controls (Figure 4.6C; P<0.05).  Increased 
macrophage infiltration was observed in epididymal, but not in subcutaneous 
adipose tissue from either group. 
4.4.5 Adipocyte AhR deficiency protects against PCB-77 induced disruptions 
in glucose homeostasis and adipose tissue inflammation during weight loss. 
To examine if adipocyte AhR deficiency would protect against PCB-77 induced 
disruptions in glucose homeostasis during weight loss, AhRAdQ mice and 
littermate controls were fed the HF diet for 12 weeks and orally gavaged with 
vehicle or PCB-77 (50 mg/kg) in weeks 1, 2, 9, and 10. Following the weight gain 
portion of the study, mice were then fed the LF diet for 4 weeks to promote 
weight loss. Even though AhRAdQ mice gained more weight when fed the HF diet 
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(Figure 4.4), all groups reached statistically similar body weights following 4 
weeks of weight loss (Figure 4.7). 
 Similar to previous findings (7), administration of PCB-77 during the 
weight gain phase of the study resulted in significant impairments of glucose and 
insulin tolerance following weight loss in AhRfl/fl mice (Figure 4.8A-D; P<0.05).  In 
contrast, effects of PCB-77 to impair glucose (Figure 4.8A,C) and insulin 
tolerance (Figure 4.8 B,D) during weight loss were mitigated in AhRAdQ mice. As 
indicated by area under the curve quantification of blood glucose levels following 
glucose or insulin administration, adipocyte AhR deficiency conferred partial 
protection from PCB-77 induced disruptions in glucose tolerance (Figure 4.8C), 
and totally prevented PCB-77-induced impairment of insulin tolerance (Figure 
4.8D; P<0.05).    
 We quantified adipose levels of PCB-77 and the metabolite hydroxy PCB-
77 mice of both genotypes administered PCB-77, in obese mice of both 
genotypes at week 12 and post weight loss at week 16. HF-fed AhRAdQ mice 
accumulated significantly higher levels of PCB-77, but not hydroxyl PCB-77 in 
adipose tissue (Figure 4.9A,B), potentially related to increased body weights and 
fat mass of these mice. With weight loss, both genotypes of mice exhibited 
reductions in adipose tissue levels of PCB-77 (Figure 4.9A), and increased levels 
of the metabolite hydroxyl PCB-77 (Figure 4.9B), suggesting that weight loss 
promoted liberation of PCB-77 from adipose lipids with potential CYP1A1-
mediated metabolism to hydroxyl PCB-77.  In addition, adipocyte AhR deficient 
mice undergoing weight loss exhibited significantly lower levels of metabolite 
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hydroxyl PCB-77 compared to controls (Figure 4.9B; P<0.05), suggesting that 
AhR-mediated induction of CYP1A1 contributed to metabolism of the parent 
toxin.   
 To determine the extent of AhR activation in mice of each genotype, we 
quantified epidydmal adipose tissue mRNA abundance of CYP1A1. 
Administration of PCB-77 significantly increased mRNA abundance of CYP1A1 
in AhRfl/fl, but not AhRAdQ mice (Figure 4.10A; P<0.05).  Similarly, mRNA 
abundance of TNF-α was significantly increased by administration of PCB-77 in 
adipose tissue of AhRfl/fl, but not AhRAdQ mice (Figure 4.10B; P<0.05).   
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4.5 Discussion 
Results from this study demonstrate that the adipocyte AhR mediates effects of 
PCB-77 to impair glucose and insulin tolerance in lean mice, and in obese mice 
experiencing weight loss.  Consistent with previously reported findings (7), PCB-
77 impaired glucose homeostasis in lean wild type mice (week 2 of LF feeding), 
effects that were abolished in adipocyte AhR deficient mice. Furthermore, PCB-
77 had no effect on glucose or insulin tolerance in obese mice of either genotype 
(week 12 of HF feeding). However, PCB-77 exposed wild type mice undergoing 
weight loss demonstrated previously reported impairments in glucose 
homeostasis, an effect which was not observed in AhRAdQ mice (week 16, 
concluding 4 week LF feeding weight loss period). We uncovered the surprising 
finding that adipocyte AhR deficiency, in the absence of toxin administration, 
promoted an increase in fat mass in mice fed a LF or HF diet.  These results 
suggest that location of this receptor to adipocytes influences the distribution of 
fat mass.  Our results confirm previous findings that obese mice exhibit greater 
adipose levels of PCB-77(7), and extend these findings to demonstrate that 
sequestration to adipose lipids most likely protects the parent PCB-77 molecule 
from metabolism and detoxification.  However, with weight loss adipose levels of 
the parent toxin decrease while metabolite levels increase, and these effects are 
most likely mediated through adipocyte AhR-induction of CYP1A1.  Moreover, 
PCB-mediated induction of TNF-α expression in adipose tissue following weight 
loss was abolished in mice with adipocyte AhR deficiency.  Reductions in 
adipose TNF-α expression most likely contributed to improved glucose and 
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insulin tolerance with weight loss in adipocyte AhR deficient mice previously 
exposed to PCB-77. These results indicate a pivotal role for adipocyte AhR in 
diabetes-inducing effects of PCB-77.  
 AhRAdQ mice fed HF diet for 12 weeks demonstrated significant increases 
in macrophage infiltration to epidydmal adipose tissue compared to littermate 
controls, as shown by mRNA abundance of macrophage marker F4/80. 
Epidydmal adipocytes from obese AhRAdQ mice were larger than controls, 
however this increase in size did not meet criteria for statistical significance. 
Increased macrophage recruitment to epidydmal adipose tissue may have 
occurred as a result of this modest epidydmal adipocyte hypertrophy. 
Alternatively, the adipocyte AhR may have undocumented effects on the 
regulation of macrophage recruitment signaling in adipocytes, which could be the 
basis of future studies. 
 An unexpected finding of the present study was that adipocyte AhR 
deficiency led to increased body weight and adipose depot-specific changes to 
adipocyte size and cell number during HF feeding. Interestingly, two month old, 
male AhRAdQ mice fed standard chow diet also had increased body fat mass and 
larger visceral adipose depots, despite displaying no significant differences in 
body weights. These findings suggest that the adipocyte AhR plays a previously 
unrecognized role in body fat deposition, perhaps in an adipose depot-specific 
manner, and that this role becomes more important under HF feeding conditions.  
These intriguing findings warrant further study. Currently, there are several 
putative endogenous AhR ligands that could have contributed to these findings, 
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including arachidonic acid and one of its ecosanoid products, such as lipoxin A4 
or prostaglandin G2 (325-326). Bui et. al. demonstrated that treatment of wild 
type mice with TCDD led to a significant increase in liver ecosanoids 
(unfortunately, adipose tissue was not examined in this study), but this effect was 
not observed in mice with whole body AhR deficiency. The authors concluded 
that TCDD-mediated binding of AhR resulted in antagonism of the receptors 
interaction with endogenous ecosanoid ligands, leading to an increase of these 
products in examined tissues (326). Our laboratory has previously demonstrated 
that coplanar PCB exogenous ligands of the AhR promoted adipocyte 
differentiation when incubated with predipocytes (6). It should be noted that AhR 
expression was present in the stromal vascular fraction from mice with adipocyte 
AhR deficiency; however, AhR expression levels were reduced in mature 
adipocytes that would experience increased expression of the Cre-driven 
promoter, adiponectin.  Therefore, increased adipocyte size in mice with 
adipocyte AhR deficiency was most likely not the result of regulation of adipocyte 
differentiation by an endogenous ligand.     
 Another potential explanation for the unusual phenotype observed in 
AhRAdQ mice may relate to crosstalk between the adipocyte AhR and other 
nuclear receptors or transcription factors. Interestingly, recent studies 
characterized a mouse model with adipocyte-specific deficiency of aryl-
hydrocarbon receptor nuclear translocator-like, ARNTL (also known as BMAL1 or 
MOP3)(327). Not only has signaling between the circadian protein ARNTL and 
AhR been postulated to have metabolic effects on glucose and insulin tolerance 
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(87), but the adipocyte-specific ARNTL knock out mice demonstrated a similar 
phenotype in response to HF feeding as observed in the present study (327). 
 Crosstalk between AhR and estrogen receptor-alpha (ERα) and estrogen 
receptor-beta (ERß) has been recognized for some time (328-332), with several 
studies demonstrating that activation of AhR by synthetic ligands effectively 
mutes ER signaling, and vice versa (328-332). Moreover, PCB-77 and its 
metabolites can demonstrate both estrogenic or anti-estrogenic properties that 
may have influenced findings of the present study (333-334). CYP1B1, a 
member of the classical AhR gene battery, is a known monooxygenase activator 
of 17beta-estradiol. CYP1B1 hydroxylates 17beta-estradiol to generate catechol 
estrogen metabolites with carcinogenic and estrogenic potential (331). Although 
the present studies were conducted utilizing male mice, adipose tissue 
expresses aromatase and could therefore convert androgens to estrogens. It is 
possible that a combination of these factors are contributing to the gynoid pattern 
of fat distribution (i.e. larger subcutaneous adipose depots) demonstrated by 
male AhRAdQ mice. 
 Another potential mechanism for the increased fat mass phenotype 
observed in AhRAdQ mice might be that removing AhR from adipocytes then frees 
the AhR dimerization partner, aryl-hydrocarbon receptor translocator (ARNT) to 
interact with other adipocyte transcription factors. Hypoxia has been shown to 
inhibit AhR activity in an ARNT-dependent fashion (335), while conversely AhR 
activation has been shown to suppress the expression of hypoxia inducible factor 
1 alpha (HIF1-α), a transcription factor that is also dependent on ARNT for gene 
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regulation (336). Taken together, these findings suggest that activation of AhR or 
HIF1-α would tend to sequester ARNT away from the opposing pathway, 
effectively muting downstream cellular pathways. Interestingly, Jiang et. al. 
demonstrated that adipocyte-specific HIF1-α deficient mice gained less weight 
than controls during HF feeding (337). It is possible that deficiency of adipocyte 
AhR resulted in increased interaction between ARNT and HIF1-α, functionally 
increasing HIF1-α activity and increasing body weight. 
 In conclusion, the adipocyte AhR may represent a novel therapeutic target 
for individuals from PCB exposed populations, or overweight subjects attempting 
to lose weight in general. This therapeutic should be cautiously considered until 
the mechanisms behind adipocyte AhR regulation of body weight and adipose 
tissue deposition are more clearly delineated. 
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Figure 4.1. Development of mice with adipocyte deficiency of AhR. A, AhR 
mRNA abundance was analyzed in liver, kidney, brain, heart, retroperitoneal fat 
(RPF), and brown adipose tissue (BAT). B, mRNA abundance of AhR in stromal 
vascular fractions (SVF) and adipocyte fractions from epidydmal adipose tissue 
of each genotype. C, AhR mRNA abundance in SVF cells isolated from 
subcutaneous adipose tissue of mice from each genotype that were then 
differentiated to mature adipocytes.  Data are mean ± SEM from n = 4-6 
mice/group. *, P < 0.05 compared to AhRfl/fl.  
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Figure 4.2. Body weight and composition of adipocyte AhR deficient mice. 
A, Body weights from 2 month old, chow-fed male AhRAdQ mice versus littermate 
controls.  Circles represent individual mice with mean ± SEM represented as the 
horizontal line. B, Body composition from male AhRAdQ mice versus littermate 
controls. C, Percent weight of adipose depots normalized as a percentage of 
total body weight from AhRAdQ mice compared to littermate controls. Data are 
mean ± SEM from n = 10 mice/group. *, P < 0.05 compared to AhRfl/fl; **, P < 
0.01 compared to AhRfl/fl. 
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Figure 4.3. Adipocyte AhR deficiency abolishes PCB-77-induced 
impairment of glucose and insulin tolerance in lean mice. A, Blood glucose 
levels following administration of glucose. B, Blood glucose levels following 
administration of insulin. C, Area under the curve (AUC) for insulin tolerance test 
(ITT) in panel B. D, Body composition of AhRAdQ mice compared to littermate 
controls. Data are mean ± SEM from n = 6-8 mice/group. *, P < 0.05 compared to 
vehicle treated AhRfl/fl; **, P < 0.01 compared to vehicle treated AhRfl/fl; #, P < 
0.05 effect of genotype. 
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Figure 4.4. Adipocyte AhR deficiency promotes the development of obesity. 
A, Body weights during 12 weeks of HF feeding in each genotype. B, Body 
composition after 12 weeks of HF feeding in each genotype. Data are mean ± 
SEM from n = 6-8 mice/group. *, P < 0.05 compared to AhRfl/fl; **, P < 0.01 
compared to AhRfl/fl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
 
 
 
149 
 
Figure 4.5. Adipocyte AhR deficiency modestly impairs glucose tolerance.  
A, Glucose tolerance test. B, Insulin tolerance test. Data are mean ± SEM from n 
= 6-8 mice/group. *, P < 0.05 compared to AhRfl/fl. 
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Figure 4.6. Adipocyte AhR deficiency promotes adipocyte hypertrophy and 
increases adipose F4/80 gene expression.  A, Quantification of adipocyte size 
normalized to number of adipocytes/field in subcutaneous adipose tissue from 
each genotype. B, Representative subcutaneous and epidydmal adipose tissue 
sections. C, Epidydmal adipose tissue F4/80 mRNA abundance. Data are mean 
± SEM from n = 3 mice/group for adipocyte quantifications, n = 5 for RT-PCR 
measurements. *, P < 0.05 compared to vehicle treated AhRfl/fl. 
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Figure 4.7. Following weight loss body weight is similar between genotypes 
and treatments.  Body weights following 4 weeks of weight loss in mice of each 
genotype and treatment group. Data are mean ± SEM from n = 6-7 mice/group.  
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Figure 4.8. Adipocyte AhR deficiency prevents PCB7-77-induced 
impairment of glucose and insulin tolerance following weight loss. A, Blood 
glucose levels following administration of glucose. B, Blood glucose levels 
following administration of insulin. C, Area under the curve (AUC) of glucose 
tolerance test (GTT) data in panel A. D, AUC of insulin tolerance test ( ITT) data 
in panel B. Data are mean ± SEM from n = 6-8 mice/group. *, P < 0.05 compared 
to vehicle treated AhRfl/fl; #, P < 0.05 effect of genotype. 
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Figure 4.9. Adipose levels of PCB-77 and hydroxy PCB-77 metabolite in 
obese mice (week 12 of HF feeding) and after 4 weeks of weight loss. A, 
PCB-77 levels in epidydmal adipose tissue from mice of each genotype and 
treatment group at weeks 12 and 16. B, Hydroxy PCB-77 levels in epidydmal 
adipose tissue from mice of each genotype and treatment group at weeks 12 and 
16. Data are mean ± SEM from n = 5 mice/group. *, P < 0.05 compared to 
AhRfl/fl; ***, P < 0.001 compared to AhRfl/fl ; #, P < 0.05 effect of genotype. 
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Figure 4.10. PCB-77-induced increases in mRNA abundance of CYP1A1 and 
TNF-α are abolished in mice with adipocyte AhR deficiency.  A, Epidydmal 
adipose tissue CYP1A1 mRNA abundance in mice of each genotype and 
treatment group. B, Epidydmal adipose tissue TNF-α mRNA abundance in mice 
of each genotype and treatment group. Data are mean ± SEM from n = 5 
mice/group. *, P < 0.05 compared to vehicle treated AhRfl/fl; #, P < 0.05 effect of 
genotype. 
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SECTION V: GENERAL DISCUSSION  
5.1 Summary 
The purpose of the studies described in this dissertation was to test the 
hypothesis that PCB-77 regulates adipose tissue glucose homeostasis and 
inflammation through the adipocyte AhR, and that resveratrol would protect 
adipose tissue against PCB-77 induced insulin resistance. A mouse model of 
PCB-77 induced diabetes was developed in lean mice and in obese mice 
undergoing weight loss. PCB-77 had no effect on glucose or insulin tolerance in 
the context of obesity. In lean mice and obese mice undergoing weight loss, 
PCB-77 induced impairments in glucose homeostasis were associated with 
increased levels of TNF-α specifically in adipose tissue. Administration of 
resveratrol supplementation improved glucose homeostasis in lean PCB-77 
treated mice, and simultaneously promoted NRF2 activity and restored insulin 
signaling pathways in adipose tissue of these mice. Moreover, 3T3-L1 adipocytes 
demonstrated a dose dependent increase in NRF2 signaling during cotreatment 
with PCB-77 and resveratrol. Also in vitro, resveratrol protected from PCB-77 
induced oxidative stress and restored glucose uptake in PCB-77 treated cells in a 
concentration-dependent manner. A mouse model of adipocyte-AhR deficiency 
was developed using the Cre/LoxP system to investigate the potential roles of 
the adipocyte-AhR in mediating toxicities of PCB-77 in lean and obese mice, as 
well as obese mice undergoing weight loss. Lean AhRAdQ mice fed a LF diet and 
acutely exposed to PCB-77 demonstrated a modest improvement in glucose 
tolerance and a more pronounced improvement in insulin sensitivity than AhRfl/fl 
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mice. AhRAdQ mice fed HF diet for 3 months unexpectedly gained more weight, 
had greater fat mass, and deposited more subcutaneous adipose tissue than 
littermate controls; however, PCB-77 had no effect on glucose homeostasis in 
obese mice of either genotype. During weight loss, obese AhRAdQ mice exhibited 
partial protection against PCB-77 during glucose tolerance test and total 
protection from PCB-77 induced insulin resistance (see Figure 5.1 for a summary 
of these findings).  
5.2 The interplay between adipose tissue and persistent organic pollutants: 
Insights from mouse models of PCB-77 induced diabetes  
5.2.1. PCB distribution in the body 
During exposure to PCBs, these lipophilic pollutants are stored in liver and 
adipose tissue (169, 289). This may avert the action of these pollutants in other 
susceptible tissues and might be protective to a certain extent or under some 
metabolic conditions (i.e. obesity) (7, 338). PCBs released from their storage in 
adipose tissue may also represent a source of low-level internal exposure or may 
act on the adipocyte directly as obesogens or disruptors of adipose tissue 
structure and function (6, 9). Strong evidence from both in vivo and in vitro 
studies suggests that PCBs can influence the development of adipose tissue, 
principally through the promotion of preadipocyte differentiation at low doses, and 
conversely preventing differentiation at high doses (6). Furthermore, storage of 
PCBs in adipose tissue could impact offspring via fetal programming, probably 
through epigenetic mechanisms, impacting the development of diseases in 
adulthood (339-340). Additionally PCBs might alter adipose tissue function and 
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structure later in life, primarily through metabolic disruption and inflammation, 
conditions which favor the development of metabolic diseases (6-7). 
 The findings described herein would suggest that obesity could adversely 
impact overall health in that expanded adipose stores might improve storage of 
lipophilic POPs, thus increasing total body burden of environmental 
contaminants.  If obese subjects subsequently lose weight, this enhanced store 
of POPs can then be released from adipose tissue via lipolysis, where they may 
have effects systemically or on adipocytes directly. Observations in humans 
suggest that pollutants released from adipose tissue are a significant source of 
blood POPs. Many studies have demonstrated an increase in blood POPs after 
weight loss by either dietary changes alone or coupled with bariatric surgery (9, 
341). The importance of fat mass in the regulation of POP blood levels was 
additionally reported by Lim et al. (275) who showed an inverse correlation 
between long-term weight changes and POP serum concentrations.  
 An important question is if the release of POPs from adipose tissue during 
weight loss could negatively impact other organs and tissues. A limited amount of 
data is available in humans from weight loss studies. Studies have demonstrated 
that increased serum POPs due to weight loss are associated with impairments 
in resting metabolic rates, thermogenesis, and oxidative capacity of skeletal 
muscle (276, 342-343). Kim et al. reported that individuals undergoing weight 
loss had improved blood lipid and liver toxicity parameters, but those with the 
highest serum POP levels had delayed improvement of these metabolic 
parameters (9). Thus POPs may counteract the beneficial effects of weight loss. 
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5.2.2. Potential target organs of coplanar PCB induced diabetes 
5.2.2.1. Adipose tissue  
As previously discussed, we have demonstrated that adipose tissue can be a 
critical target organ of PCB induced insulin resistance in male C57BL/6 mice (7). 
It should be noted that our studies only examined molecular pathways of 
impaired insulin signaling in adipose tissue which were dependent on increased 
levels of TNF-α expression or reactive oxygen species. Insulin resistance in 
adipose tissue can also be regulated by lipolysis and relative free fatty acid 
levels, adiponectin, and other proinflammatory cytokines. Kim et. al. dosed 
C57BL/6 mice and AhR-KO mice with a single i.p. injection of TCDD (10 µg/kg) 
and harvested adipose tissue 48 hours later (277). TCDD significantly increased 
a number of additional proinflammatory adipokines associated with insulin 
resistance, such as IL-1ß, in wild type mice but not AhR-KO mice, demonstrating 
that these effects were AhR-dependent. Additionally, the method of POP dosing 
and the metabolic state of experimental animals appears to be a critical factor in 
studies of adipose-specific effects of POPs. In a study by Ibrahim et. al. (88), 
male C57BL/6J mice were fed a HF diet enriched with low concentrations of 
POPs for 8 weeks and glucose and insulin tolerance were measured. Contrary to 
findings reported here, obese mice in this study demonstrated significantly 
impaired glucose and insulin tolerance in response to POP feeding. Taken with 
the findings presented here, this would suggest that the method POP dosing and 
metabolic state of experimental animals may have differential effects on POP-
induced impairment of glucose homeostasis. Future studies could examine the 
163 
 
kinetics of different types of PCB dosing and how this modulates subsequent 
PCB metabolism and body partitioning. Other modulators of insulin resistance, 
influenced by PCBs in adipose tissue could also be explored in future studies. 
5.2.2.2. Liver 
The liver is also a potential site of insulin resistance, and highly active in the 
metabolism of coplanar PCBs. While our efforts to quantify hepatic inflammation 
did not yield significant results (7), it is plausible that coplanar PCBs reduce 
insulin sensitivity in the liver via other mechanisms, and /or alter hepatic glucose 
output, contributing to the PCB-77 induced diabetes observed in male mice. A 
consistent observation of the experiments described in this dissertation were that 
PCB-77 treated mice demonstrated hepatomegaly due to high levels of ectopic 
lipid accumulation in the liver (6). This factor alone could have unexplored 
consequences on overall insulin resistance, given that fatty liver is a condition of 
other pathologies associated with T2D, such as non-alcoholic fatty liver disease 
(NALFD). 
 Attempts were made in these studies to determine the effect of PCB-77 
administration on hepatic gluconeogenesis. Surprisingly, RT-PCR results for 
mRNA abundance of an array of gluconeogenic enzymes, in particular 
phosphoenol pyruvate carboxykinase (PEPCK), found that expression of all 
enzymes were decreased in PCB-77 treated animals compared to controls 
(Figure 5.2), suggesting that enhanced hepatic glucose output was not the 
mechanism behind impaired glucose tolerance in those mice. This observation 
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using PCB-77 is consistent with AhR-dependent effects of TCDD reported by 
others (344-345). 
 In a recent study, Wang et.al. examined glucose tolerance, insulin 
resistance, hepatic expression of peroxisome proliferator–activated receptor-α 
(PPAR-α), and genes affecting glucose metabolism and fatty acid oxidation 
rhythms in wild-type (WT) versus AhR-deficient [knockout (KO)] mice (87). In this 
study, KO mice displayed enhanced insulin sensitivity and improved glucose 
tolerance, accompanied by decreased hepatic peroxisome proliferator activated 
receptor-α (PPAR-α) and key gluconeogenic and fatty acid oxidation enzymes, 
indicating a link between AhR signaling and glucose metabolism. The authors 
further conclude that hepatic activation of the PPAR-α pathway might be a 
mechanism underlying AhR-mediated insulin resistance. Findings presented here 
would suggest that the adipocyte AhR is a critical mediator of PCB-induced 
insulin resistance, as insulin resistance was completely abolished in AhRAdQ mice 
treated with PCB-77 both acutely and chronically (unfortunately the study by 
Wang et. al. did not treat experimental mice with either AhR agonists or POPs 
(87), making comparison to the studies described here difficult). 
 Nault et.al. utilized livers from chow-fed C57BL/6 mice for gene 
microarray, 1, 3 and 7 days after a single oral gavage of 30 μg/kg TCDD (85). 
Administration of TCDD resulted in robust activation of not only genes involved in 
the xenobiotic response, but also genes associated with steroid, phospholipid, 
fatty acid, and carbohydrate metabolism. Arzuaga et.al. performed gene DNA 
analysis on livers from C57BL/6 mice fed diets enriched with high-linoleic acid 
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oils (20% and 40% as calories), with  half of each group exposed to PCB-77 (84). 
This study demonstrated a significant interaction between dietary fat and PCB 
exposure, such that deregulated genes were organized into patterns describing 
the interaction of diet and PCB exposure. Control animals demonstrated a 
significant high-fat mediated induction of genes associated with fatty acid 
metabolism, triacylglycerol synthesis and cholesterol catabolism, but this effect 
was down-regulated in animals exposed to PCB-77. Several of these genes are 
regulated by PPAR-α and as predicted, changes in PPAR-α gene expression 
followed the same pattern as described above, demonstrating that dietary fat can 
interact with environmental pollutants to compromise lipid metabolism. Taken 
together, the results of these gene microarray studies would suggest not only 
that there is a distinctive role for the AhR in lipid and glucose metabolism, but 
that overall nutritional status and the presence of lipids can modulate the 
interaction between AhR and exogenous ligands. These findings would suggest 
that the liver could be the subject of future research for its complex roles in PCB 
detoxification and nutrient metabolism. 
5.2.2.3. Skeletal Muscle 
Skeletal muscle can be a potential site of insulin resistance, but was not a major 
focus of these studies utilizing PCB-77, given that detectable amounts of PCB-77 
were not found in skeletal muscle from treated mice. Additionally PCB-77 treated 
mice in our study did not demonstrate differences from controls in skeletal 
muscle TNF-α protein levels, a well known contributor to insulin resistance.  In a 
recent study by Trumble et.al., muscle and blubber samples were collected from 
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Weddell seals in Antarctica and measured for 41 different persistent organic 
pollutants, including PCBs (346). The greatest distribution of POPs were found in 
blubber and reduced amounts found in skeletal muscle; however the muscle 
samples demonstrated similar orders of POP prevalence. The author’s further 
suggest that POPs may exert local effects on skeletal muscle via their attraction 
to intramuscular lipid. An additional possibility is that POPs stored in blubber may 
be released over time and constitute a source of low-level internal exposure that 
might chronically damage other tissues including skeletal muscle. The chronic 
effects of PCB dosing on skeletal muscle were not included in the present study, 
but could certainly be examined in future studies. 
5.2.2.4. Pancreas 
The pancreas is a glandular organ in the digestive and endocrine system, 
producing several important hormones, including insulin, glucagon, pancreatic 
polypeptide, as well as pancreatic juice which contains digestive enzymes that 
assist the absorption of nutrients. These enzymes aid in the breakdown of 
carbohydrates, proteins, and lipids. Given that pancreatic beta cell secretion of 
insulin is impaired in T2D, PCB toxicities in the pancreas might represent a 
further area of study utilizing these mouse models. In our LF diet time course 
study in male C57BL/6 mice, mice were administered two or four oral doses 
(weeks 1, 2, 9, and 10) of vehicle or PCB-77 (50 mg/kg) and sacrificed at weeks 
2, 4, and 12. At weeks 2 and 4, no significant difference in fasting plasma insulin 
was observed between treatment groups; however at week 12, PCB-77 treated 
mice had a significant decrease in fasting plasma insulin compared to controls 
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(Figure 5.3). A possible explanation may be that in longer term PCB dosing 
studies, coplanar PCBs may exert beta cell damaging effects, or through some 
other mechanism inhibit insulin secretion. Furthermore, it has been previously 
reported that pancreatic beta cell lines exposed to TCDD experience high 
degrees of cytotoxicity in addition to reduced levels of glucose-stimulated insulin 
secretion (347). Taken together, these studies would suggest that pancreatic 
beta cell destruction might be an additional mechanism of PCB induced diabetes. 
5.2.3. The progression of adipose inflammation in LF time course studies 
5.2.3.1. ROS as the initiating event for adipose inflammation 
An interesting finding of these studies is that PCBs contribute to a progression of 
inflammation in adipose tissue. In time course studies of mice fed a LF diet and 
dosed with vehicle or PCB-77 (50 mg/kg, oral gavage), PCB treated mice 
experienced an AhR-dependent and adipose-specific increase in TNF-α protein 
at week 4 (2 weeks post final PCB dose) which was correlated with observed 
impairments in glucose and insulin tolerance (7). However, no difference was 
found in adipose TNF-α mRNA abundance in PCB treated mice at week 2 (48 
hours post final PCB dose), despite the fact that these animals also exhibited 
impaired glucose homeostasis. In subsequent studies using resveratrol as a 
therapeutic against coplanar PCB-induced diabetes, mice sacrificed 48 hours 
after the last dose of PCB-77 also displayed no difference in adipose TNF-α 
expression levels; however, these mice displayed glucose intolerance and insulin 
resistance consistent with previously reported findings (7). These results suggest 
that acute effects of PCB-77 to increase oxidative stress and impair downstream 
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insulin signaling in adipose tissue contribute to deficits in glucose homeostasis, 
and these acute effects were ablated by supplementation with resveratrol (7). 
 It has been hypothesized by others that AhR activation by synthetic 
ligands induces oxidative stress in target tissues via the upregulation of 
xenobiotic metabolizing enzymes such as CYP1A1 (162, 348). CYP1A1 can 
produce hydrogen peroxide and super oxide anions as a byproduct of xenobiotic 
catalyzing activity (159, 322-323). However, our results did not define if 
progressive increases in adipose tissue TNF-α are dependent on initial 
dysregulation of oxidative stress.  An informative experiment could utilize the 
existing experimental design of PCB induced diabetes with CYP1A1 deficient 
mice (or adipose-specific CYP1A1 deficient mice) to better understand the 
mechanisms linking AhR, oxidative stress, and inflammation. Conversely, 
CYP1A1 si-RNA could be utilized to inhibit enzyme activity in vitro and determine 
effects on PCB-induced regulation of oxidative stress and insulin signaling in 
adipocytes. 
5.2.3.2. Potential role of PCB-77 metabolites 
An additional question raised but not directly answered by the present studies 
are the potential impact of PCB-77 metabolites on the observed impairments in 
glucose homeostasis and adipose inflammation. It is interesting to note that in 
both the LF diet time course study as well as the obesity/weight loss time course 
study there was no difference in adipose TNF-α mRNA abundance when 
extremely high adipose concentrations of the parent molecule PCB-77 detected 
in adipose tissue (LF diet time course, week 2).  Conversely, the highest levels of 
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adipose TNF-α expression occurred in tandem with extremely low adipose 
concentrations of parentPCB-77 (LF time course, week 4; obesity/weight loss 
time course, week 16) (7). These data suggest that PCB-77 metabolites 
contribute to adipose tissue inflammation. Unfortunately, in early studies of this 
project, facilities were not available to quantify PCB-77 metabolites in serum or 
tissues. It should also be noted that the current mass spectrometry protocol for 
PCB-77 metabolite detection only screens for hydroxy and dihydroxy metabolites 
of PCB-77, but not the larger pool of potential metabolites such as 
glucuronidated or sulfated variants. To more comprehensively address the role of 
PCB-77 metabolites, future studies could utilize two different approaches. The 
most direct would be to utilize the aforementioned CYP1A1 deficient mice in the 
previously established PCB induced diabetes experimental design. However, this 
approach ignores other metabolizing enzymes in the AhR gene battery and 
would not control for alternate PCB-77 metabolites. An alternative approach 
could utilize the existing mouse model of PCB-77 induced diabetes, but instead 
dose mice with commercially available PCB-77 metabolite analogues (available 
from Canadian distributors). 
5.3. The potential therapeutic benefits of resveratrol supplementation in PCB 
exposed populations: Insights from resveratrol supplementation mouse model of 
PCB-77 induced diabetes  
5.3.1. Resveratrol intervention in populations with known PCB exposures 
The data presented herein suggest that supplementation with resveratrol or 
potentially other AhR antagonizing nutrients or pharmaceuticals may be a 
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therapeutic for populations with known coplanar PCB exposures. It should be 
noted that a limitation of our study is that it only examined effects of resveratrol 
against acute PCB-77 exposure, and that mice were pre fed resveratrol for one 
week prior to initiating the study. An experiment with greater implications for 
comparison to human exposures would be to dose mice with PCB-77 and then 
supplement the diet with resveratrol, because in reality, humans are unlikely to 
take large doses of resveratrol as a preventative measure against possible PCB 
exposure.  
5.3.2. General use of resveratrol supplements for weight loss 
This study would more generally suggest that resveratrol might be a beneficial 
supplement for patients post bariatric surgery, or even subjects more generally 
involved in weight loss programs, given that nearly all individuals are exposed to 
persistent organic pollutants on a daily basis via food or air (11), and likely have 
significant adipose stores of PCBs to release with increased lipolysis (23). A 
relevant follow up experiment would be to dose obese mice with PCB-77, and 
then feed a resveratrol enriched LF diet to induce weight loss, and determine if 
resveratrol ameliorates the negative effects of PCBs during weight loss. The 
ability of PCBs to attenuate the beneficial effects of weight loss might explain in 
part why most individuals find sustained weight loss incredibly challenging, and 
why compliance in weight loss programs is generally low. For example, 
hyperinsulinemia in response to insulin resistance in peripheral tissues can 
promote feelings of hunger (91, 93), which may potentially derail an individual’s 
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motivation in regards to weight loss. Blunting the effects of POPs released with 
weight loss might improve weight loss program outcomes.  
5.3.3. Pharmaceutical resveratrol analogues and resveratrol use in tandem 
with other nutritional supplements 
Because the levels of resveratrol endogenously available in food are limited, it 
would be worthwhile to consider the use of pharmaceutical resveratrol 
analogues, should future research demonstrate that this compound is a clinically 
relevant strategy for treating PCB exposed populations. A benefit of utilizing 
pharmaceutical analogues would be that the compound could be conjugated to 
or formulated as a mixture with other nutrients that might protect against PCB 
exposure. For example, the fat substitute Olestra has been shown previously to 
effectively lower adipose burdens of Arochlor in humans (349). Olestra is a fat 
substitute that is resistant to lipases in the human digestive tract; because of 
Olestra’s fatty acid-like molecular structure, it has been shown that it can create a 
lipophilic ‘sink’ in the intestinal lumen and thereby promote enhanced elimination 
of stored PCBs and organochlorines. A pharmaceutical preparation of resveratrol 
and Olestra might present a “two-pronged” strategy for protecting against PCB 
exposure. However, an interesting study by Arguin et.al. compared plasma 
organochlorine concentrations in subjects on vegan, omnivorous, and a fat-
substituted Olestra diet, and found the significant improvement on plasma PCB 
levels only in the vegan diet group (350). Because the vegan diet group did not 
gain weight over the study, which could promote organochlorine partitioning from 
blood to adipose tissue, it is possible that the vegans ate greater amounts of 
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plants containing antioxidants and fewer PCB laden foods (i.e. high fat dairy and 
meats) (351). It may also be suggested by this study that a pharmaceutical blend 
of antioxidants might confer more PCB protective effects than Olestra; however 
drug forms of antioxidants are unlikely to change food related behaviors, and 
thus the efficacy of this drug in lowering body burdens of PCB might be limited if 
users continued to ingest food high in organochlorines. Future research should 
determine if this is a clinically relevant avenue of potential drug development. 
5.4. Adipose AhR: Role in mediating PCB-77 induced diabetes, and a potentially 
novel role in regulating body weight, body composition, and fat deposition  
5.4.1 Limitations of the model of adipocyte-AhR deficiency  
5.4.1.1. Non-specific reductions in AhR mRNA abundance  
The model of adipocyte-AhR deficiency used in these studies was developed 
using the Cre/LoxP system, in which exon 2 of the AhR gene was flanked by 
LoxP sites and mice were bred to transgenic mice expressing Cre recombinase 
driven by the adiponectin (AdQ) promoter. Adiponectin was originally described 
as an adipocyte-specific protein and thus the promoter was used by several 
groups to reduce gene expression in adipocytes. However, as more models 
using this promoter have been developed, it has become clear that the 
adiponectin gene is also expressed in other tissues, such as cardiomyocytes. 
Indeed, mRNA abundance of AhR in AhRAdQ mice was reduced in the heart, but 
these reductions fell short of statistical significance. Quantification of heart weight 
to body weight ratios as a measure of cardiac hypertrophy revealed no 
differences between AhRfl/fl and AhRAdQ mice (Figure 5.4). Additionally, given that 
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these mice were utilized for glucose and insulin tolerance studies and not 
examined for cardiovascular parameters per se, it is unknown if AhR deficiency 
in the heart impacted other physiologic measures, but it is unlikely to have 
influenced study endpoints.  
5.4.1.2. Model validation  
AhR mRNA abundance was quantified in whole adipose tissue lysates, the 
adipocyte fraction of collagenase-digested adipose tissue, as well as in 
subcutaneous adipocytes differentiated from isolated stromal vascular cells. 
Some level of residual AhR mRNA abundance was detected in all of these 
adipocyte sources from AhRAdQ mice. This may reflect sub-optimal efficiency of 
Cre recombinase enzyme activity at the LoxP sites surrounding exon 2 of the 
AhR gene. Given that there was total deletion of AhR mRNA abundance in 
adipocyte fractions from visceral adipose tissue, the minimal AhR expression 
seen in subcutaneous adipocytes at Day 8 might suggest residual receptor 
turnover.  
5.4.2. HF diet induced phenotype in adipose AhR deficient mice 
5.4.2.1 Differential expression of AhR in LF versus HF feeding 
Preliminary studies in our lab examined if there were diet-induced changes in 
AhR gene expression in adipose tissue, liver, and kidney. Tissues were taken 
from C57BL/6 mice fed either a LF or HF diet for three months, and RNA was 
extracted for subsequent RT-PCR measurements. In liver and kidney, AhR 
mRNA abundance did not change between LF and HF feeding (Figure 5.5). 
However, in subcutaneous, epidydmal, and brown adipose tissue, HF feeding 
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significantly increased AhR mRNA abundance (Figure 5.5). While it should be 
noted that the sample size for these preliminary studies was small (n = 3-
4/group), this data may lend support to the hypothesis that the endogenous AhR 
ligand is a fatty acid or fatty acid derivative, given that HF feeding would increase 
the influx of fatty acids to adipose tissue.  
5.4.2.2. Arachidonic acid or ecosanoid metabolites as a potential 
endogenous AhR ligand 
The unexpected increased body weight phenotype of HF-fed adipocyte AhR 
deficient mice may be due to a number or combination of different factors. 
Currently, the endogenous AhR ligand(s) remains unknown; however, some 
studies have suggested ligands may include arachidonic acid or one of its 
eicosanoid products, such as lipoxin A4 or prostaglandin G2 (326, 352). Bui et. 
al. demonstrated that treatment with TCDD in wild type mice led to a significant 
increase in liver eicosanoids , but this effect was not observed in whole body 
AhR deficient mice, demonstrating AhR dependency. The authors concluded that 
AhR binding with TCDD antagonized receptor interaction with endogenous 
eicosanoid ligands, leading to an increase of these products in examined tissues 
(326). Further studies utilizing AhRAdQ mice and lipid profiling techniques may 
provide novel insight into the endogenous AhR ligand. 
5.5. Further exploration of the adipose AhR: Dietary manipulations  
In our studies, adipocyte-AhR deficiency was studied under several conditions 
including lean mice, obese mice, and obese mice undergoing weight loss. The 
most striking effects of PCB-77 induced impairments on glucose homeostasis 
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were observed in obese mice undergoing weight loss, suggesting that the effects 
of adipocyte-AhR deficiency may be most relevant when the kinetics of PCB 
dosing favor rapid sequestration to expanded adipose stores, and subsequent 
chronic release with weight loss. Interestingly, effects of adipocyte-AhR 
deficiency on body weight, body composition, and fat deposition were only seen 
on the HF diet (60% fat by calories). Dietary manipulations could be performed in 
future studies to examine how fatty acid composition of the diet impact effects of 
adipocyte-AhR deficiency.  
 For example, it has been suggested that the polyunsaturated, omega 6 
arachidonic acid or eicosanoid metabolites lipoxin A4 or prostaglandin G2 may 
be endogenous AhR ligands (35), perhaps leading to the phenotype observed in 
HF fed AhRAdQ mice. However, it has also been published by Hennig et.al. that 
omega 6 fatty acids can enhance PCB toxicity, whereas polyunsaturated omega 
3 fatty acids can protect against the harmful effects of PCBs (348, 354). AhRAdQ 
mice and littermate controls could be dosed with PCB-77 during HF feeding of 
diets with modified ratios of omega 3 and omega 6 polyunsaturated fatty acids, 
and then tested for glucose and insulin tolerance following a weight loss period. 
By this method, a dose-response to arachidonic acid in adipocyte-AhR deficient 
mice could be observed during obesity, and conversely it could be determined if 
omega 3 fatty acids conferred a protective effect against PCB-77 induced 
diabetes during weight loss in AhRfl/fl mice. 
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5.6. Additional future directions 
5.6.1. The role of noncoplanar PCBs in the development of diabetes 
An important question raised by this research is the effect that noncoplanar 
PCBs might have on the development of T2D and obesity, especially given that 
noncoplanar PCBs are also positively associated with T2D in epidemiology 
studies (271, 355-357). Mechanistic studies of these compounds would likely 
prove challenging given that noncoplanar PCBs can activate both the CAR and 
PXR signaling pathways (358). PXR activation by noncoplanar PCBs might be a 
more critical pathway in the development of PCB-induced diabetes than the CAR 
pathway, given that studies have shown that CAR activation during HF feeding 
improves insulin sensitivity (359), whereas PXR ablation alleviates diet induced 
and genetic obesity and insulin resistance in mice (360). Furthermore, studies in 
our lab using 3T3-L1 adipocytes demonstrated that exposure to noncoplanar 
PCB-153 had no effect on inflammation or insulin-stimulated glucose uptake 
(6)(Figure 5.6). This would suggest that noncoplanar PCBs might exert their 
effects on organs other than adipose tissue, or that this particular cell line is not 
responsive to PCB-153. Finally, Shi et.al. have reported that the metabolic 
effects of PCB-153 are highly dependent on macronutrient interactions during HF 
feeding (361), which might be an additional complicating factor in studies of this 
nature. 
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5.6.2. The role of mixtures of persistent organic pollutants in the development 
of diabetes 
A limitation of this data is that only two coplanar PCB congeners were studied; in 
reality, it is highly unusual for human subjects to be exposed to only one 
congener of PCB. In fact, given that nearly all individuals are exposed to a variety 
of persistent organic pollutants on a daily basis via food or air (11), and that 
obesity is rapidly increasing in the U.S. (362-363), it is likely that many people 
have significant and variable distributions of an assortment of lipophilic POPs 
stored in adipose tissue. Ibrahim et. al. pioneered the use of a “POP diet” (88), in 
which Atlantic salmon were fed fish feed enriched with low concentrations of 
POPs. Salmon were filleted after 8 weeks of feeding, and fillets were 
homogenized and fish oil extracted. Fish oil extracts were added to purified 
rodent diets (72% kcal as fat), which were subsequently fed to male C57BL/6J 
mice for 8 weeks. Interestingly, obese mice in this chronic feeding study 
demonstrated dramatically impaired glucose and insulin tolerance in response to 
POP exposure compared to controls. This finding, taken with the findings 
described in this dissertation, are suggestive that the method of POP exposure 
and the metabolic state of experimental mice have a significant impact on the 
kinetics of POP body distribution and / or metabolism and the POP-induced 
impairment of glucose and insulin tolerance. Experiments utilizing the “POP diet” 
developed by Ibrahim et. al. and examining a variety of metabolic states would 
be beneficial in determining the efficacy or potential toxicity of resveratrol 
supplementation in populations exposed to POP mixtures. Furthermore, feeding 
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a similar diet to AhRAdQ mice and littermate controls could give a more complete 
understanding of the overall importance of the adipocyte AhR in mediating PCB-
induced diabetes during chronic POP exposure through feeding. 
5.6.3. Potential gender differences in development of PCB or POP associated 
diabetes  
Some epidemiology studies, including the Anniston community survey by 
Silverstone et.al., have indicated that PCB exposure has a stronger positive 
association with development of T2D in females than males (158, 364-365); 
however, other clinical studies show no impact of gender on the positive 
correlation between POP exposure and diabetes risk or severity (268, 271, 290, 
366-368). Whether gender-specific responses to PCB exposure are due to 
interaction with additional environmental or genetic factors remains unknown. 
Furthermore, it is possible that there are gender differences in AhR expression, 
activation, activity, gene regulation, signaling pathways, or receptor turnover, 
which could present an alternate avenue of future study. However, it is more 
likely that gender differences in response to PCBs stem from AhR crosstalk with 
other steroid receptors, particularly by AhR induced inhibition of the estrogen 
receptor (369-370). We repeated the experimental design using two oral doses of 
either vehicle or PCB-77 (50 mg/kg) administered to female LF-fed mice, and 
quantified glucose and insulin tolerance within 48 hours of the second dose 
(Figure 5.7A and 5.7B, respectively). At 48 hours post gavage, females exposed 
to PCB-77 had a more robust impairment to glucose tolerance than that 
observed in males; conversely, females had no impairment of insulin tolerance, 
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contrary to what has previously been observed in males (7). While not having 
significantly different body weights, PCB-77 treated females had greater fat mass 
than controls which was associated with enlarged visceral and subcutaneous 
adipose depots, an effect that was not observed in male C57BL/6 mice in 
experiments described in this dissertation (Figure 5.8). Gender differences 
relating to the AhR represent an important and clinically relevant direction for 
future research. 
5.7 Clinical Implications  
The data presented here raise broad clinical implications. Firstly, our data 
suggest that supplementation with resveratrol or potentially other AhR 
antagonizing nutrients or pharmaceuticals may be a therapeutic for populations 
with known coplanar PCB exposures. It should be noted that our study only 
examined effects of resveratrol to protect against acute PCB-77 exposure, and 
that mice were pre fed resveratrol for one week prior to initiating the study. An 
important and informative experiment would be to dose mice with PCB-77 and 
then supplement the diet with resveratrol, as this would more closely mirror the 
therapeutic potential of the compound in subjects with known, accidental 
exposures to PCBs. As previously noted, it is unusual for human subjects to be 
exposed to only one congener of PCB; experiments examining resveratrol 
supplementation utilizing the “POP diet” developed by Ibrahim et. al. (88) would 
be beneficial in determining the efficacy or potential toxicity of resveratrol in 
populations exposed to POP mixtures. Secondly, it would suggest that 
resveratrol might be a beneficial supplement for patients post bariatric surgery, or 
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even subjects more generally involved in weight loss programs, given that nearly 
all individuals are exposed to persistent organic pollutants on a daily basis via 
food or air (11), and likely have significant adipose stores of POPs to release with 
increased lipolysis (7). An interesting follow up experiment would be to dose 
obese mice with PCB-77, and then feed resveratrol enriched LF diet to induce 
weight loss, and determine if resveratrol ameliorates the negative effects of 
PCBs during weight loss. The ability of POPs to attenuate the beneficial effects 
of weight loss might explain in part why most individuals find sustained weight 
loss incredibly challenging, and why compliance in weight loss programs is 
generally low. For example, hyperinsulinemia in response to insulin resistance in 
peripheral tissues can promote feelings of hunger (91, 93), which may potentially 
derail an individual’s motivation in regards to weight loss. Blunting the effects of 
POPs released with weight loss might improve weight loss program compliance 
and outcomes. Finally, study in greater detail of adipocyte AhR regulation of body 
weight, body mass, and fat deposition may have significant implications both 
clinically or in pharmaceutical research. 
5.8 Concluding remarks  
Overall these studies suggest a critical role of coplanar PCB-bound AhRs on 
adipocytes to promote insulin resistance in adipose tissue during lean and weight 
loss conditions, and a more general and novel role in regulating body mass and 
fat deposition. The consequences on glucose homeostasis of PCB-77 acting 
through adipocyte AhRs are most prominent in lean/weight loss conditions and 
are absent in the setting of obesity, lending further credence to the hypothesis 
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that lipophilic pollutants are sequestered to lipid pools during obesity and freed 
during weight loss. Future studies should explore resveratrol supplementation in 
the weight loss model of PCB-77 induced diabetes and investigate the feasibility 
of clinical resveratrol supplementation studies in PCB exposed Kentucky 
populations.  Additionally, the impact of adipocyte AhR deficiency on body 
weight, fat mass, and fat deposition should be studied in greater detail. 
Furthermore, this model of adipocyte AhR deficiency may provide important 
clues to the identity of the endogenous AhR ligand, which would perhaps have 
far reaching clinical implications. 
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Figure 5.1. Summary of findings: Proposed mechanism of PCB-77 induced 
adipocyte mediated T2D and inhibition with resveratrol. PCB-77 is 
transported in blood and highly attracted to expanded lipid pools present in 
hypertrophied adipocytes during obesity. During lean or weight loss conditions 
(blue pathway), PCB-77 is released from adipocyte lipid droplets with lipolysis, 
and returns to blood to act systemically and / or act at the cytosolic adipocyte 
AhR. AhR activation leads to increased expression of CYP1A1 and TNF-α, and 
the generation of reactive oxygen species. The culmination of these changes 
induces glucose intolerance and insulin resistance in adipocytes. Resveratrol 
stimulates Nrf2 signaling to suppress oxidative stress and restore insulin 
sensitivity and glucose tolerance to adipocytes (red pathway). 
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Figure 5.2. PCB-77 treatment decreases hepatic mRNA abundance of 
gluconeogenic enzymes. Mice were administered vehicle (VEH) or PCB-77 (50 
mg/kg, two divided doses during weeks 1 and 2). At week 4, hepatic mRNA 
abundance of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate 
carboxylase (PC), and glucose 6-phosphatase (G6P) were measured. Genes 
were normalized to reference gene 18S. Data are mean ± SEM from n = 4 
mice/group.  *, P < 0.05 compared to VEH within gene of interest. 
 
 
 
 
 
184 
 
Week 2 Week 4 Week 12
0.0
0.5
1.0
VEH
PCB77
*
Pl
as
m
a 
In
su
lin
 (n
g/
m
L)
 
Figure 5.3. PCB-77 treatment decreases fasted plasma insulin in LF fed 
mice. Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg, two divided 
doses during weeks 1 and 2, a second set of 2 doses during weeks 9 and 10 for 
mice studied at 12 weeks).  At 2, 4 or 12 weeks, mice in each treatment group 
were fasted for 4 hours prior to sacrifice, and plasma was collected for 
commercial insulin ELISA. Data are mean ± SEM from n > 5 mice/group.  *, P < 
0.05 compared to VEH within time point. 
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Figure 5.4. Adipocyte AhR deficiency does not affect heart weight. Hearts 
were harvested from two month old, male AhRAdQ mice and littermate controls. 
Data are mean ± SEM from n = 6 to 8 mice/group.  
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Figure 5.5. Differential expression of AhR in adipose tissue during LF vs. 
HF feeding.  Male C57BL/6 mice were fed either LFD (10% kcal as fat) or HFD 
(60% kcal as fat) for 3 months. AhR mRNA abundance was quantified in liver, 
kidney, subcutaneous adipose tissue (SUBQ), epidydmal adipose tissue (EF), 
and brown adipose tissue (BAT). Genes were normalized to reference gene 18S. 
Data are mean ± SEM from n = 3 to 4 mice/group.  *, P < 0.05 compared to VEH 
within tissue type. 
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Figure 5.6. PCB-153 has no effect on insulin-stimulated glucose uptake in 
3T3-L1 adipocytes. Coplanar PCB-77 abolishes insulin-stimulated 2DG uptake 
in 3T3-L1 adipocytes, while PCB-153 has no effect on insulin-stimulated glucose 
uptake. Data are mean ± SEM from n = 2 experimental triplicates. *, P<0.05 
compared to basal. 
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Figure 5.7. PCB-77 impairs glucose tolerance (A) in female C57BL/6 mice, 
but has no effect on insulin tolerance (B).  Mice were administered vehicle 
(VEH) or PCB-77 (50 mg/kg, two divided doses during weeks 1 and 2).  48 hours 
post-second gavage administration, mice in each treatment group were 
administered a bolus of glucose (20% glucose, A) or insulin (0.0125 µM/gm body 
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weight, B) and blood glucose concentrations were quantified. Data are mean ± 
SEM from n = 5 mice/group. *, P < 0.05 compared to VEH within time point. **, P 
< 0.01 compared to VEH within time point. ***, P < 0.001 compared to VEH 
within time point. 
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Figure 5.8. PCB-77 increases adipose depot weight of female C57BL/6 
mice. Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg, two divided 
doses during weeks 1 and 2). Mice were sacrificed at week 4 and adipose depot 
weights in retroperitoneal fat (RPF), periovarian fat (POF), and subcutaneous 
adipose tissue (SUBQ) were quantified. Data are mean ± SEM from n = 10 
mice/group.  *, P < 0.05 compared to VEH within tissue type. 
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